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Abstract 
Up to 10 percent of systemic sclerosis (SSc) patients develop pulmonary arterial 
hypertension (PAH). This risk persists throughout the disease and is time dependent, 
suggesting that SSc operates as a susceptibility factor. Outcomes for SSc-PAH 
patients remain poor compared with heritable (HPAH) or idiopathic (HPAH) forms, 
despite clinical and pathological similarities. Whereas susceptibility in HPAH and 
HPAH is strongly associated with gene mutations that lead to reduced expression of 
functional bone morphogenetic protein type II receptor (BMPRII), these mutations 
have not been observed in SSc-PAH.  
My initial aim was to investigate BMPRII expression and downstream signalling 
pathways in whole lung tissue and explant cultured fibroblasts derived from a murine 
model of SSc (TβRIIΔk-fib) that is susceptible to developing PAH Complementary 
studies examined SSc or control lung tissue and fibroblasts. My results suggest 
reduced BMPRII levels, impaired signalling and altered receptor turnover could be 
due to increased TGFβ activity in a model of SSc-PAH. Similarly a significant 
reduction in BMPRII expression is observed in SSc lung tissue and fibroblasts. 
Increased proteasomal degradation of BMPRII appears to underlie this and may 
result from heightened TGFβ activity. Proteasomal inhibition restored BMPRII 
expression and cellular responses. Collectively suggesting that impaired TGFβ/BMP 
signalling leading to increased receptor degradation, may promote PAH 
susceptibility in SSc and provide a unifying mechanism across different forms of 
PAH. 
Since more than one cell type contribute to the development of PAH and the 
pathophysiology of the disease BMPRII expression and TGFβ responses in 
pulmonary arterial smooth muscle cells (PASMCs) were also investigated. Initial 
studies generated a synthetic “disease” like PASMC that also displayed a reduction 
in BMPRII expression and increased response to TGFβ, which was similar to IPAH 
cells  
Finally, the role of epigenetic inhibition in the TβRIIΔk-fib model was investigated. 
The epigenetic inhibitor JQ1 was able to attenuate the spontaneous development of 
PAH in the TβRIIΔk-fib model of PAH. Taken together, work described in this 
thesis strongly suggests that a reduction in BMPRII is a susceptibility factor to the 
development of PAH in a pre-clinical model of SSc and in SSc patients.  
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1. Introduction 
1.1 Pulmonary hypertension 
1.1.1 Pulmonary hypertension 
Pulmonary Hypertension (PH) is defined by an elevated mean resting pulmonary 
arterial pressure (mPAP) greater than or equal to 25 mmHg at rest [1]. Pulmonary 
Hypertension (PH) is currently classified into five major groups based upon shared 
pathological, clinical features and treatment regimens (Table 1) [2]. The 
classification of PH was first determined at the inaugural World Health 
Organization’s (WHO) scheme in 1973 [3]. The first major revision in 1998, divided 
PH into five separate groups based on clinical features and pathobiology [4]. Further 
revisions were made in 2003 leading to changing the term primary pulmonary 
hypertension to idiopathic pulmonary arterial hypertension (IPAH). The most recent 
WHO meeting took place in 2013 and no changes were made to the current 
classifications. The definition of PH will remain the same and experts decided there 
is still insufficient data to introduce the term “borderline PH” for patients with 
mPAP levels between 21 and 24 mm Hg [5]. However some debates continued 
mainly around whether the definition should be remain as resting mean mPAP 
greater than 25 mmHg at rest or should it defined as resting mean mPAP greater than 
20 mmHg and should the term borderline PH be introduced for patients with an 
mPAP between 21 and 24 mmHg. Another question around the definition was 
should pulmonary vascular resistance be introduced to the definition of PH/PAH and 
is a pulmonary artery wedge pressure (PAWP) of 15 mmHg be appropriate to 
distinguish between pre-capillary and post-capillary PH and should PAWP be 
required to distinguish pre-capillary and post-capillary PH [6]. 
Group 1 is comprised of a diverse group of diseases and is termed pulmonary 
arterial hypertension (PAH), this group can be further sub-divided into IPAH; 
heritable PAH (HPAH) if there is a family history of PAH of which greater than 
70% of patients have mutations in bone morphogenetic protein receptor 2 
(BMPRII) [7]; or associated PAH (APAH) where other diseases are present such 
as the connective tissue disease systemic sclerosis (scleroderma/SSc). Group 2 is 
PH due to left heart failure, which previously has been reported to be the most 
frequent cause of PH, however this is now thought to be that associated with 
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schistosomiasis infection [8-11]. Group 3 is PH owing to lung disease and/or 
hypoxia. This includes chronic obstructive pulmonary disease (COPD), as well as 
interstitial lung diseases including idiopathic pulmonary fibrosis (IPF) and SSc. 
Group 4 is composed of chronic thromboembolic pulmonary hypertension 
(CTEPH) whereby obstruction of the pulmonary vasculature occurs due to 
thromboembolism, and may be revered by surgical intervention. Finally Group 5 is 
PH with unclear or multi-factorial etiologies. The pathological characteristics of 
PH are multifactorial and include, increased pulmonary arterial blood pressure, 
vascular remodelling of the pulmonary small arteries, right ventricular hypertrophy 
and ultimately, right ventricular failure [2].   
1.1.2 Diagnosis 
PH is suspected in any patient with unexplained dyspnea, breathlessness during 
minimal exercise and any sign of right ventricular dysfunction. PH is diagnosed by 
right heart catheterisation (RHC) because this method can determine if elevated PAP 
is due to increased precapillary resistance or postcapillary resistance [5]. 
Echocardiography cannot determine these differences but it can be used as an initial 
screening tool, to follow disease progression and response to therapy. The 
combination of the measuring biomarkers and the 6-minute walking test can be used 
to measure response to treatments in longitudinal trials and to manage disease 
progression [5].  
Echocardiography continues to be the most commonly used non-invasive technique 
to suspect the development of PAH. One major problem with IPAH is the failure to 
detect the onset of disease for >2 years after the development of initial symptoms 
[12, 13]. Family screening occurs in patients with HPAH but due to low penetrance 
of BMPRII mutations there are some concerns about screening [14]. Patients with 
connective disease, HIV, congenital heart disease and liver disease are all screened 
for the development of PAH. There has been no new study based around these 
indications except for in SSc where the use of a two-step algorithm is improving the 
diagnosis of PAH in SSc [15]. The first step used in the DETECT study is to test 
patients for telangiectasia, anticentromere antibodies, right axis deviation on 
electrocardiogram, and reduced diffusing lung capacity for carbon monoxide 
(DLCO) and important serum biomarkers, urate and N-terminal pro–B-type 
natriuretic peptide (NT-proBNP). The second step in this study is the use of 
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echocardiography in patients with increased risk, followed by RHC to determine if 
the patient has PAH. Using this methodology, the number of missed PAH cases was 
4% compared with 29% previously reported leading to earlier diagnosis and better 
treatment for patients [15]. 
1.1.3 Pathophysiology of PAH 
PAH is characterised by excessive pulmonary vasoconstriction and vascular 
remodelling that can lead to the formation of concentric lesions, reduced blood flow, 
right heart failure and ultimately death. Alteration in cellular processes can 
contribute to this remodelling, altered proliferation and apoptotic resistance occurs in 
both endothelial cells and vascular smooth muscle cells (VSMCs) [16, 17]. It is also 
believed that changes in the microenvironment by increased secretion of the pro-
inflammatory cytokines interleukin-6 (IL-6) and interleukin-8 (IL-8), increased 
levels of platelet derived growth factor two B chains (PDGFBB) and connective 
tissue growth factor (CTGF) may all contribute to the differentiation of pulmonary 
arterial smooth muscle cells (PASMCs) from a healthy to a disease relevant cell [18-
20]. These changes in the microenvironment can induce these altered cellular 
responses and the production of extracellular matrix (ECM) [21]. The fibroblast also 
acquires a myofibroblast phenotype that exhibits increased proliferation and 
migration, these altered responses contribute to cells migrating and proliferating into 
the lumen of the pulmonary artery [22]. In healthy individuals there is a tightly 
regulated balance of locally released and circulating constrictive and dilatory agents. 
However in PAH, there is a rise in the levels of vasoconstrictors, for example 
endothlein-1 and serotonin and a decrease in vasodilators, for example 
prostaglandins and nitrous oxide [23].  
It is also believed that the impact of BMPRII mutations and or a reduction in the 
receptors functionality can also contribute to remodelling. PASMCs isolated from 
control donors undergo apoptosis in response to bone morphogenetic protein (BMP) 
2, 4 and 7 however patients harbouring BMPRII mutations are resistant to apoptosis 
[24]. It has also been reported that proliferation responses in PASMCs from HPAH 
patients and in the BMPRII (+/-) mouse model are altered. BMPRII reduction 
consistently conferred insensitivity to growth inhibition by transforming growth 
factor-beta 1 (TGF-β1) in both models in this study [17]. In comparison to PASMCS, 
BMP4 induced migration and tubule formation in endothelial cells, in PAH it is 
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hypothesised that survival of endothelial cells leads to occlusion of the lumen in the 
artery and the formation of concentric rings [25]. It has been shown that BMPs 
protect endothelial cells from apoptosis suggesting that a reduction in BMPRII 
contributes to the early endothelial dysfunction in PAH [26]. All of these different 
factors ranging from cellular switching, secretion of cytokines and altered cellular 
responses contribute to pathogenesis and development of PAH in patients. 
1.1.4 The genetics of PAH 
The genetics of PAH is constantly evolving with a host of germline mutations being 
reported to date. Initial work in the 1990s and early 2000s highlighted that altered 
BMPRII signalling is a major risk factor for the development of PAH via BMPRII 
gene mutations [27, 28]. The exact rate of BMPRII mutations in the general 
population is not known but it is believed to be quite low, in HPAH it is reported that 
around 70% of patients display BMPRII mutations. BMPRII mutations are also 
reported in IPAH and around 15% of IPAH patients have BMPRII mutations [27]. 
These studies highlighted the importance of the TGFβ superfamily and signalling 
and focused future studies to investigate this pathway in more detail. These genetic 
studies also highlighted that ALK-1, endoglin and Smad 9 mutations are also linked 
to the development of PAH and all of these mutations are members of the TGFβ 
superfamily.  
The development of screening technologies has also led to the discovery of other 
mutations  associated with PAH, for example the KCNK3 gene (Potassium channel, 
subfamily K, member 3) and the caveolin-1 gene (CAV-1) [27, 29]. The number of 
CAV-1 mutants with PAH is low but there is still an association and increased risk 
of developing PAH. Interestingly a reduction of caveolin-1 expression has been 
previously reported in the lungs of PAH patients and caveolin-1 has been reported to 
alter TGFβ signalling and reduce BMPRII signalling [30]. This mutation again 
highlights the importance of the TGFβ superfamily in the development of PAH. 
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Group 1: 
Pulmonary 
arterial 
hypertension 
(PAH) 
Idiopathic (IPAH)  
Heritable (HPAH)  Bone morphogenetic protein 
receptor type 2 (BMPR2) 
Activin receptor-like kinase 1 
gene (ALK1), endoglin 
Unknown 
Drug- and toxin-induced  
Associated with (APAH) Connective tissue diseases 
Persistent pulmonary 
hypertension of the new-born 
(PPHN) 
Human immunodeficiency virus 
(HIV) infection 
Portal hypertension 
Congenital heart disease (CHD) 
Schistosomiasis 
Chronic haemolytic anaemia  
Group 2: PH due to left heart diseases 
Group 3: PH due 
to lung diseases 
and/or hypoxia 
Chronic obstructive 
pulmonary disease (COPD) 
 
Interstitial lung disease (ILD)  
Sleep-disordered breathing  
Alveolar hypoventilation 
disorders 
 
Chronic exposure to high 
altitude 
 
Other pulmonary diseases 
with mixed restrictive and 
obstructive pattern 
 
Group 4: Chronic thromboembolic PH (CTEPH) 
Group 5: Haematological disorders 
 
Table 1.1 The Nice 2013 disease classification of pulmonary hypertension 
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1.2 Scleroderma 
Systemic sclerosis (SSc), also referred to as  scleroderma is a complex 
heterogeneous autoimmune disease characterised by autoantibodies and pathological 
remodelling of connective tissues, which affects the skin and internal organs [18]. 
The most evident signs of SSc are manifested in the skin and it is to this that the 
disorder owes its original name, scleroderma (Greek: skleros, hard, and derma, skin). 
The most commonly adopted clinical classification for SSc is based upon the extent 
of clinical involvement of the skin, serological markers and natural history 
associations [31]. Clinically affected areas of skin are often referred to as involved, 
and regions clinically unaffected on the same patient as uninvolved. The 
classification based on skin involvement essentially divides the systemic disease into 
limited cutaneous SSc (lcSSc) and diffuse cutaneous SSc (dcSSc). In lcSSc fibrosis 
is mainly restricted to the extremities; whereas in dcSSc the skin involvement is 
more widespread, affecting the trunk as well as the hands, face and feet [32].  
Pathologically SSc is divided into several processes: 1) microvascular injury; 2) 
inflammation and the development of autoantibodies; 3) accumulation of ECM and 
tissue fibrosis; 4) atrophy. Tissue fibrosis is almost universally preceded by 
microvascular dysfunction and inflammation in the development of the disease 
suggesting these phases represents an early stage in the disease process [32]. In SSc 
patients virtually all organ systems can be affected by fibrosis to varying degrees, 
however of major clinical significance are the heart, gastrointestinal tract, kidneys 
and lungs (Figure 1.1). 
1.2.1 Auto-antibodies in SSc 
Autoantibodies are present in the majority of patients with SSc, and may be used as 
an important diagnostic tool. Three major autoantibody groups anti-topoisomerase I 
(ATA), anti-centromere (ACA) and anti-RNA polymerase (ARA), have been 
described to be associated with different forms of SSc [33]. For example patients 
with ATA are associated with dcSSc [34], whereas ACA are more commonly 
associated with lcSSc patients [35]. A host of autoantibodies specific to SSc have 
been reported to be associated with, but not unique to, PAH, including ACA and 
anti-U3 ribonucleoprotein [36]. 
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1.2.2 Epidemiology 
The prevalence of SSc ranges from 30 to 300 cases per 1 million persons, and the 
incidence ranges from 2.3 to 22.8 cases per 1 million per year. Women are also at 
much higher risk of developing SSc than men with a slight increase in susceptibility 
for those of African heritage [32]. The overall survival rate in SSc patients is 60-83% 
at 5 years and 40-75% at 10 years depending on disease subset [37]. The cumulative 
frequencies of organ based complications from a cohort of SSc patients at the Royal 
Free are shown in Figure 1.1. A major cause of mortality currently associated with 
SSc patients are pulmonary complications, including pulmonary fibrosis (PF) and 
PH (Figure 1.1). The incidence of pulmonary fibrosis is significantly higher in dcSSc 
compared to lcSSc, whereas the incidence of PH is comparably in both disease 
subsets [38]. 
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Figure 1.1. Organ based end-points in scleroderma (SSc) disease sub-sets: 
Kaplan Meir one minus survival curve of organ based complications in SSc, 
Adapted from [38].  
These graphs highlight the cumulative incidence organ based complications 
including pulmonary fibrosis (PF, blue), pulmonary hypertension (PH, red), 
scleroderma renal crisis (SRC, purple) and cardiac SSc (green) in diffuse cutaneous 
systemic sclerosis (dcSSc) and limited cutaneous systemic sclerosis (lcSSc). 
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1.2.3 Pathophysiology of SSc 
The pathophysiology of SSc is quite a complex process with vascular injury causing 
increased production of pro-inflammatory cytokines, for example interleukin-1 beta 
IL-1, IL-6, IL-8 and growth factors like CTGF and type-1 collagen have all been 
previously reported to be elevated in SSc [39-43]. The changes in the 
microenvironment contribute to altered cellular responses and excessive deposition 
of ECM which can disrupt the tissue’s architecture and phenotype leading to the 
development of fibrosis and atrophy [32]. SSc patients can develop complications in 
a host of different organ systems (Figure 1.1). The excessive deposition of ECM 
proteins that leads to fibrosis, the loss of tissue architecture, and ultimately the loss 
of function is also seen in the skin of patients. In the skin, fibrosis is initiated in the 
lower dermis and upper subcutaneous layer and leads to a decrease in appendages in 
the skin, loss of microvasculature and loss of reticular structure. The dermis is 
thickened in SSc due to the excessive accumulation of ECM [44]. The main focus of 
our work is based around pulmonary complications and the development of PAH in 
patients with SSc. 
1.2.4 Vascular changes 
Vascular injury represents the earliest disease manifestation in SSc, and consists of 
endothelial cell damage and the recruitment of leukocytes. Causing inflammation 
through the release of inflammatory mediators such as tumour necrosis factor-alpha 
(TNF-α), the release of degradative enzymes including matrix metalloproteinase 
(MMPs) and the production of reactive oxygen species [45]. A significant number of 
SSc patients exhibit vascular abnormalities; for example, Raynaud’s phenomena is 
present in over 90% of SSc patients [46]. Vasculopathy can affect a number of 
tissues, including the digital vascular bed (digital ulcers), the kidney (SRC) and lung 
(PAH) [47]. In fibrotic human skin apoptotic endothelial cells have been detected in 
the inflammatory stage of disease [48]. Anti-endothelial cell antibodies, present in 
the serum of SSc patients, induce endothelial cell apoptosis in-vitro and may 
represent a link between immune dysfunction and vascular damage [48]. 
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1.3 Pulmonary complications in SSc  
Pulmonary complications of SSc are the leading cause of mortality in SSc. The 
major pathological complications associated with the lungs of SSc patients are PF 
and PH. 
1.3.1 Pulmonary fibrosis in SSc 
PF is observed in dcSSc and lcSSc with higher incident rates observed in the dcSSc 
group [38]. PF is characterised by excessive deposition of ECM proteins in the 
interstitium [18], and the loss of alveolar spaces and tissue architecture thereby 
preventing efficient gas exchange. It is a progressive disease which eventually leads 
to respiratory failure and premature death [49]. Idiopathic pulmonary fibrosis (IPF) 
is another form of fibrosis in the lung, IPF has a poor median survival from 
diagnosis of 3-5 years and an incidence in the United Kingdom of 4.6 per 100,000 
people, and quite astonishingly the incidence between 1991 and 2003 increased each 
year by 11% [50] 
Increased expression of proteoglycans and fibrillins are typical observed in the early 
stages of fibrosis whilst in later stages, type I collagen is the archetypal marker [32]. 
A key cell in the development of fibrosis is the fibroblast. Activation of this cell type 
plays a major role in the excessive deposition of ECM including fibronectin and 
collagen type I [18]. Activated fibroblasts present in wound healing are termed 
myofibroblasts and the activation of a fibroblast to a myofibroblast is potently 
induced by mediators such as TGF-β and PDGFBB which are two factors that are 
upregulated in SSc [51]. Interestingly, the kinase-deficient human type II TGFβ 
receptor (TβRIIΔk-fib) murine model, which has perturbed TGFβ signalling in 
explants of dermal and lung fibroblasts, represents a model of SSc exhibiting clinical 
and biochemical similarities to SSc patients [52-57]. 
1.3.2 Pulmonary hypertension in SSc 
PH is defined as elevation in the blood pressure in the arties of the lung; greater than 
25 mmHg at rest and is sub-divided into a number of groups. PAH (Group 1) results 
from specific vascular changes in the structure of vessels that in turn leads to the 
enhanced pressures. In contrast, the development of PAH associated to other 
underlying pathologies, such as the connective tissue diseases can be far more 
complex. SSc patients may develop elevated pulmonary pressures as a result of 
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clinically significant (20% of lung is fibrotic) PF, termed PH-SSc (Group 3; Table 1) 
or independently of major pulmonary fibrotic complications termed SSc-PAH 
(Group 1; Table 1). It is currently considered that around 15% of SSc patients 
develop PAH (Royal Free cohort). The overall prevalence of all types of PAH is 
estimated to be 30-50 cases per million [58]. Of these, the HPAH form of PAH 
represent a relatively small component of cases, 2-3 per million per year [58, 59]. 
The incidence of all PAH has been estimated to be between 6-60% of all patients 
[60]. SSc-PAH exhibits similar pathological changes to other forms of PAH 
including excessive pulmonary vasoconstriction, vascular remodelling and occlusion 
of the lumen and the occurrence of plexiform lesions [16, 61]. These processes that 
affect the intima, media and adventitia, lead to the narrowing of the lumen. These 
changes are associated with cellular changes in smooth muscle cell morphology, 
apoptosis of endothelial cells and proliferation of vascular cells including PASMCs 
endothelial cells and fibroblasts [16]. Collectively these processes lead to the 
narrowing and occlusion of the pulmonary arterioles.  
Survival studies have shown patients with SSc-PAH have a particularly poor 
prognosis compared to those with PAH alone, with 1-year survival estimated at 55% 
compared to 84% in HPAH patients [62, 63].  
1.3.3 Treatment of pulmonary fibrosis in SSc 
Pulmonary fibrosis occurs in 48% of dcSSc and 25% of lcSSc patients and their 
prognosis is poor [38]. Immunosuppressive therapy is selected for patients with 
severe and progressive PF, cyclophosphamide is one drug of choice and has been 
shown to improve patient’s forced vital capacity (FVC) and mycophenolate mofetil 
also exhibits efficacious results in patients with SSc-ILD [64-66]. Other therapies of 
choice are N-acetylcysteine, this drug has exhibited beneficial effects when added to 
standard treatment of azathioprine and prednisone, compared to that treatment alone. 
In end-stage cases and severe disease, lung transplantation can be considered [67-
69]. Until recently there was no treatments have been approved for pulmonary 
fibrosis recent clinical trials have shown that pirfenidone and nintedanib has had 
significant improvements for patients [70]. Pirfenidone is a novel anti-fibrotic, anti-
inflammatory drug that has demonstrated efficacy and safety in IPF patients. The 
mechanism of this drug is not completely understood but it is believed it exerts its 
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action by inhibiting fibroblast proliferation. Nintedanib is a tyrosine kinase inhibitor 
that has also been approved for the treatment of IPF patients [71]. 
1.3.4 Treatment of pulmonary hypertension in SSc 
Survival studies have shown patients with SSc-PAH have a particularly poor 
prognosis compared to those with PAH alone, with 1-year survival estimated at 55% 
compared to 84% in HPAH patients [62]. General treatment of the PH involves 
diuretics, anticoagulation, oxygen and Digoxin for the treatment of heart failure with 
exercise also proving beneficial [72]. The specific therapies available to patients are 
divided into three main classes the phosphodiesterase-5 inhibitors (sildenafil and 
tadalafil), endothelin receptor antagonists (bosentan, ambrisentan and recently 
macintentan) and the prostanoids (iloprost and treprostinil) [73]. 
 1.4 Vascular muscularisation in the development of PAH 
A cardinal feature of SSc-PAH is the remodelling of blood vessels that leads to the 
occlusion of the vessel and contributes to a rise in pulmonary pressures [74]. The 
migration and proliferation of -SMA positive cells including both fibroblasts 
(myofibroblasts) and PASMCs are the main mediators of pulmonary vascular 
remodelling.  
1.5 The fibroblast in SSc 
The connective tissue confers a structural scaffold that facilitates organ function. 
Composed of ECM, the most common cell found in the connective tissues are 
spindle shaped cells termed ‘fibroblasts’. These cells express vimentin, but not 
desmin or α-SMA are found in the majority of organs, and are essential for 
connective tissue homeostasis [75]. An imbalance in the deposition of ECM proteins 
including collagen type I and III leads to the pathological changes observed in SSc. 
Fibroblasts are highly active cells and each cell synthesises approximately 3.5 
million pro-collagen molecules per cell per day [76]. Fibroblasts regulate matrix 
turnover through the expression of MMPs, which degrade ECM, and inhibitors of 
MMPs - tissue inhibitors of metalloproteinases (TIMP). Consistent with increased 
ECM deposition in SSc patients, serum levels of TIMP in dcSSc and lcSSc are 
significantly raised compared to healthy controls [77]. This supports the hypothesis 
that fibroblast regulated matrix accumulation occurs through an imbalance in 
turnover of the ECM and this plays a pivotal role in SSc [77].  
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Fibroblasts are also key contributors to fibrosis in patients with SSc. In healthy 
individuals fibroblasts are protected from stress by the surrounding ECM, during 
connective tissue diseases the damaged fibroblasts are no longer protected causing 
the fibroblasts to attach to the ECM [78]. Upon tissue injury, fibroblasts migrate 
towards the wound and due to the presence of growth factors released by immune 
and blood cells the fibroblasts differentiate into a secretory myofibroblasts that are 
involved in repair during wound healing [18]. 
1.5.1 Fibroblast to myofibroblast transition 
In response to tissue injury mesenchymal cells of fibroblastic lineage accumulate at 
the wound site and deposit and remodel new ECM and contract the wound site. The 
main fibroblastic cells responsible for this process are termed myofibroblasts and 
exhibit specific markers and phenotypic properties that are suited to this role. 
Normally as wounds repair and resolve myofibroblast are lost from the site of injury, 
whereas in fibrotic pathologies such as SSc, they remain [79-83]. The persistent and 
accumulation of large numbers of myofibroblasts in connective tissues is responsible 
for the exaggerated and uncontrolled production of ECM during the development 
and progression in fibrotic pathologies such as SSc [75, 80]. Myofibroblasts can 
arise from resident fibroblasts in a process termed fibroblast to myofibroblast 
transition or fibroblast to mesenchymal transition (FMT) as shown in Figure 1.2 
[75]. More recently it has become recognised myofibroblasts can arise from different 
cellular sources, including pericytes, smooth muscle and epithelial cells via a number 
of biological processes.  
Histological analysis of SSc skin has shown an abundance of myofibroblasts 
involved in lesional skin and fibrotic areas of the visceral organs from SSc patients 
[75, 84]. Gene expression profiling studies demonstrate a number of genes are 
differentially regulated in wound healing fibroblasts to those derived from fibrotic 
regions of SSc patients [85]. Furthermore, comprehensive transcriptional analysis of 
skin biopsies has demonstrated differences in the gene expression profile of dermal 
fibroblasts from SSc patients into subsets including inflammatory and TGF gene 
signatures [86, 87]. The different gene expression profiles exhibited by fibroblasts 
from SSc patients may reflect the diverse origins of the cells that contribute to the 
formation of myofibroblasts. It remains unclear if SSc fibroblasts arising from these 
diverse cellular pools will respond to similar therapeutic interventions, and future 
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studies will be needed to explore the relevance to the pathological development of 
fibrosis in SSc patients [88-90]. 
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Figure 1.2 – The cellular origins of ‘activated’ fibroblasts and myofibroblasts  
Myofibroblasts may arise from a number of cellular sources. The differentiation and 
activation of tissue resident cells: Fibroblast to, myofibroblast transition (FMT); 
Endothelial to Mesenchymal Transition (EndoMT); Epithelial to Mesenchymal 
Transition (EMT); Pericyte to Mesenchymal Transition (PeMT); Smooth muscle cell 
differentiation. The recruitment and differentiation of circulating bone marrow 
derived cells (BMDC) and fibrocytes may also contribute to the myofibroblast 
population.  
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1.5.2 Positional identity of fibroblasts – relevance to SSc 
Fibroblasts isolated from different tissues display similar morphology, however 
exhibit diverse functional properties. For example, the capacity of fibroblasts from 
different anatomical sites to migrate, or express extracellular matrix proteins varies 
[91]. These differences are consistent with the wide variety of biological and 
physical environments these cells are found in. Chang et al elegantly highlighted the 
‘positional memory’ of fibroblasts in gene expression profiling studies of fibroblasts 
from a variety of anatomical sites in the adult and foetus [92]. A striking feature in 
this study was the distinct and characteristic transcriptional patterns displayed by 
fibroblasts, including genes associated with lipid metabolism, the TGF and Wnt 
cell signaling pathways, as well as fate determination [92]. This study highlighted 
the context dependent activity of fibroblasts to generate appropriate extracellular 
microenvironments. For example, foetal lung and skin fibroblasts expressed high 
levels of the basement membrane protein type IV collagen in the skin and lung 
alveoli. In contrast, skin not lung fibroblasts, expressed significant levels of type I 
and V collagen that confers the tensile strength in the dermis [92]. Consistent with 
the different anatomical environmental requirements of organs, fibroblasts exhibit 
distinct immune-modulatory effects on leukocytes including recruitment [91]. The 
mechanism(s) by which fibroblasts acquire their positional identify remains unclear; 
however it is likely epigenetic mechanisms play a significant role [18, 93]. It remains 
to be investigated if SSc fibroblasts lose their positional identity and if this in turn 
promotes the development of a pro-fibrotic environment. It is plausible that location-
specific signatures for fibroblasts and other cell types explain the diverse patterns of 
fibrosis between and within different subsets of SSc [18]. 
1.5.3 Origin of fibroblasts in SSc: resident cells, trans-differentiation, and 
circulating fibrocytes  
The origin of activated fibroblasts or myofibroblasts in fibrotic tissues was, until 
comparatively recently believed to result from the expansion and activation of 
resident fibroblasts [75, 94]. However, recent studies have highlighted the potential 
for other tissue resident and blood borne cells to contribute to the pool of 
myofibroblasts that arise in fibrotic tissues [95-97]. A number of tissue resident cells 
including endothelial, epithelial and SMCs can differentiate into fibroblast like cells 
[95, 96, 98, 99]. In addition to tissue resident cells, blood borne cells such as 
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fibrocytes also contribute to the heterogeneity of these myofibroblasts (Figure 1.3) 
[100]. 
The differentiation of resident cells has been proposed as an important mechanism 
that contributes to the development of tissue fibrosis in SSc (Figure 1.3). For 
example, endothelial to mesenchymal transition (EndoMT) was thought to be a rare 
phenomenon confined to embryonic development, however Arciniegas et al 
elegantly demonstrated the capacity of adult endothelial cells to lose vascular 
markers such as E-cadherin and acquire myofibroblast markers, including -SMA 
and type I collagen [96]. Consistent with a putative pathological role of EndoMT in 
SSc, the bleomycin murine model of pulmonary SSc suggests lung capillary 
endothelial cells have been shown to contribute to the pool of 
myofibroblasts/fibroblasts present in the bleomycin model of pulmonary SSc [95]. 
Like EndoMT, epithelial cells in a process termed epithelial to mesenchymal 
transition or EMT is induced by TGF-β [95].  
EMT has been linked to cellular differentiation and tumour invasion for a number of 
years [14]. More recently EMT has become strongly associated with renal and 
pulmonary fibrosis in pre-clinical models [101]. However, it remains contentious the 
contribution of EMT in the development of fibrotic pathologies including SSc. 
During EMT, epithelial cells down regulate epithelial markers, such as E-cadherin 
and acquire mesenchymal/myofibroblast markers including α-SMA [75, 97]. EMT, 
like EndoMT are likely to lead to significant loss of the functional capacity of these 
cells to act as biological barriers, and contribute further to the development of 
fibrosis. EMT can be induced by a number of secreted factors including TGFβ, 
CTGF and fibroblast growth factor-2 FGF-2 all of which have been implicated in 
remodelling diseases as well as SSc [102]. For example, in SSc patients TGFβ is 
elevated in serum and several studies have demonstrated activation of components of 
the canonical and non-canonical TGFβ signalling pathway. Studies from our own 
group have further highlighted a cellular link between microvascular damage and 
fibrosis via pericyte trans-differentiating into myofibroblasts (PeMT) [103]. The 
presence of activated pericytes in dcSSc skin and the capability of these cells to 
transition into myofibroblasts when activated, further support their likely 
contribution dermal fibrosis in SSc [104].   
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In addition to local precursors, circulating cells are also able to contribute to the 
myofibroblasts that populate fibrotic tissues. For example, TGFβ promotes fibroblast 
to myofibroblast transition (FMT); endothelial to mesenchymal Transition 
(EndoMT); epithelial to mesenchymal Transition (EMT); pericyte to mesenchymal 
Transition (PeMT); and smooth muscle cell differentiation. In addition ET-1 
promotes the recruitment and differentiation of circulating fibrocytes which are 
likely to contribute to the SSc fibroblast population. (Figure 1.3). Fibrocytes were 
initially described in early 1990s as blood borne collagen-producing cells, with 
antigen presenting capability [105]. Since then, they have been associated with a 
broad range of fibrosing disorders including SSc, sickle cell lung disease, asthma, 
PH and atherosclerosis, [106-110] Although the cell surface markers that identify 
fibrocytes remains ambiguous, it is widely accepted that these cells share immune 
and mesenchymal cell surface markers [111] and migrate to sites of tissue injury 
[112]. The pre-clinical bleomycin insult model, which serves as a model of SSc 
fibrosis, exhibits enhanced fibrocyte recruitment in the dermis and lung, supporting 
the notion that fibrocytes play a key role in SSc [101, 107]. Previous studies have 
demonstrated mice dosed with adenosine A2A (A2A) antagonists were protected from 
the development of bleomycin induced lung fibrosis [113]. The use of these A2A 
antagonists also halted lung fibrocyte recruitment, suggesting that these receptors are 
involved in fibrocyte recruitment and supporting the contribution of fibrocytes in the 
development of pulmonary fibrosis [107]. Consistent with fibrocyte recruitment to 
sites of tissue injury, these cells express a number of chemokine receptors, including 
chemokine receptor type 4 (CXCR4). Analysis of SSc patients demonstrated the 
presence of CXCR4+/collagen type I + cells only in SSc-ILD patients. Furthermore, 
the expressions of CXCR4, and its ligand stromal cell-derived factor 1 (CXCL12), 
were also highly upregulated in SSc lung compared to healthy controls [27]. The SSc 
lungs that overexpress CXCR4 also lack caveolin-1 (Cav-1), and display enhanced 
monocyte migration compared to controls. In the bleomycin model the use of 
caveolin scaffolding domain (CSD) diminishes fibrocyte accumulation in the lung 
and may represent a novel therapy in SSc [109]. 
The cellular origin of the mesenchymal cells that contribute to the excessive 
accumulation of ECM and loss of tissue architecture in SSc fibrosis remains unclear. 
Indeed the contribution through the cellular processes that give rise to these cells, 
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including expansion of resident tissue fibroblasts, EMT, FMT and accumulation of 
bone marrow–derived and circulating fibrocytes that have been reported may vary in 
an organ specific manner (Figure 1.3). Future studies will be required to assess the 
relative contribution and therapeutic relevance in SSc. 
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Figure 1.3 – SSc fibroblasts promote a pro-fibrotic microenvironment  
SSc fibroblasts secrete elevated growth factors, chemokines and cytokines including 
endothelin-1 (ET-1), transforming growth factor-beta (TGF) and connective tissue 
growth factor (CTGF), which promote a pro-fibrotic microenvironment that can act 
in an autocrine and paracrine manner to expand the pool of pro-fibrotic fibroblasts in 
lesions  
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1.6 Smooth muscle cells 
Vascular smooth muscle cells (VSMCs) are essential for normal vascular functions, 
and pathological changes are associated with a number of diseases including PAH 
[21, 114]. PASMCs in mature adults are predominantly involved in the contraction 
of the pulmonary arterioles and maintenance of normal blood flow and pressure [21]. 
In comparison to both skeletal or cardiac muscle which are terminally differentiated, 
VSMCs are unique due to their plasticity and their ability to undergo reversible 
changes in response to changes in stimuli from their local environment which 
normally maintain a contractile phenotype [21, 115]. 
1.6.1 Factors that contribute to SMC differentiation in SSc-PAH 
In adults SMCs can adopt two different phenotypes known as contractile and 
synthetic SMCs and it is believed that these PASMCs play a key role in vascular 
remodelling in SSc-PAH [16]. PASMCs play an essential role in the maintenance of 
the vasculature [16]. Under normal circumstances PASMC are maintained in a 
contractile phenotype, however under pathological conditions these cells may de-
differentiate into a synthetic phenotype. Contractile and synthetic SMCs differ in 
their cellular activities. For example, contractile SMCs are less proliferative and 
migratory than synthetic SMCs [21], whereas synthetic SMCs deposit more matrix 
proteins such as collagen-type I [21]. The switching of a contractile SMC to a 
synthetic cell type plays a key role in PAH by promoting vascular remodelling and 
occlusion of the vessel [21]. The maintenance of a healthy contractile cell is 
determined by a host of factors including hypoxia, cell-to-cell contact, growth 
factors and cellular injury. It has been previously highlighted that BMPs promote a 
contractile SMC phenotype which is characterised by the up-regulation of the 
contractile marker α-SMA; while the addition of PDGFBB in culture to PASMCs 
reduces the expression of α-SMA promoting a synthetic SMC phenotype (52). In 
HPAH, 70% of patients have mutations in the BMPRII gene (53), which leads to a 
reduction in the expression of functional BMPRII receptors on the cell surface and 
reduced responsiveness to BMP ligands. This dysregulation of BMP signalling in 
patients with HPAH is likely to play a role in the normal homeostasis of PASMCs 
and their phenotypic modulation promoting differentiation from a contractile to 
synthetic phenotype [20]. 
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1.7 Animal models of SSc 
1.7.1 Transgenic models of SSc 
A number of animal models have been extensively used to explore the pathological 
mechanisms of SSc, perhaps the most well studied being the bleomycin insult model 
and the tight skin mouse (TSK; Table 1.2). However these models lack the 
pathological changes associated to SSc-PAH. More recently a number of transgenic 
models have sought to recapitulate the systemic features of SSc. A transgenic model 
is a model that has been genetically modified, for example by the transfer of a gene 
to create a phenotype that is similar to a disease of interest. Genetics in biology is the 
study of genes and genetic variation in organisms. The alteration of gene expression 
in transgenic models similar to genetic mutations in humans can lead to the 
development of disease. For example the TβRICA/Cre-ER and TβRIIΔk-fib 
transgenic mouse models have sought to modulate the TGFβ pathway and exhibit 
many of the pathophysiological changes observed in SSc patients (Table 2). The fos-
related antigen (FRA-2) [116] and TβRIIΔk-fib transgenic mouse models of SSc 
develop pulmonary vasculopathies independently of pulmonary fibrosis, and thus 
represent a Group I SSc-PAH model. In contrast the bleomycin model develops 
raised right ventricular systolic pressure (RVSP) as a result of pulmonary fibrosis 
and more closely represents a more Group 3 PH-SSc model [117]. 
The TβRIIΔk-fib transgenic mouse model expresses, under the control of the 
collagen 1α2 enhancer/promoter, a kinase-deficient TβRII gene. These animals 
exhibit a paradoxical enhancement in TGFβ signalling, including activation of the 
canonical Smad signalling pathway, Smad2/3 [52]. Consistent with the observed 
phenotype of the TβRIIΔk-fib transgenic mouse model, Loeys-Dietz syndrome 
patients who possess TβR-II mutations exhibit increased expression of collagen and 
CTGF, as well as increased phosphorylated Smad2 in the nuclei, which is indicative 
of increased TGFβ signalling [118]. 
The TβRIIΔk-fib transgenic mice exhibit increased expression of latent TGFβ in the 
ECM and develop dermal fibrosis, as well as fibrosis in a number of internal organs, 
including the gut and lung [54, 57]. Furthermore, intratracheal administration of 
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bleomycin to these mice induced the appearance of myofibroblasts, and increased 
apoptosis of type II alveolar epithelial cells [55]. Interestingly these mice exhibit 
vascular defects in the lung independently of pulmonary fibrosis [56].  
The administration of SU5416 (a VEGR2 antagonist) further enhanced the 
vasculopathy of this model including more severe vascular remodelling and a further 
enhancement in RVSP [119]. SU5415 also contributes to a further increase in TGFβ 
activity with increased phosphorylated Smad2/3 positive nuclei similar to that 
observed in PAH patients. Collectively this suggests the TβRIIΔk-fib transgenic 
mouse model may represent a good model to understand the molecular mechanisms 
that contribute to the development SSc-PAH. 
The FRA-2 transgenic mouse model is another model of SSc that exhibits a 
pulmonary vasculopathy. These mice also exhibit dermal and lung fibrosis which is 
highlighted in histological studies by an increase in ECM (Table 2.1). FRA-2 is also 
overexpressed in patients with pulmonary fibrosis and this suggests that this model is 
representative of this cohort of patients [120]. In another study the FRA-2 mice were 
used alongside the chronic Graft versus Host disease (cGvHD) and tight skin 1- 
mutation (TSK-1) models to determine the best model of cardiac complications in 
SSc patients. Histological analysis highlighted accumulation of collagen in the hearts 
of SSc patients and FRA-2 mice in comparison to no rise in collagen expression in 
the cGvHD and Tsk-1 models suggesting the FRA-2 model better represents cardiac 
complications in SSc [121].  
The Cav-1 transgenic mice are another example of murine model of SSc and these 
mice develop skin and lung fibrosis due to Cav-1 deficiency as highlighted in (Table 
1.1). The loss of caveolae leads to the initiation of fibrosis that is observed 
histologically in the lungs with marked hypertrophy of type II pneumocytes [122, 
123].  
In terms of all the transgenic models of SSc, each individual model offers different 
platforms for different cohorts of patients. The FRA-2 mouse seems to replicate the 
best model for cardiac complications in SSc with these mice displaying loss of 
capillaries due to endothelial cell apoptosis similar to patients [121]. But the 
TβRIIΔK model of SSc and SSc-PAH is a representative model of patients with SSc-
PAH due to similarities observed in vascular remodelling and pulmonary 
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vasculopathy [119]. Due to the heterogeneity of SSc each model offers differential 
benefits depending on the disease characteristics each patient displays.  
1.7.2 Spontaneous models of SSc 
The TSK models, TSK has a spontaneously occurring dominant mutation of the 
fibrillin-1 gene which results in a partial inframe duplication of fibrillin-1 leading to 
an altered phenotype that exhibits skin and lung fibrosis. In the skin cutaneous, 
fibrosis is observed and the mice also produce autoantibodies to SSc specific 
antigens [124]. Interestingly a genetic study identified single nucleotide 
polymorphisms (SNPs) in the fibrillin-1 gene in Japanese and Choctaw populations 
that increased the risk of developing SSc [125]. Microarray studies comparing the 
TSK-1 mouse to WT controls showed no difference in pro-fibrotic genes, nor 
activation in the TGFβ axis suggesting there is some weakness in this model [126]. 
A recent comparative study between TSK-1 and WT mice, exhibited an increase in 
collagen in the hearts of TSK-1 mice compared to WT. Interestingly, the collagen 
content of hearts from TSK-1 and WT males was amplified in comparison to their 
relative female mice. However no significant differences in collagen content were 
observed in the lung or kidney between the TSK-1 and WT mice [127]. The TSK2/+ 
mouse has also been proposed as a murine model of SSc. These mice only 
demonstrate skin fibrosis (Table 1.1), which can be seen by increased collagen 
synthesis and accumulation in the dermis. There is also evidence of mononuclear cell 
infiltration into the dermis of these mice. Furthermore, the TSK2/+ mouse has 
numerous auto-antibodies within its plasma, some of which are common to patients 
of SSc [128]. 
1.7.3 Chemical injury models of SSc 
The bleomycin model is a model of skin and lung fibrosis and also a model of PH-
SSc [117, 129, 130]. The bleomycin model is one of the most extensively used 
models in SSc research and provides many of the key features associated with SSc. 
This model exhibits both skin and lung fibrosis (Table 1.1) depending on the route of 
administration of the bleomycin. The administration of repeated subcutaneous 
injections of bleomycin leads to a model of skin fibrosis that recapitulates many key 
features of SSc: increase in collagen deposition, vascular thickening and 
inflammatory infiltrates [131]. It was also observed that there was an upregulation of 
TGFβ receptors and a rise in cytokines like IL-6 in serum [131]. The administration 
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of intratracheal bleomycin induces lung fibrosis in mice. Histological analysis of the 
lung highlighted an increase in collagen content and an increase in inflammatory 
infiltrate [132]. It has also been published that bleomycin induced lung fibrosis leads 
to enhance RVSP and a reduction in BMPRII levels suggesting it represents a strong 
model of PH-SSc as well as SSc alone [133].  
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Table 2.1. Murine models of SSc fibroblast dysfunction: Comparison of mouse 
models of SSc that exhibit fibroblast driven pathophysiology.  
 Model Skin Lung Kidney Heart Gut Vessels 
S
S
c 
M
u
ri
n
e 
M
o
d
el
s 
Transgenic 
TβRIIΔK   [52]  [52]    
[57] 
 [56] 
TβR1CA;Cr
e-ER  
 [134]  [134]  [134]    [134] 
COL1α2- 
CTGF 
 [135]  [135]  [135]    [135] 
Fra-2   [120]  [120]   
[121] 
  
Caveolin-1   [123, 
136] 
 [123, 
136] 
   [123, 136] 
Relaxin   [137]  [137]  [137]  
[137] 
  
Wnt10b  [138]      
Spontaneous 
Tsk-1   [124]  [124]     
Tsk-2  [128]      
Insult models 
Bleomycin   [131]  [95]     
HCLO   [139]  [139]     
 
TβRIIΔK, Kinase deficient type-II transforming growth factor-β receptor mice. 
TβR1CA Cre-ER, constitutively active transforming growth factor-β receptor 1 
mice. COL1α2-CTGF, Collagen type-1,alpha-2,connective tissue growth factor 
mice. Fra-2, fos-related antigen 2 transgenic mice. Caveolin-1, caveolin-1 deficient 
mice. Relaxin, relaxin knockout mice. Wnt10b, Wnt10b overexpressing mice. Tsk-
1, tight-skin mice 1. Tsk-2, tight skin mice 2. HCLO, hypochlorous acid. 
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1.8 Animal models of pulmonary hypertension 
A number of rodent models have been developed to model the development of 
pulmonary hypertension, the most commonly used models are the monocrotaline 
(MCT), the chronic hypoxic model and the combination of hypoxia and the systemic 
administration of the tyrosine kinase inhibitor, SU5416 (Sugen; Sigma 
Chemicals,UK) to C57BL/6 mice maintained in hypoxia. All of these models have 
been shown to recapitulate many of the features of PAH [140, 141]. 
1.8.1 Chronic hypoxia 
Chronic hypoxia (10% O2) is a common model of PH, both normobaric and 
hypobaric hypoxia and has been used to induce PH in many different animals 
including murine, rodent and bovine models [142-145]. The hypoxia model is a 
robust model of PH and shows high reproducibility between age matched animal 
strains however there is inter species variation [144]. The most common models used 
for PH research are the mouse and rat models, where the rodents are exposed to 
hypoxia for 21 and 14 days, respectively. These models display muscularisation and 
expansion of α-SMA positive cells, myofibroblasts and SMCs [144, 146]. The 
changes in the microenviroment induced by chronic hypoxia leads to hyperplasia and 
anti-apoptotic features in SMCs [147-150]. BMP ligands play a key role in 
regulating apoptosis in the pulmonary artery and the reduction of BMPRII at both a 
protein and gene level contributes to apoptotic resistance in SMCs, because BMP 
ligands are unable to induce their normal apoptotic effect [151]. In concordance with 
a reduction in BMPRII, an increase in plasminogen activator inhibitor-1 (PAI-1) 
gene expression is observed in the lung and histological analysis also shows a rise in 
phosphorylated Smad 2/3 levels, which is indicative of enhanced TGFβ signalling 
[146]. Direct comparisons between the hypoxia and MCT model have suggested that 
the MCT model exhibits a more exacerbated response with greater TGFβ activity 
and reduction in BMPRII [146]. These features are similar to what is observed in 
PAH patients with a reduction in BMPRII expression and enhanced phosphorylated 
Smad2/3 levels observed in muscularised vessels and concentric lesions [152].  In 
terms of muscularisation there is a rapid increase in thickening of the pre-capillary 
pulmonary arteries due to the expansion and hypertrophy α-SMA positive cells. It is 
also believed that this model is a pro-inflammatory model with an increase in 
cytokines and mononuclear inflammatory cells observed in the lung [153]. It has 
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been noted that there is thickening in the larger proximal arteries are observed in rats 
and after 2 weeks there is approximately a doubling in RVSP with very little studies 
reported RV failure [154]. Although this model recapitulates some features of PH, 
there is very little endothelial dysfunction observed akin to patients with severe PH, 
so a double hit model involving hypoxia and agents that induce endothelial 
dysfunction were investigated. 
1.8.2 Sugen/hypoxia model 
The sugen/hypoxia model is a recently developed model of severe pulmonary 
hypertension with enhanced vessel musculurisation and endothelial cell dysfunction 
compared to hypoxia alone [141, 155]. The addition of a vascular endothelial growth 
factor (VEGF) receptor antagonist sugen to the hypoxia model led to endothelial 
dysfunction due to uncontrolled proliferation of endothelial cells [140]. Hypoxia 
alone caused expansion of -SMA positive cells but in combination with sugen more 
profound muscularisation was observed. The first study using this model was 
reported by Taraseviciene-Stewart et al and this pilot study investigated different 
dosing regimens of sugen to initially optimise the model [140]. Sugen was 
administered as a single dose 200 mg/kg at the commencement of the experiment or 
multiple doses of 200 mg/kg or 20 mg/kg once weekly for 3 weeks. Rats in all three 
groups exhibited a significant increase in RVSP with very little difference observed 
in each of the three groups. Histological analysis using -SMA confirmed expansion 
of smooth muscle cells and a reduction in VEGFR2 staining in and an increase in 
caspase-3 staining in the sugen/hypoxia group suggested endothelial cell death and 
dysfunction leading to muscularisation of the pulmonary artery [141]. Other studies 
using this rodent model explored signalling pathways that are relevant to patients 
with PAH. Interestingly the addition of sugen to the hypoxia model has no additive 
effect to the reduction of BMPRII induced by hypoxia but it does lead to a further 
enhancement of TGF signalling due to an increase in phosphorylated Smad2/3 and 
PAI-1 expression in whole lung [140, 141, 155] This study used mice rather than 
rats, muscularisation observed in mice was not as severe as in rats but medial wall 
thickening and concentric lesions were still observed [140]. Although some 
components of this model are shared with PAH patients, such as reduced BMPRII 
and increased TGF signalling; gene-array studies showed that modification in a 
mere four genes were shared between lungs isolated from this model and lungs from 
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patients with PAH [156]. There have been other doubts in this model as previous 
publications have reported that sugen exerts its effect on the lung alone and does not 
cause changes to other organs [144]. 
1.8.3 Monocrotaline model 
MCT, a plant alkaloid was first shown in 1967 to induce muscularisation of the small 
and medium arteries, an increase in the number of cells positive for α-SMA, in 
addition to increased pulmonary pressures of up to 80 mmHg in rats [157, 158]. 
Similarly, prolonged exposure to hypoxia induces elevated pulmonary pressures in 
both mice and rats and vascular muscularisation, although the latter is less 
pronounced in mice [144]. However, the MCT and hypoxia models lack some of the 
pathological changes observed in patients such as endothelial cell dysfunction [159]. 
There have been some reports to suggesting that there might be some endothelial cell 
dysfunction but pulmonary arterial medial hypertrophy is the main way in which the 
model has been characterised. It still remains unclear whether MCT induced 
endothelial cell damage leading to uncontrolled proliferation of SMCs or whether the 
MCT is inducing endothelial-mesenchymal transition.  These ambiguities by which  
MCT induces PH is another limitation of the model and the understanding of the 
initial endothelial cell damage leading to SMC hypertrophy needs to be better 
understood [159, 160]. There has also been report of toxicity in other organs with 
changes observed in veins, liver and kidney as well as reports of myocarditis which 
affects both the left and right ventricle [161], There has been extensive publications 
reporting that more than 30 potential treatments/agents of PH are able to reverse or 
prevent PH in the MCT model which does not recapitulate in human PH, suggesting 
further limitations as a pre-clinical model of PH [144, 161]. 
1.8.4 BMPRII knock out and hypoxia model 
As previously discussed BMPRII mutations play a key role in the development of 
some forms of HPAH and IPAH, however it has been reported that not all people 
with BMPRII mutations develop PAH [162, 163]. This suggests that BMPRII 
mutations alone do not cause PAH but they predispose patients to the development 
of the disease in combination with other factors. Since BMPRII mutations are 
important in the disease, animal models that are BMPRII centric are essential to 
recapitulate this specific cohort of patients. One group of HPAH patients have 
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heterozygous mutations in the BMPRII protein so mice harbouring this mutation 
were generated to investigate the effect of these mutations on the vasculature. 
Initially mice were generated with global deletion of BMPRII but these mice were 
not viable and lethal so heterozygous mice were used. Studies have shown that mice 
with heterozygous mutations in the BMPRII develop mild PAH and impaired 
response to hypoxia [164]. This study also compared BMPRII 
(+/-)
 with WT mice in 
normoxic conditions, showing that BMPRII 
(+/-) 
mice have an increased pulmonary 
vascular resistance and PAP, increased wall thickness of the muscularised 
pulmonary arteries and an increased number of alveolar capillary units [164]. 
However other studies using this model have not reported such differences between 
WT and BMPRII 
(+/-)
 mice questioning the robustness of this model [146].  
Other transgenic approaches have also been used because another group of patient’s 
have reported BMPRII mutations in coding and non-coding regions of the gene, and 
collectively these mutations result in lower levels of BMPRII and reduced 
functionality of the receptor. Mice expressing dominant negative forms of BMPRII, 
either a kinase-dead dominant negative form of BMPRII, or clinically relevant 
functional mutations in the BMPRII gene also develop pulmonary vascular 
remodelling and PH. BMPRII mutations are quite common in the tail domain of the 
receptor, so BMPR2
R899X
 mice are another transgenic model of PAH. Around one 
third of these mice develop increased RVSP, extensive vascular pruning, 
muscularisation of small pulmonary vessels, and development of large structural 
pulmonary vascular changes. This study reports that the phenotypic result of 
BMPRII tail domain mutations in smooth muscle causes vascular pruning leading to 
elevated RVSP [26]. This model is also associated with early dysregulation in 
multiple pathways which are relevant to PAH patients. This model could represent a 
platform for interrogating the early molecular pathways and phenotypic changes that 
contribute to the development of PAH [26].  
Conditional knock outs of BMPRII have also suggested that BMPRII plays a key 
role in vascular function in the endothelium with mice and pulmonary endothelial 
cells (PAECs) expressing reduced levels of BMPRII. These mice exhibit an increase 
in permeability in cell based assays suggesting that reduction of BMPRII is 
contributing to an increase in vascular leak and leukocyte recruitment. These mice 
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also demonstrate RV hypertrophy and some common histological defects to that of 
PAH patients [165].  
Although it is clearly evident that mutations or reduced levels of BMPRII increase 
patient’s susceptibility to the development of PAH the current animal models do not 
recapitulate disease in patients as effectively as other models. One success of these 
models is delineating that BMPRII is linked to vascular defect by contributing to a 
rise in vascular leak and the production of pro-inflammatory cytokines, for example 
IL-8. Other pre-clinical models of PAH, the Sugen/hypoxia and the TβRIIΔK 
transgenic model could also be used to investigate the role of BRMPRII in PAH. 
These models report reduced levels of BMPRII, enhanced TGFβ signalling and 
histological changes that exhibit a more representative phenotype to that of patients. 
However experts might argue that these models only recapitulate non-heritable forms 
of the disease and can’t be used for the genetic cohort of patients. 
In conclusion the MCT, chronic hypoxia, the combination of hypoxia and SU5416 
and BMPRII knock out model all represent useful tools to investigate and understand 
the development of PAH. The advantage of the hypoxia model is that the mechanism 
by which these rodents develop PAH is similar to the pathology observed in humans. 
The MCT model recapitulates many key features of the disease; however the 
addition of a chemical is a unique mechanism that is not observed in patients. The 
advantage of the SU5416 hypoxia model is that the rodents display much more 
severe muscularisation which is similar to patients, gene-array studies showed that 
modification in just four genes were shared between lungs isolated from this model 
and lungs from patients with PAH [156]. This suggests that each model has both 
advantages and disadvantages and to understand the mechanism of novel 
therapeutics in PAH more than one in-vivo model in combination with in-vitro 
studies are essential.  
 
1.8.5 TβRIIΔk-fib model of associated PAH 
As discussed in section 1.7.1 the TβRIIΔk-fib transgenic mouse model expresses, 
under the control of the collagen 1α2 enhancer/promoter, a kinase-deficient TβRII 
gene. These animals exhibit a paradoxical enhancement in TGFβ signalling, 
including activation of the canonical Smad signalling pathway, Smad2/3 [52]. 
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Consistent with the observed phenotype of the TβRIIΔk-fib transgenic mouse model, 
Loeys-Dietz syndrome patients who possess TβR-II mutations exhibit increased 
expression of collagen and CTGF, as well as increased phosphorylated Smad2 in the 
nuclei, which is indicative of increased TGFβ signalling [118]. The TβRIIΔk-fib 
model exhibits a constitutive pulmonary vasculopathy with medial thickening, a 
perivascular proliferating chronic inflammatory cell infiltrate, and mildly elevated 
pulmonary artery pressure, which resembles the chronic hypoxia model of PAH. 
The hypothesis that the TβRIIΔk-fib model is susceptible to the development of 
PAH, following the administration of SU5416 this model recapitulated many key 
features of SSc-PAH which enhanced RVSP, further expansions of SMCs and 
endothelial dysfunction leading to the development of the concentric lesions in the 
pulmonary artery [119]. Sugen also contributes to a further increase in TGFβ activity 
with increased pSmad2/3 positive nuclei similar to that observed in PAH patients. 
Collectively this suggests the TβRIIΔk-fib transgenic mouse model may represent a 
superior model to understand the molecular mechanisms that contribute to the 
development SSc-PAH. 
1.9 The TGFβ/BMP superfamily  
1.9.1 Canonical and non-canonical signalling in the TGFβ/BMP pathway 
TGFβ is the founding member of the TGFβ superfamily comprised of over 30 
peptide cytokines in mammals including activins,  [166], inhibins [167] BMPs [168], 
and TGF-βs [51]. Members of the TGFβ superfamily are characterised by a cysteine 
‘knot’ of six of these residues at the carboxyl terminal. TGFβs are synthesised by 
many cell types including macrophages and fibroblasts as large inactive precursor 
proteins, which are modified intracellularly and secreted as a latent complex [169, 
170]. Although still poorly understood several factors have been shown to promote 
the release of bioactive TGF-β from this latent complex including MMPs and 
thrombospondin-1 (TSP-1) [171] The resultant bioactive TGF-β regulates several 
hundred target genes in fibroblasts promoting a variety of cellular effects including 
proliferation and differentiation in addition to promoting matrix deposition and 
reducing matrix turnover [172]. 
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The effects of all the TGF-β superfamily members are transmitted from membrane to 
nucleus through the activation of serine-threonine (Ser-Thr) kinases (Figure 1.4). 
The TGFβ ligand binds to the constitutively active serine/threonine kinase TβRII and 
in turn TβRI (ALK5) is recruited, forming a heterotetrameric complex (59). This 
leads to the activation of the canonical Smad signalling pathway via Smads 2 and 3. 
In contrast BMP ligands bind the BMPRII receptor and in turn recruit either ALK3 
or ALK6, leading to the activation of Smads 1, 5 and 8. In addition to the activation 
of the ‘canonical’ Smad signalling pathway by members of the TGF-β superfamily, 
non-canonical’ signalling pathways include members of the mitogen-activated 
protein kinases (MAPKs), such as p38 MAPK, p42/44MAPK (ERK1/2), and c-Jun-
N-terminal kinase (JNK) are activated by members of this family (64).  
1.9.2 The TGFβ superfamily in SSc and PAH 
TGFβ has been implicated in fibrosis research for over the last decade and enhanced 
signalling and increased expression of TGFβ regulated genes and proteins have been 
extensively published in renal, lung, liver and skin fibrosis [45].    
Previous reports have highlighted that PASMCs isolated from HPAH patient’s 
exhibit a pro-proliferative response to TGFβ compared to healthy donors [17]. The 
pro-proliferative effect of TGFβ in PASMCs was also replicated in mice harbouring 
a nonsense BMPRII mutation [173]. Interestingly in SSc phosphorylated levels of 
Smads 2 and 3 are increased and more localised to the nucleus which is indicative of 
enhanced TGFβ signalling and this phenomenon is also seen in concentric lesions of 
PAH patients [152, 174]. Although no studies have investigated BMPRII expression 
in SSc lungs it has been published that BMPRII is reduced in SSc skin and 
microvascular endothelial cells, whereas there were no significant differences in the 
expression levels of BMPRIA and BMPRIB [175] suggesting a reduction in BMPRII 
may play a key role in patients with SSc developing PAH. This phenomenon of 
enhanced TGFβ signalling in PAH and SSc is also reported in pre-clinical models of 
the disease. Increased TGFβ signalling has been observed in the monocrotaline rat 
model, the hypoxia model in rodents, the hypoxia Sugen model in rodents, the 
bleomycin PH model and the aortopulomnary shunt model in lambs in concordance 
with a reduction in BMPRII levels [133, 141, 146, 176].The reduction in cell surface 
associated BMPRII levels in HPAH SMCs leads to a reduction in BMP activation of 
Smad1 and 5 and this dysregulated signalling is replicated in preclinical models [24, 
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177].This imbalance that lies in TGFβ/BMP signalling may contribute to the 
development of PAH in SSc. 
  
55 
 
 
Figure 1.4. Schematic of the direct and modifying effects of the non-Smad 
signalling pathways 
TGF-β and BMP ligand-receptor complex activates the canonical Smad signalling 
pathway (TGF-β activates Smad 2/3 and BMP activates Smad 1/5/8) and target 
genes in the nucleus (Black arrows). Non-Smad (non-canonical) signalling (p-38, 
ERK 1/2, JNK) mechanisms are shown in grey arrows. The TGF-β/BMP receptor 
complex directly activates protein A, which modulates the activity of the Smad 
pathway (A); the activated Smad complex activates protein B, which then transmits 
further signals into the nucleus (B); The TGF-β/BMP receptor complex directly 
activates protein C, which signals independently of Smads (C).  Modified from 
Moustakas et al. [178]. 
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2 Materials and methods 
2.1 Generation of genetically modified mice 
2.1.1 Generation of TβRIIΔk-fib transgenic mice 
The generation and characterisation of TRIIΔk-fib transgenic mouse model of SSc 
have been described previously by colleagues in the Department of Rheumatology 
[52, 54]. The cDNA encoding the extracellular and transmembrane portion of the 
human type II TGF receptor (comprising amino acids 24–184 of human TβRII) was 
subcloned into the Sal1 site of the pCD3 expression vector. The vector also includes 
the intron and polyadenylation signal from the murine protamine-1 gene. An internal 
ribosome entry site from the encephalomyocarditis virus was subcloned at the 5′-end 
of the Escherichia coli β-galactosidase (LacZ) gene. It was then excised as a NcoI-
ClaI fragment from the internal ribosome entry site-LacZ-containing plasmid pWH8 
and introduced into the pRM-6kb-LacZ plasmid using directional cloning between 
the same restriction sites. Progeny were backcrossed with wildtype (WT) mice to 
establish lines. Founders were previously shown to demonstrate consistent transgene 
expression in fibroblastic tissues and littermate WT C57BL/6 mice were used as 
controls [52]. 
2.1.2 Conditional genetic recombination  
Methods for conditional alteration of gene expression add further refinement to gene 
targeting. For instance in TGF gene and receptor knockouts, where constitutive 
deletion proves fatal, it allows gene targeting to occur at predetermined time points. 
The Cre-lox mechanism was discovered in the P1 bacteriophage, where the virus 
uses Cre-lox recombination to circularize and facilitate replication of its genomic 
DNA when reproducing. This recombination strategy has been developed as a 
technology for genome manipulation-commonly gene deletion occurs in mice and 
other organisms and cells. It requires the Cre recombinase enzyme to catalyse 
recombination between two loxP sites: a specific sequence consisting of an 8-bp core 
sequence, where recombination takes place, and two flanking 13-bp inverted repeats. 
Inducible postnatal deletion of TRII in fibroblasts of mice was achieved using this 
approach. 
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Figure 2.1 - Generation of TβRIIΔk-fib transgenic mice (Adapted from Derrett 
Smith, 2013).  
2.1.3 Identification of genetically modified transgenic groups. 
Neonatal pups were genotyped by polymerase chain reaction (PCR) analysis of 
genomic DNA extracted from ear-clip specimens. DNA was extracted using the 
HotSHOT DNA extraction method, 1470 μl of distilled H20 (dH20) was added to 50x 
stock solutions of - 1.25M NaOH, 10mM EDTA at pH12 (#1) and 2M Tris-HCL at 
pH2 (#2). 75 μl of #1 was added to each tube and placed in PCR machine at 95°C for 
30 minutes. 75 μl of #2 was added to #1 and mixed. 
PCR expansion of genomic DNA from TβRIIΔk-fib mice was performed using 
Qiagen fast PCR kit (Qiagen) including primers specific for the β-galactosidase 
reporter gene (5’-CGGATAAACGGAACTGGAAA-3’ and 5’-
TAATCACGACTCGCTGTATC-3’) (Sigma-Genosys, Haverhill, UK) to create a 
500 bp product, primers specific for fabpi-200 as an internal control (5’-
TGGACAGGACTGGACCTCTGCTTTCCTAGA-3’ and 5’- 
TAGAGCTTTGCCACATCACAGGTCATTCAG-3’.) with a product size of 194 bp 
and water as negative control. Amplification was undertaken by 30 cycles of 3 mins 
of annealing at 68 °C, and 20s of extension at 96°C. Samples were run on a 2% 
agarose gel in 0.5% tris, boric acid and ethylenediaminetetraacetic acid (EDTA) 
(TBE) buffer with 0.05ul/ml Sybr safe (Sigma,UK) for 60 minutes at 120V. 
Negative samples were identified by presence of 1 band corresponding to internal 
control, positive samples were identified by 2 bands, 1 corresponding to internal 
control and one to target gene when viewed under ultraviolet light (Bio Spectrum, 
AC Imaging System, CA,USA) (Figure 2.2). The water sample acted as a negative 
control and no bands appeared on the gel (Figure 2.2). 
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Figure 2.2: Genotyping results for TRIIΔk-fib transgenic mice 
2.2 Animal Procedures 
2.2.1 Animal housing 
All animals were bred in a specific pathogen free (SPF) facility and housed after 
weaning in a clean conventional colony, exposed to a 12 hour dark/light cycle, with 
access to food and water ad libitum. Strict adherence to institutional guidelines was 
practiced and full local ethics and Home Office approval were obtained prior to all 
animal procedures.  
2.2.2 In-vivo measurement of mean arterial blood pressure and right 
ventricular systolic pressure  
Ten to twelve week old TRIIΔk-fib and WT littermate mice (20–25g) were 
anaesthetised with 1.5% isofluorane and placed on a thermostatically controlled 
heating blanket at 37°C. Hemodynamic measurements of right ventricular systolic 
pressure (RVSP) and mean arterial blood pressure (MABP) were obtained from the 
animals after six weeks of hypoxia exposure and relevant drug treatment. The 
animals were anaesthetised with 1.5% isofluorane and placed supine onto a heating 
blanket that was thermostatically controlled at 37
o
C. First the right jugular vein was 
isolated and a pressure catheter (Millar mouse SPR-671NR pressure catheter with a 
diameter of 1.4F, Millar Instruments, UK) introduced and advanced into the right 
ventricle to determine RVSP. Second, MABP was measured by isolating the left 
common carotid artery and a pressure catheter introduced. Both RVSP and MABP 
were recorded onto a precalibrated PowerLab system (ADInstruments, Australia). 
The animal was euthanised via isofluorane anaesthetic overdose, the heart was 
removed, and individual chamber weights were measured to evaluate right 
59 
 
ventricular hypertrophy (right ventricle: left ventricle plus septum [RV/LV+S] ratio). 
Lungs were perfused with 10ml of saline via the right ventricle. The left lung was 
fixed by inflation with 10% formalin before paraffin embedding and sectioning. The 
whole blood was centrifuged (220 x g; 2 min), plasma removed and stored at -80
o
C 
for further analysis. All measurements were made by observers blinded to genotype 
or treatment category. These experiments were performed by Dr S Trinder, Centre 
for Rheumatology and Connective Tissue Diseases, University College London. 
 
2.2.3 Drug administration procedures 
Pharmacological agents were administered orally (in chow) or via intraperitoneally 
(IP) injection. For studies investigating endothelial stress in the pulmonary 
circulation, SU5416 (3-(3,5-dimethyl-1H-pyrrol-2-ylmethylene)-1,3-dihydroindol-2-
one: Sigma chemicals, UK), a small molecule tyrosine kinase inhibitor with 
specificity for vascular endothelial growth factor receptor 2 (VEGFR2) was 
administered IP in carboxymethylcellulose vehicle (0.5% carboxymethylcellulose  
sodium, 0.9% NaCl, 0.4% polysorbate, 0.9% benzyl alcohol in deionized water) to 
adult transgenic and wildtype littermate mice. The treatment protocol of SU5416 was 
a single injection (50 mg/kg) at the beginning of the 3 week experiment as published 
previously [140, 141].  
For studies investigating the effects of JQ1 on the TβRIIΔk-fib, Animals were fed 
with either rodent Chow #5001 mixed with JQ1 and a coloring dye to identify the 
correct formulation for each group (Ssniff, Spezialdiaten, GmbH, Soest).  The two 
formulations contained 999.392 g of Chow, 0.458 g of JQ1, and 0.15 g Green Dye to 
achieve a daily dose of 55 mg/kg or control Chow diet, 0.15 g Blue Dye.  These 
doses were calculated on the assumption that the mice would consume 2.5 g per day 
and food consumption was monitored. Animals remained on this diet every day until 
the end of the study. At day 21 mice were sacrificed and RVSP, MABP and 
RV/LV+S ratios were recorded. Hearts, lungs and serum were collected and stored 
in appropriate manner for analysis (detailed in section 2.3). 
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2.3 Sample Collection 
2.3.1 In-vivo serum collection 
Animals under terminal anaesthetia were bled from the inferior vena cava and blood 
was collected in microcentrifuge tubes. The collected blood was allowed to clot then 
spun down at 5000 pm for 5 minutes, serum removed and stored at -80°C until 
analysed. 
2.3.2 Post mortem collection 
Animals were sacrificed using increasing concentrations of CO2 and death was 
confirmed by cervical dislocation. Lungs were collected, divided and either snap 
frozen for protein analysis, immersed in 4% formaldehyde (Cell Path, UK) 
containing 10% saline for histological analysis, or stored in RNAlater for 24 hours 
before being placed in -80°C for RNA quantification. 
 
2.4 Histology 
2.4.1 Routine Histology 
Before staining, sections were de-waxed in xylene (VWR, France) and passed 
through a graded ethanol (VWR, France) series to water. Lung architecture and 
degree of inflammation was determined by staining with haematoxylin and eosin 
(H&E) as per standard protocols. Collagen deposition was detected by sequential 
staining with the Lillie-Mayer’s sequence followed by picrosirius red. Following 
staining slides were rinsed in water and dehydrated through an ethanol to xylene 
gradient and mounted with a coverslip using DPX. Staining was visualised using the 
Carl Zeiss Axio Vision microscope (Carl Zeiss GmbH, Jena, Germany). 
2.4.2 Immunohistochemistry 
Immunohistochemical analysis was performed on paraffin embedded lung sections 
from WT, TβRIIΔk-fib mice, control and scleroderma patients. Sections were 
deparaffinised using a xylene to ethanol gradient followed by rehydration, followed 
by methanol block for 10 minutes and running water for 5 minutes. Antigen retrieval 
was performed in pre heated citrate buffer (pH 6.0) for 10 minutes and slides washed 
for 5 minutes except in the case of BMPRII where antigen retrieval was performed 
by placing the slides in proteinase K (20 µg/ml in PBS, Dako,UK) for 20minutes at 
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room temperature. Slides were washed in PBS and blocked with the appropriate 
serum (20%) for 30 minutes followed by incubation in primary antibody or IgG 
control for 1 hour at room temperature (Table 2.3). PBS was repeated followed by a 
30 minute incubation of secondary antibody (Table 2.3). Sections were incubated in 
Vectastain Elite ABC (Vector Laboratories) for 30 minutes, washed in PBS before 
being incubated for up to 10 minutes in DAB Peroxidase Substrate Kit, 3, 3’-
diaminobenzidine (DAB) (Vector Laboratories). Slides were again washed in PBS 
and counterstained in Mayer’s haematoxylin for 5 minutes and then dipped in acid 
alcohol and placed in blueing solution for 5 minutes. Sections were rinsed in water 
and dehydrated through an ethanol to xylene gradient and mounted with a coverslip 
using DPX. Staining was visualised using the Carl Zeiss Axio Vision microscope 
(Carl Zeiss GmbH, Jena, Germany). 
 
Table 2.1 – Primary Antibodies used in IHC 
Antigen Species Source Catalogue No Dilution 
BMPRII Rabbit Abcam Ab78422 1:200 
Phospho-Smad 2/3 
(Ser423/425) 
Goat Santa Cruz sc-11769 1:300 
α-SMA Mouse Sigma Aldrich A2547 1:100 
Von Willebrand 
Factor 
Rabbit Dako A0082 1:200 
Phospho-Smad 1 Rabbit Abcam Ab63439 1:100 
 
2.5 Patient Samples 
2.5.1 Sample Collections 
Lung post mortem samples were collected from patients at the Royal Free Hospital 
Scleroderma Unit. Additional clinical information was determined including patient 
date of birth, age, gender and organ complications. Age and gender matched controls 
were obtained (Novartis, Horsham). Lung post mortems were sub-divided into four 
regions: One section was placed in an eppendorf tube and snap frozen in liquid 
nitrogen, and stored at -80°C for subsequent protein analysis; The second region for 
RNA extraction was stored with RNAlater™ RNA stabilisation reagent (Ambion, 
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Austin, Tx) according to manufacturer’s guidelines. The third region was immersed 
in 10% formal saline containing 4% formaldehyde (CellPath, UK) for histological 
processing. 
The final remaining portion was collected in Dubecco’s Modified Eagle Medium 
(DMEM; with 2mM L-glutamine and 1 mM sodium pyruvate; Invitrogen) and cut 
into 2-3 mm
2 
pieces  using scalpels and placed in 75cm flasks. Lung tissue was 
allowed to adhere and then covered in fibroblast growth medium, DMEM; 
supplemented with 10 % (v/v) foetal bovine serum (FBS, Biosera) and 1 % (v/v) 
Penicillin-Streptomycin (Gibco). Cells were grown in 75cm flasks in a temperature 
controlled, humidified incubator with 5% CO2 at 37°C. Outgrowths of fibroblasts 
were determined by morphological assessment and immunofluorescence staining for 
fibroblast growth factor-2 (FGF-2) were observed after 7-10 days and medium was 
changed every 2-3 days. Upon reaching 90% confluence cells were passaged using 
0.25% Trypsin-EDTA solution (Sigma). Subsequen t experiments were performed 
on cells between passages 2 and 4. Prior to being exposed to treatments fibroblasts 
were serum starved in 0.1% FCS DMEM medium (low serum). 
2.5.2 Ethical Approval and consent 
Consent forms for post mortems followed the guidelines of the NHS trusts to meet 
requirements of the Human Tissue Act (HTA) 2004. The HTA 2004 covers England, 
Wales and Northern Ireland and was formed to regulate activities concerning the 
removal, storage, use and disposal of human tissue. Consent is the main principle of 
the act and underpins the lawful removal, storage and use of body parts, organs and 
tissue. In relation to post-mortems the HTA provides the necessary guidelines to 
ensure these examinations on deceased people are treated with dignity and respect. 
These include the essential consent and communication; the coroner’s post-mortem 
examination; the hospital post-mortem examination and the relevant storage of 
tissue, tissue blocks and slides. 
 
2.6. In-vitro tissue culture 
2.6.1 Explant culture of murine lung fibroblasts  
Whole lungs were isolated from WT and TβRIIΔk-fib mice. Lungs were washed in 
Dubecco’s Modified Eagle Medium (DMEM; Invitrogen 2mM L-glutamine and 1 
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mM sodium pyruvate) and cut into 2-3 mm
2 
pieces using scalpels and placed in 
75cm flasks. Explant cultured fibroblasts were established as described in section 
2.5.1. 
2.6.2 Culture of human pulmonary arterial smooth muscle cells  
Pulmonary arterial smooth muscle cells (PASMCs) (Promocell) were maintained in 
contractile SMC medium (Promocell) supplemented with 5 % (v/v) FBS and 1 % 
(v/v) Penicillin-Streptomycin (Gibco). Smooth muscle cell (SMC) medium 
supplemented with 15% (v/v) of FBS (Biosera), which promoted synthetic smooth 
muscle cell de-differentiation. Cells were grown in 75cm flasks in a temperature 
controlled, humidified incubator with 5% CO2 at 37°C. Culture medium was 
changed every 2-3 days and cells were passaged by washing cell monolayer in 
phosphate buffered saline (PBS;Gibco) followed by trypsinisation (Sigma). 
Experiments were performed on cells between passages 3 and 6. 
2.6.3 Immunostaining of cells 
Explant cultured lung fibroblasts and PASMCs were seeded at 5 x 10
3 
cells per well 
of a four well chamber slide and grown to 40% confluence.  Cells were then fixed in 
an ice-cold methanol and acetone mixture (1:1 ratio) at -20
o
C for 4 minutes. 
Chamber slides were then washed 3 times at room temperature for one minute in 
PBS and stored at 4
o
C overnight. The following day slides were incubated for 30 
minutes in PBS containing 10% serum of the host of the secondary antibody. 
Primary antibodies were diluted in PBS as shown in Table 2.2, and 350 µl was added 
to each chamber slide and incubated overnight at 4
o
C. The following day, chamber 
slides were washed three times for 5 minutes in 0.05% (v/v) PBS-Tween (PBS-T). 
An appropriate Alexa Fluor® fluorescent secondary antibodies against primary 
antibody species IgG heavy and light chain (Invitrogen, UK) were incubated at 1:200 
for 30 minutes followed by a wash for 5 minutes in 0.05% (v/v) PBS-T. Slides were 
mounted using Vectashield  mounting medium with DAPI (Vector Laboratories) and 
Fluorescence signal was detected using AxioSkop2 fluorescence microscope and 
Axiovision v4.8 software (both Carl Zeiss GmbH, Jena, Germany). 
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Table 2.2 – Primary Antibodies used in immunostaining 
Antigen Species Source Catalogue No Dilution 
α-SMA Mouse Sigma  A2547 1:75 
Calponin Rabbit Abcam ab46794 1:250 
Type 1 Collagen Goat Millipore ab758 1:200 
CTGF Rabbit Abcam ab6992 1:400 
Smoothelin  Mouse Abcam ab8969 1:300 
Phospho-Smad1  Rabbit Cell Signalling #9516 1:80 
2.6.5 Cell migration assay 
Explant cultured fibroblasts and human PASMCs (PASMCs) were seeded at 2 x10
4
 
cells per well of a 96-well plate overnight in the appropriate culture medium to 
ensure a confluent monolayer. The following day medium was replaced with low 
serum DMEM supplemented with 1% (v/v) FBS and 1 % (v/v) penicillin-
streptomycin for a further 24 hrs. Using a 96 well floating pin (V&P Scientific Inc) 
array a uniform scratch was applied to each well and the scratch confirmed by visual 
inspection. The medium was replaced with 1% (v/v) FBS and 1 % (v/v) penicillin-
streptomycin in the presence of 10 μg/ml mitomycin (Calbiochem) and treatments. 
Treatments used were 10 ng/ml PDGF BB (Peprotech,USA), or 50 ng/ml BMP4 
(Stemgent, UK), or 1 µM JQ1 (Sigma, UK). The extent of wound closure was 
assessed after 24 hours. Cellular wound closure was visualized on the Olympus Ck2 
microscope and images stored for analysis using Carl Zeiss Axio Cam software (Carl 
Zeiss GmbH, Jena, Germany). Data was analysed by quantifying the percentage of 
area covered by treatment groups compared to area of wound at time zero. 
2.6.6 Cell proliferation assay 
PASMCs and explant cultured lung fibroblasts were seeded at 5x10
3 
cells per well of 
a 96 well plate. After 24 hours, media was supplemented with low serum medium 
alone or in the presence of 50 ng/ml PDGFBB (Peprotech, USA) or a concentration 
range of JQ1. After 24 and 72 hours cell proliferation was determined by crystal 
violet incorporation. Briefly, a media was removed from the cells at the times 
specified and washed twice in PBS. 50 μl of the prepared crystal violet solution 
(0.025% (w/v) crystal violet, 10% (v/v) methanol (VWR, USA)) was added to each 
well, and incubated at room temperature for 10 minutes. The crystal violet solution 
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was then removed, and the plate washed with dH2O to remove non-cell bound crystal 
violet. The plate was dried for 3 hours and crystal violet was solubilised with the 
addition of 50ul of 10 % acetic acid (Sigma,UK) solution, and the absorbance at 
560nm determined using a plate reader (Mithras LB940). 
2.6.7 Cell apoptosis assay 
Contractile and synthetic PASMCs were seeded at 5x10
3
 cells per well for 24 hours. 
Medium was removed from cells and washed with sterile PBS. Contractile and 
synthetic PASMCs were treated with 0, 0.5, 5 and 50 ng/ml of BMP4 
(Stemgent,UK) and BMP7 (Stemgent,UK)  dissolved in low serum FBS. Cells were 
incubated with BMP ligands. After 8 hours Caspase-Glo® 3/7 Reagent (comprising 
Caspase-Glo® 3/7 buffer (Promega) was mixed with the Caspase-Glo® 3/7 
Substrate (Promega) in a 1:1 ratio) was added to each well in a 1:1 ratio. The plate 
was sealed with a plate sealer and mixed using a plate shaker at 300–500rpm for 30 
seconds. Readings were taken between 1 and 3 hours after Caspase Glo was added; 
with 2 hours giving the optimum results. The luminescence of each sample was 
determined using using a plate reader (Mithras LB940). 
2.6.8 Gel contraction assay 
To study collagen gel contraction, fibroblasts were cultured within three-dimensional 
(3-D) collagen lattices (fibroblast populated collagen lattices; FPCL). 24-well tissue 
culture plates (Costar) were pre-coated with sterile 2% BSA (w/v) in PBS (2ml/well) 
and incubated at 37oC overnight, and were then washed three times with sterile PBS. 
For FPCL, neutral collagen solution (containing one part of 0.2 M HEPES, pH8.0; 
four parts collagen (Vitrogen-100, 3 mg/ml, Celltrix, Santa Clara, CA) and five parts 
DMEM medium were prepared. Solutions were mixed with cells, to bring the final 
concentrations to 80,000 cells and 1.2mg collagen/ml alone or in the presence of 5 
ng/ml TGFβ, 50 ng/ml BMP4 (Stemgent,USA) and 1 μm JQ1.The collagen-cell 
suspension (1 ml) was added to each well, and allowed to gel for 1 hour. After 
polymerisation, 1 ml of medium was added to each well, causing detachment of the 
FPCL from the tissue culture plastic. Contraction of the gel was quantified by loss of 
gel weight
 
and decrease in gel diameter over a 24-h period.  
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2.6.9 FITC-albumin permeability assay  
Pulmonary arterial endothelial cells (PAECs) were seeded at 1x10
5
 cells, into 3µm 
pore transwell inserts (VWR, 734-0037) and allowed to reach confluence after 24 
hours. Monolayers were then exposed to conditioned medium from contractile and 
synthetic SMCs grown in complete EGM-2 for 24 hours with 800µl in the bottom 
well and 200µl in the transwell insert. After 24 hours 200µl was removed from the 
lower and replaced with 5mg/ml BSA, and 200 µl was removed from the top of the 
insert and replaced with 0.5% w/v (5mg/ml) FITC-albumin (Sigma, A9771). 20µl 
was removed from the lower well after 0.5, 1, 2 and 4 hours, and fluorescence 
determined on a plate reader at an 485nm and absorbance of 535nm (Mithras 
LB940). 
2.6.10 Neutrophil migration assay 
PAECs were seeded at 1x10
5
 cells per insert and exposed to conditioned medium 
from contractile and synthetic PASMCs as described in 2.6.9. Peripheral blood 
mononuclear cells (PBMCs) were isolated from peripheral blood using ficoll-paque. 
PBMCs were isolated by Mr Robert Good, Centre for Rheumatology and Connective 
Tissue Diseases, University College London. PBMCs were re-suspended in 
PBS/2%FCS at a concentration of 5x10
6 
cells/ml.  200µl of medium was removed 
from the lower well and replaced with 200µl 2%FCS in PBS. 200µl was removed 
from the insert and replaced with 200µl containing 1x10
6
 PBMCs to each insert. 
Neutrophil transmigration was determined after 2 hours by removing the inserts from 
the wells and washing off any attached neutrophils to the lower surface using PBS. 
Medium was removed and added into eppendorfs and centrifuged at 7000rpm for 5 
minutes. Medium was aspirated and neutrophils resuspended in 100µl PBS and 
counted using a haemocytometer.  
2.6.11 Enzyme-linked immunosorbent assay  
Enzyme-linked immunosorbent assay (ELISA) was performed on conditioned 
medium from contractile and synthetic hPASMCs, explant cultured control and 
scleroderma fibroblasts in the presence or absence of recombinant proteins and 
inhibitors. Levels of human IL-6 Duoset ELISA kit (R&D Systems®, MN, USA), 
Human IL-8 Duoset ELISA kit (R&D Systems®, MN, USA) and Human CTGF 
Standard ELISA development kit (Peprotech, USA) were determined in conditioned 
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media as per manufacturer’s protocol. Capture antibodies were prepared to 
appropriate concentrations and 100 µl added to each well in a 96 well microplate. 
The microplate was sealed and allowed to incubate overnight at room temperature. 
Following overnight incubation, the capture antibody was removed, and the wells 
were washed to ensure complete removal of liquids. Plates were then blocked using 
100μl per well of 0.2μm sterile-filtered 1% bovine serum albumin (BSA) in PBS (pH 
7.4) for 1 hour at room temperature. Blocking solution was aspirated, and the wells 
washed. A seven-point standard curve was prepared using two fold dilutions and 100 
µl of standards and sample were added to each well in duplicate and incubated at 
room temperature for 2 hours. Standards and samples were discarded and the wells 
were washed again. Detection antibody was prepared and 100 μl applied to each well 
for 2 hours at room temperature followed by washing. 100 μl streptavidin 
horseradish peroxidase (HRP) was added to each well for 20 minutes at room 
temperature followed by washing. Glo Substrate Reagent (R&D systems®, MN, 
USA)  used as directed by manufacturer’s protocol by mixing  one part of Glo 
substrate reagent A (luminol) with two parts of Glo substrate reagent B (hydrogen 
peroxide) and 100 μl was added to each well. Plates were incubated in the dark for 5 
minutes and the luminescence determined using a microplate reader (Mithras 
LB940). IL-6, IL-8 and CTGF concentrations of each sample were calculated using a 
standard curve of known concentrations. 
 
2.7 RNA quantification and analysis 
2.7.1 RNA isolation from tissue and cells 
Whole lung lysates were prepared from WT and TβRIIΔk-fib mice stored at -80°C in 
RNAlater. Lung samples were ground to fine powder using a dry ice cooled pestle 
and mortar. Lung homogenates were re-suspended in RLT buffer and homogenised 
using an automated homogeniser (IKA, Ultra Turrax T8). Explant cultured 
fibroblasts were lysed by adding 350 µl of RLT buffer to each well and lysing with 
needle and syringe. Using spin-column technology 350 µl of 70% ethanol was added 
to the homogenised lung or cell lysate and mixed well by pipetting.700 µl of the 
sample was transferred to a RNeasy spin column placed in a 2ml collection tube and 
centrifuged for 15s at 10,000 rpm. The flow through was discarded and 700 µl buffer 
68 
 
RW1 was added to the spin column and centrifuged for 15s at 10,000 pm. Flow 
through was discarded and  500 µl buffer RPE was added to the RNeasy spin column 
and centrifuged for 15s at 10,000 pm. Flow through was discarded  and  500 µl 
buffer RPE was added to the RNeasy spin column and centrifuged for 2 minutes at 
10,000 pm. Spin column was replaced with a new collection tube and spun at max 
speed for 1 minute and in a another new collection tube 30-50 µl RNase-free water 
was added directly to the spin column membrane and centrifuge for 1 minute at 
10,000 rpm to elute the RNA. 
 
2.7.2 RNA quantification 
RNA was quantified using a Nanodrop ND-8000 spectrophotometer (Thermo-
Scientific). Briefly, 1l samples were placed on the spectrophotometer and measured 
for quantity and purity judged by 260/280 ratio and this was repeated three times to 
ensure accuracy. The minimum 260/280 ratio accepted was 1.90. The quality of the 
isolated RNA was determined using an Agilent 2100 Bioanalyzer (Agilent 
Technologies UK Limited) using the Agilent RNA 6000 nano kit and chips 
according to manufacturer’s instructions. The RNA integrity algorithm was used to 
determine integrity and values ranged from 8 to 10 (Figure 2.3).  
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Figure 2.3 – Agilent NA 6000 Nano chip assay results for explant cultured 
fibroblasts and hPASMCs 
2.7.3 Primer Design 
Primers were designed using Roche Universal Probe library software and mouse 
accession numbers. Intron-spanning amplicons placed towards the 3’ end of the gene 
of interest were preferred. Sequences were analysed for nearest neighbour melting 
points, GC content and GC clamps to ensure that primers were not self-annealing 
using a sequence manipulation site (bioinformatics.org/sms2/pcr_primer_stats.html). 
GC content of 40-60, and a difference of <2
o
C in Tm were considered acceptable. 
Ideal amplicon length was 70-140 bp. In order to ensure specificity, primer 
sequences were then subjected to BLAST analysis 
(http://blast.ncbi.nlm.nih.gov/Blast.cgi). Specificity was confirmed using melt curve. 
2.7.4 cDNA synthesis 
500 ng or 1 g of total RNA was reverse transcribed using the Quantitect reverse 
transcription kit (Qiagen). Briefly, this first involves a genomic DNA elimination 
step, followed by reverse transcription using a mix of random and oligoDT primers. 
The completed cDNA reaction was diluted five-fold with tRNA 0.2 g/mL.  
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2.7.5 qPCR 
l of diluted cDNA was used for real-time quantitative RT-PCR in a 10 L reaction 
volume using Sensimix NoRef in a SYBR green-based assay (Quantace, London, 
UK) on a Rotorgene-6000 (Corbett Life Sciences, Sydney, Australia) under the 
following conditions (unless primer design required otherwise): 95
o
C for 10 min, 
followed by 40 cycles of 95
o
C for 10s, 57
o
C for 15s and 72
o
C for 5s. Primer dimers 
were excluded by melt curve analysis. The four most stable reference genes were 
identified and normalisation factors were obtained using geNorm (Vandesompele et 
al, 1999). Gene of interest copy numbers were corrected using these normalisation 
factors.  
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      Table 2.3 – Primers used for qPCR 
Reference Genes 
Primer 
Name 
Gene Forward Reverse 
mSdha Mus musculus succinate dehydrogenase complex, subunit A 5’-TGTTCAGTTCCACCCCACA-3’ 5’-TCTCCACGACACCCTTCTGT-3’ 
mRpl13 Mus musculus 60S ribosomal protein L13 5’-CAGTGAGATACCACACCAAGGTC 
-3’ 
5’–GTGCGAGCCACTTTCTTGT-3’ 
Gene Targets 
Primer Name Gene Forward Reverse 
mBMPRII Mus musculus bone morphogenetic protein receptor, 
type II 
5’-GAGCCCTCCCTTGACCTG -3’ 
 
5’-GTATCGACCCCGTCCAATC-3’ 
 
mSerpine-1 Mus musculus serpine peptidase inhibitor 5'-GACGTTGTGGAACTGCCCTA-3' 5'-AGCTGCTCTTGGTCGGAAAG-3' 
mGrem1 Mus musculus gremlin 1 5'-CCACGGAAGTGACAGAATGA-3' 5'-GGGCATTTCCGACCATCTGA-3' 
mCTGF Mus Musclus connective tissue growth facor 5’-TGACCTGGAGGAAAACATTAAGA 
-3’ 
5’-AGCCCTGTATGTCTTCACACTG-3’ 
Table 2.3 – Primers used for qPCR
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2.8 Western Blotting 
2.8.1 Preparation of cell lysates for Western Blotting 
Monolayers of fibroblasts (murine and human) maintained in DMEM medium and 
PASMCs maintained in either synthetic or contractile media SMC media were 
grown to 60-80 % confluence in 6-well plates. Cell monolayers were washed in 1x 
PBS and lysed in 120 μl lysis buffer comprising Radio Immuno Precipitation Assay 
(RIPA) buffer (Sigma) containing (150 mM NaCl, 50mM Tris pH 7.4; 1mM PMSF; 
1% PMSF; 1% NP-40; 1% Sodium deoxycholic acid; 0.1% SDS; 10% complete, 
Mini, EDTA-free protease inhibitor cocktail (Roche) and phosphatase inhibitor 
cocktail 3 (serine/threonine protein phosphatases and L-isozymes of alkaline 
phosphatase inhibitor (Sigma,UK). Protein concentrations were determined using the 
BCA Protein Assay kit (Pierce # 23225), and 15 g of protein mixed with 4x SDS 
Loading Buffer (8% SDS, 250mM Tris HCl pH 6.8, 20% glycerol) and 5% -
mercaptoethanol were denatured at 96C for 5 minutes. 
 
2.8.2 Preparation of tissue for Western blotting 
Whole lung lysates were prepared from snap frozen lungs from WT and TβRIIΔk-fib 
mice. Lung samples were ground to fine powder using a dry ice cooled pestle and 
mortar. Lung homogenates were re-suspended in lysis buffer supplemented EDTA-
free Protease Inhibitor Cocktail (Roche) and phosphatase inhibitor cocktail 3 
(Serine/Threonine Protein phosphatases and L-Isozymes of Alkaline Phosphatase 
inhibitor, Sigma) and homogenised using an automated homogeniser (IKA, Ultra 
Turrax T8) Protein concentrations were determined using the BCA Protein Assay kit 
(Pierce # 23225). 
2.8.3 Electrophoresis and transfer of protein samples for Western blotting 
Protein samples (15 μg per sample) were resolved on pre-cast 4-12% Tris-Glycine 
gel (Invitrogen), alongside a Novex Sharp pre-stained protein standard (Invitrogen) 
at 200V, until the dye front had reached the bottom of the gel (approximately 45 
minutes). Each gel was removed from its casing and placed within a transfer set-up 
using chromatography paper and Hybond C+ (Amersham) cut to 8cm by 6cm.  All 
these components had previously been soaked in 1x Transfer buffer (Invitrogen), 
containing 20% (v/v) methanol (VWR, France). The transfer set-up was then 
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carefully placed within a transfer module (Invitrogen) and put into an electrophoresis 
tank (Invitrogen), and completely submerged in 1x transfer buffer.  To prevent 
overheating, spaces surrounding the transfer module were filled with cold water.  
The transfer was then allowed to proceed at 35V for 1½ hours.  After this time 
membranes were rinsed with Ponceau Red (Sigma) solution to confirm protein 
transfer to the Hybond™ membrane. Membranes were then washed 3 times in 0.5% 
PBS-T for 10 minutes each before immunoblotting (2.8.4). 
2.8.4 Immunoblotting 
Membranes were incubated in 10 ml of blocking buffer 5% (w/v) Marvel dried 
skimmed milk in 0.5% PBS-T, for 1 hour at room temperature to block non-specific 
protein binding to the membrane. The blots were washed for ten-minutes for three 
times in 0.5% PBS-T with constant agitation.  Primary antibodies were diluted at 
concentrations as shown in Table 2.1 in blocking buffer and incubated at 4°C 
overnight. Membranes were then washed as before and an appropriate HRP linked 
secondary antibody diluted in blocking buffer added for further 1 hour at room 
temperature.  The membranes were subsequently washed and proteins detected using 
an ECL Detection Kit (GE healthcare).  The blot was exposed to ECL-specific film 
(GE healthcare), for between 5 seconds and 5 minutes and developed using Xograph 
Imaging Systems Compact x4 Western blotting machine.  
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Table 2.4 – Primary Antibodies used in Western blots 
Antigen Species Source Catalogue 
Number 
Working 
dilution  
BMPRII Rabbit Thermo 
Scientific 
PA5-11863 1:500 
BMPRIA Rabbit Santa Cruz sc-20736 1:1000 
Smad 1 Rabbit Cell Signalling #9512 1:1000 
Phospho-Smad1 (Ser 206) Rabbit Cell Signalling #5753 1:1000 
Phospho-Smad 2/3 (Ser 
423/425) 
Goat Santa Cruz sc-11769 1:1000 
Smad 2 Mouse BD Transduction 610842 1:1000 
p-p38 MAPK Rabbit Cell Signalling 9211 1:1000 
p38 MAPK Rabbit Cell Signalling 9212 1:1000 
p-p44-42 MAPK Rabbit Cell Signalling 9101 1:2000 
p42 MAPK (ERK) Mouse Santa Cruz sc-1647 1:1000 
CTGF Goat Santa Cruz sc-14939 1:1000 
α-SMA Mouse Sigma Aldrich A2547 1:2000 
Smoothelin Rabbit Santa Cruz sc-28562 1:1000 
Calponin Rabbit Abcam ab46794 1:500 
Type 1 Collagen Goat Millipore ab758 1:1000 
SM-22 Goat Abcam ab10135 1:1000 
GAPDH Mouse Abcam ab9484 1:50,000 
β-tubulin Rabbit Abcam ab6046 1:50,000 
Anti-Rabbit IgG HRP Goat Cell Signalling #7074 1.1000 
Anti-Mouse IgG HRP Horse Cell Signalling #7076 1.1000 
Anti-Goat IgG HRP Rabbit Dako P0160 1:1000 
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2.9 Statistical Analysis 
Statistical tests and graphs for both in-vitro and in-vivo studies were generated using 
GraphPad Prism 6.0 (GraphPad Software, La Jolla, CA). Results were expressed as 
mean ± S.E.M, P<0.05 denoted significance using the Mann-Whitney Test. 
For in-vivo studies variation in MABP, RVSP, LV/RV ratio and muscularisation of 
arteries were analysed by one-way analysis of variance (ANOVA) with Bonferroni post-
hoc analysis. Results were expressed as mean ± S.E.M, P<0.05 denoted significance. 
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3. Aberrant BMP signalling may contribute to pulmonary 
arterial hypertension in a TGFβ dependent murine model 
of scleroderma. 
3.1 Introduction   
A number of transgenic and insult based animal models have been used to better 
understand the biological processes that contribute to the development of SSc [18]. 
As outlined in chapter 1, (Table 2.1) a number of these models have been shown to 
develop pulmonary vascular remodelling including the Fra-2, and COL1α2-CTGF 
(Holmes et al unpublished observations). The TβRIIΔk-fib transgenic mouse model 
exhibits many of the complications associated with that of SSc patients [52, 54]. 
Furthermore, these mice exhibit a more severe response to intratracheal 
administration of bleomycin elevated myofibroblast numbers, and increased 
apoptosis of type II alveolar epithelial cells [55]. These mice display enhanced TGFβ 
signalling characterised by activation of the canonical Smad signalling pathway, 
Smad2/3 [52].  
Consistent with the observed phenotype of the TβRIIΔk-fib transgenic mouse model, 
Loeys-Dietz syndrome patients which possess TβR-II mutations exhibit increased 
expression of collagen and CTGF, as well as increased phosphorylated Smad2 in the 
nuclei. [118]. Interestingly these mice also exhibit vascular defects in the lung 
independently of pulmonary fibrosis [56]. This led to the hypothesis that the 
TβRIIΔk-fib model may be more susceptible to the development of PAH. Recently 
Derrett-Smith et al. demonstrated the TβRIIΔk-fib transgenic mouse model of SSc 
spontaneously develops raised right ventricular systolic pressures (RVSP) and 
vascular remodelling [119]. The TβRIIΔk-fib mouse model displays a modest but 
significant elevation in RVSP and moderate vascular remodelling, but no change in 
the Fulton index [119]. However  administration of the VEGF receptor antagonist 
SU5416, led to a further enhancement in RVSP and more extensive vascular 
remodelling with associated muscularisation of vessels and endothelial apoptosis  
[119]. Collectively this suggests the TβRIIΔk-fib transgenic mouse model may 
represent a novel model to explore the molecular mechanisms that contribute to the 
development SSc-PAH.  
 
77 
 
The expression of BMPRII in the TβRIIΔk-fib model has not been previously 
investigated but BMPRII reduction is a mechanism that is shared with other models 
of lung fibrosis and PAH. The bleomycin model has previously demonstrated a 
reduction in BMPRII gene expression. It has also been demonstrated that other 
models of PAH, for example the SU5416/hypoxia rat model, the hypoxia rodent 
model and the MCT model have also previously demonstrated a reduction in 
BMPRII in concordance with enhanced TGFβ activity.  
As discussed earlier vascular remodelling can occur through the expansion of 
smooth muscle cells and fibroblasts. The final step was to examine the effect of 
PDGFBB on the proliferation and migration and explant cultured lung fibroblasts 
from TβRIIΔk-fib and WT controls. PDGFBB is known mitogen that can induce 
proliferation and migration; it has also been previously demonstrated to be 
implicated in SSc [179]. 
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3.2 Aims 
To investigate the relevance of the BMP receptor BMPRII in SSc-PAH, this work 
initially sought to assess the expression of this and associated downstream signalling 
pathways within the context of the TβRIIΔk-fib mouse model of SSc. This chapter 
investigates expression of components of the BMP signalling cascade including 
BMPRII in whole lung tissues using histological and molecular techniques. Using 
lung fibroblasts cultured from these mice, the expression of components of the BMP 
signalling cascade was assessed and the cellular response of these cells to the 
BMPRII ligand BMP4 determined. Vascular remodelling in part results from 
increases in resident cells, including fibroblasts and PDGFBB can promote 
proliferation and migration in fibroblasts [180]. Extending these studies the response 
of TβRIIΔk-fib fibroblasts to PDGFBB was assessed. 
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3.3 Results 
3.3.1 VEGFR inhibition exacerbates the hypertensive phenotype in the 
TβRIIΔk model. 
The TβRIIΔk-fib mouse model displays a modest but significant elevation in RVSP 
and moderate vascular remodelling spontaneous at eight to twelve weeks of age. The 
administration of the VEGFR antagonist SU5416 under normoxic conditions induces 
extensive pulmonary vascular remodelling with further elevation in RVSP and right 
ventricular hypertrophy [119]. 10 pulmonary arterioles (100 µm) per section were 
scored and blinded to the source of tissue (n=3). Each vessel was scored as either 
nonmuscularised or non-inflamed (0), partially muscularised or inflamed(1), or fully 
muscularised or inflamed (2). 
 Immunohistological staining for the smooth muscle cell marker α-SMA (brown) and 
the endothelial cell marker vWF (brown) displayed increased vessel wall thickening. 
There were no cardinal features of advanced or severe PAH such as plexiform 
lesions observed in TβRIIΔk-fib vessels (Figure 3.1A). In contrast the addition of 
SU5416 to WT mice induced a mild muscularisation with minimal vessel thickening, 
whilst and in the TβRIIΔk-fib SU5416 induced extensive pulmonary vascular 
remodelling and the formation of concentric lesions (Figure 3.1A). Quantification 
highlighted  a significant increase in muscularisation in the TβRIIΔk-fib group alone 
compared to WT mice. The addition of SU5416 led to a significant rise in the degree 
of muscularisation in WT and TβRIIΔk-fib compared to control mice (Figure 3.1B). 
Hematoxylin and eosin (H&E) staining highlights a slight increase perivascular 
inflammatory cell infiltrate and medial thickening in the TβRIIΔk-fib mice group 
compared to wild-type controls (Figure 3.1C). The addition of SU5416 in WT mice 
led to a mild inflammatory phenotype whereas SU5416 to TβRIIΔk-fib mice led to 
enhanced perivascular inflammatory cell infiltration compared to TβRIIΔk-fib alone 
and a more extensive medial thickening and obliteration of some smaller vessels 
(Figure 3.1C). Quantification of this inflammation showed that there was a  
significant rise in the degree of inflammation in WT and TβRIIΔk-fib compared to 
control mice (Figure 3.1D). 
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Figure 3.1 – VEGFR inhibition enhances vascular remodelling and medial 
thickening in TβRIIΔk-fib mice 
Immunohistochemical staining for alpha-smooth muscle actin (α-SMA) and von-
Willebrand factor (vWF) (A) and Hematoxylin and eosin (H&E) (D) on paraffin 
embedded formalin fixed lung sections from wild type (WT), TβRIIΔk-fib mice 
exposed in-vivo to SU5416 or vehicle alone. 10 pulmonary arterioles (100 µm) per 
section were scored and blinded to the source of tissue (n=3). Each vessel was scored 
as either nonmuscularised or non-inflamed (0), partially muscularised or 
inflamed(1), or fully muscularised or inflamed (2) (B,D). Black line indicates 100 
µm and magnification x20 using the Carl Zeiss microscope.  *p<0.05 Mann Whitney 
Test.Black line indicates 100 µm and magnification x20 using the Carl Zeiss 
microscope.  
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3.3.2 Investigation expression of BMPRII and downstream signalling 
components of the TGFβ superfamily in whole lung tissues. 
To initially assess expression of components of the TGFβ superfamily in TβRIIΔk-
fib transgenic mouse model of SSc-PAH whole lungs were isolated from WT and 
TβRIIΔk-fib mice following administration of SU5416 or vehicle control. Using 
lung homogenates the expression of BMPRII, and downstream signalling 
components of the TGFβ superfamily was assessed by Western blot (Figure 3.2). 
Lung homogenates from TβRIIΔk-fib exhibited a marked and significantly lower 
levels of BMPRII compared to that of WT mice (p<0.05; Figure 3.2A). Treatment of 
WT mice with SU5416 led to a significant (p<0.05; Figure 3.2A) reduction of 
BMPRII compared with vehicle, whereas TβRIIΔk-fib mice treated with SU5416 led 
to no further significant reduction in BMPRII expression (Figure 3.2 B). 
In contrast, no significant change was observed in phosphorylation of the 
downstream BMP activated canonical signalling pathway, Smad 1, 5 and 8 (Figure 
3.2 A, B). Whereas the addition of SU5416 induced a tread in increased total Smad1, 
5 and 8 compared to TβRIIΔk-fib (Figure 3.2 A, B).  
Lung homogenates of the TβRIIΔk-fib were assessed for expression of the TGFβ 
activated downstream canonical signalling pathways Smad 2 and 3. TβRIIΔk-fib 
mice exhibited enhanced phosphorylation of Smad2/3 compared to WT controls 
(p<0.05). The addition of SU5416 to WT mice led to a significant increase in 
phosphorylated-Smad 2/3 levels compared to vehicle treated WT mice but SU5416 
did not have a significant effect on TβRIIΔk-fib mice (Figure 3.2 A, B). 
Assessment of the phosphorylation of the non-canonical signalling pathway, 
demonstrated a significant increase in phosphorylated ERK 1/2 in vehicle treated 
TβRIIΔk-fib mice compared to WT controls (p<0.05). Treatment of WT controls 
with SU5416 led to rise in phosphorylated ERK 1/2 compared to vehicle treated 
controls which failed to reach significance. No significant effect of SU5416 was 
observed on TβRIIΔk-fib treated animals. No significant difference in 
phosphorylated or total p38 was observed in any of the four groups tested (Figure 3.2 
A, B).  
Confirmation of BMPRII and phosphorylated Smad2/3 was sought using 
immunohistochemistry (IHC) on sections from paraffin embedded lungs from WT 
and TβRIIΔk-fib mice treated with SU5416 or vehicle control. Lungs from WT mice 
exhibited BMPRII staining around vascular structures (Figure 3.3A). TβRIIΔk-fib 
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mice exhibited reduced BMPRII staining compared to WT controls. In-vivo 
administration of SU5416 led to a marked reduction of BMPRII expression in WT 
mice compared to vehicle treated animals. However in-vivo administration of 
SU5416 in the TβRIIΔk-fib mice had no overt effect on BMPRII expression 
compared to vehicle controls (Figure 3.3A). Consistent with Western blot analysis 
(Figure 3.2A), IHC assessment of phosphorylated Smad2/3 expression demonstrated 
enhanced levels in the TβRIIΔk-fib lungs compared to WT controls (Figure 3.3 B). 
Furthermore, in-vivo administration of SU5416 in WT and TβRIIΔk-fib mice 
induced an increase in phosphorylated Smad2/3 levels in both groups (Figure 3.3B).  
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Figure 3.2 – BMPRII expression is reduced in the TβRIIΔk-fib model of SSc-
PAH 
Western blots were performed on protein extracts prepared from whole lungs 
isolated from wild type (WT) and TβRIIΔk-fib mice exposed in-vivo to SU5416 or 
vehicle (n=3). Blots were probed for expression of BMPRII, phospho-Smad2/3 
(pSmad2/3), Smad3, phospho-Smad 1 (pSmad 1), Smad 1, phospho-ERK 1/2 (pERK 
1/2), ERK 1/2, phospho-p38 (p-p38) and p38. Protein loading was determined by β-
tubulin levels and representative blots are presented above (A). Densitometry was 
performed and the mean ± SEM expression of BMPRII normalised to β-tubulin 
expression and plotted (B) pSmad 1/5/8, pSmad2/3, pERK 1/2 1/2 and p-p38 was 
normalised to each of their total proteins and plotted (n=6) (B). *p<0.05 using Mann-
Whitney Tests. (B).  
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Figure 3.3 – Immunohistochemical expression of components of the TGFβ 
superfamily in the lung of TβRIIΔk-fib model of SSc-PAH 
Immunohistochemical staining for BMPRII (A) and phopho-Smad2/3 (pSmad2/3) 
(B) on paraffin embedded formalin fixed lung sections from wild type (WT) and 
TβRIIΔk-fib mice exposed in-vivo to SU5416 or vehicle alone. Representative 
images shown of 10 images per mouse, n=3 per group. Magnification x40 using Carl 
Zeiss microscope.   
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3.3.3 Investigation of expression of BMPRII and downstream signalling 
components of TGFβ superfamily in fibroblasts 
A number of cell types have been implicated in vascular remodelling associated with 
the development of PAH, including fibroblasts. The expression of BMP receptors 
and downstream signalling components of the TGFβ superfamily was assessed in 
fibroblasts established from the lungs of WT and TβRIIΔk-fib mice (Figure 3.4).  
Initially expression of the BMP type I and II receptors, BMPRIA and BMPRRII was 
assessed by Western blot. Expression of BMPRIA was unchanged in TβRIIΔk-fib 
mice fibroblasts, compared to WT controls. Whereas BMPRII expression was 
significantly reduced TβRIIΔk-fib mice compared to WT controls (p<0.05; Figure 
3.5 A, B). Gene expression of BMPRII was assessed by qPCR and expression 
normalised to succinate dehydrogenase complex, subunit A. In contrast to protein, no 
significant difference in BMPRII gene transcript levels was observed between 
TβRIIΔk-fib mice fibroblasts, compared to WT controls (Figure 3.5 B).  
There was no significant difference observed in phosphorylation of the downstream 
BMP activated canonical signalling pathways, Smad 1,5 and 8 (Figure 3.5 A).  
Assessment of the phosphorylation of the non-canonical signalling pathway ERK1/2, 
demonstrated a significant increase in fibroblasts from TβRIIΔk-fib mice compared 
to WT controls (p<0.05; Figure 3.5). No significant difference in total levels of 
ERK1/2 was observed. TβRIIΔk-fib mice exhibited a significant increase in 
phosphorylated p38 levels compared to WT controls (p<0.05; Figure 3.5). In 
addition total levels of p38 were significantly elevated in TβRIIΔk-fib mice 
compared to WT controls (p<0.05; Figure 3.4). 
Lung fibroblasts of the TβRIIΔk-fib were further assessed for expression of the 
TGFβ activated downstream canonical signalling pathways Smad 2 and 3. 
Fibroblasts from TβRIIΔk-fib mice exhibited enhanced phosphorylation of Smad2/3 
compared to WT controls (p<0.05; Figure 3.5 A), whereas total Smad2/3 was 
unchanged. 
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Figure 3.4 – Expression of components of the TGFβ superfamily and 
downstream signalling pathways in explants cultured lung fibroblasts from WT 
and TΒRIIΔK-fib mice 
Protein was isolated from confluent monolayers of explant cultured murine lung 
fibroblasts from WT and TβRIIΔk-fib (TG) mice (n=3). Western Blots were 
performed and probed for expression of BMPRII, BMPR1A, phospho-Smad 2/3 
(pSmad 2/3),Smad 2/3, phospho-Smad1 (pSmad1), Smad1, phosphor-ERK 1/2 
(pERK 1/2), ERK 1/2, phosphorylated p38 (p-p38) and p38. Protein loading was 
determined by β-tubulin levels representative blots are presented above (A). Protein 
loading was determined by β-tubulin levels (A).  
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Figure 3.5 - Expression of components of the TGFβ superfamily and 
downstream signalling pathways in explant cultured lung fibroblasts from WT 
and TΒRIIΔK-fib mice. 
Densitometry was performed and the mean ± SEM expression of BMPRII, was 
normalised to β-tubulin expression and fold change plotted (n=6) (A). pSmad 2/3, 
pSmad 1, pERK 1/2 and p-p38 was normalised to their respective total proteins. 
*p<0.05 using Mann-Whitney Test (B). BMPRII gene expression was determined by 
quantitative polymerase chain reaction (qPCR) of RNA from explant cultured 
fibroblasts and expression normalised to the succinate dehydrogenase complex, 
subunit A (Sdha) gene (C).    
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3.3.4 TβRIIΔk-fib fibroblasts exhibit a blunted response to BMP4 
BMPs acting via the receptor BMPRII activate a number of downstream signalling 
pathways including Smad1. To investigate the functional effect of reduced BMPRII 
highlighted in 3.3.3, the induction of phosphorylated Smad1 in response to the BMP 
ligand, BMP4 was assessed.  
 
Initially the optimal dose and time dependent induction of phosphorylated Smad1 in 
response to BMP4 was assessed in WT murine fibroblasts. Induction of 
phosphorylated Smad1 by BMP4 (50 ng/ml) was assessed at 0.25, 0.5, 1, 2, and 24 
hours (Figure 3.6A). Phosphorylated Smad1 was significantly increased compared to 
base line at 0.25, 0.5, 1, 2 hours, returning to base line after 24 hours in response to 
BMP4. Fibroblasts exhibited a maximal ~3 fold induction at 0.5 hours (Figure 3.6A). 
Having established maximal temporal induction of phosphorylated Smad1 to occur 
at 0.5 hours, a dose response of lung fibroblasts to BMP4 was investigated. 
Significant induction of phosphorylated Smad1 by BMP4 was observed in lung 
fibroblasts at 5 and 50ng/ml, with maximal ~2 fold induction observed at the 5ng/ml 
treatment with BMP4 (p<0.05; Figure 3.6B).   
Using these optimised conditions I assessed the induction of phosphorylated Smad1, 
phosphorylated ERK 1/2 and phosphorylated p38 levels by BMP4 in fibroblasts 
isolated from TβRIIΔk-fib mice (Figure 3.7 A, B). TβRIIΔk-fib fibroblasts exhibited 
a significantly blunted induction of phosphorylated Smad1 (p<0.05) consistent with 
the reduced expression of BMPRII. Consistent with this, induction of 
phosphorylated ERK 1/2 and phosphorylated p38 by BMP4 was significantly 
(p<0.05) reduced in TβRIIΔk-fib fibroblasts compared to WT controls (Figure 3.7 A, 
B).  
Confirmation of the blunted responses to BMP4 exhibited by TβRIIΔk-fib 
fibroblasts was confirmed by assessing nuclear translocation of phosphorylated 
Smad1 in response to BMP4 (Figure 3.8 A). Consistent with reduced BMPRII 
expression, fibroblasts from the TβRIIΔk-fib model exhibited a significant reduction 
in phosphorylated Smad1 positive nuclei in fibroblasts compared to WT controls was 
observed (p<0.05; Figure 3.8, B). 
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Figure 3.6 – BMP4 temporal and dose dependent induction of phosphorylated-
Smad1 in lung fibroblasts by BMP4 
Monolayers of explant cultured fibroblasts established from WT mice were 
stimulated with BMP4 and phosphorylated-Smad1 (pSmad1) levels determined by 
Western blot. The temporal induction of pSmad1 in response to 50 ng/ml BMP4 at 0, 
0.25, 0.5, 1, 2 and 24 hours was determined (A).Induction of pSmad 1 stimulated 
with 0, 0.5, 5 and 50ng/ml of BMP4 for 0.5 hours was determined (B). 
Representative blots of three independent experiments (n=3). Densitometry was 
performed and the mean ± SEM expression of pSmad1 was normalised to GAPDH 
expression and plotted (A) and (B). *p<0.05 using Mann-Whitney Tests (A and B). 
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Figure 3.7 – Altered phosphorylation of downstream signalling pathways in 
response BMP4 in TβRIIΔk-fib fibroblasts 
Monolayers of explant cultured fibroblasts established from WT and TβRIIΔk-fib 
mice were stimulated with BMP4 (5 ng/ml) for 0.5 hours in three independent 
experiments and phosphorylated-Smad1 (pSmad1), phosphorylated-ERK 1/2 (ERK 
1/2) and phosphorylated-p38 (p-p38) levels determined by Western blot. p-Smad1, 
pERK 1/2 and p-p38 protein levels were determined by Smad1, ERK 1/21/2 and p38 
levels (A) (n=6). Densitometry was performed and the normalised mean ± SEM 
expression ratio of phosphor/total protein Smad1, ERK 1/2 and p38 was normalised 
and representative blots were plotted (B). *p<0.05 using Mann-Whitney Tests.  
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Figure 3.8 – Altered phosphorylation of phosphorylated-Smad 1 in response to 
BMP4 in TβRIIΔk-fib fibroblasts. 
Monolayers of explant cultured fibroblasts established from WT and TβRIIΔk-fib 
mice were stimulated with BMP4 (5 ng/ml) for 0.5 hours in three independent 
experiments and three biological replicates and total and phosphorylated-Smad1 
(pSmad1) (green) positive nuclei was determined (A) by immunoflouresence (IF). 
Magnification x20 using the Carl Zeiss microscope. The ratio of pSmad 1/Smad 1 
was determined and the mean ± SEM plotted (B). *p<0.05 using Mann-Whitney 
Tests. 
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3.3.5 Investigation of fibroblast proliferation and migration in the TβRIIΔk-fib 
model. 
Proliferation and migration are two key characteristics that can contribute to vascular 
remodelling in SSc-PAH [18]. Fibroblasts that exhibit enhanced migration and 
proliferation can contribute to medial thickening and muscularisation in pulmonary 
vessels [143,147,150,181,182]. The effect of PDGFBB, a potent inducer of 
fibroblast migration and proliferation on TβRIIΔk-fib fibroblasts was assessed. 
Confluent monolayers of TβRIIΔk-fib and WT fibroblasts were scratched and treated 
with either 1% FCS alone or supplemented with 10ng/ml of PDGFBB in the 
presence of the anti-proliferative Mitomycin-C (10 ug/ml) and migration assessed 
after 48 hours (Figure 3.9A, B). PDGFBB induced migration in both WT and 
TβRIIΔk-fib explant cultured fibroblasts. TβRIIΔk-fib fibroblasts exhibited a 
significant increased capacity to migrate across the scratched monolayer compared to 
WT controls in response to PDGFBB treated (p>0.05; Figure 3.9C).  
The proliferative response of TβRIIΔk-fib fibroblasts to PDGFBB was next 
assessed. WT and TβRIIΔk-fib fibroblasts were seeded at equal cell density in the 
presence or absence of PDGFBB (50 ng/ml) and cell number determined using the 
crystal violet proliferation assay at 72 hours. PDGFBB induced cell numbers were 
normalised to media alone controls and plotted as indicated in Figure 3.9C. A 
significant increase in TβRIIΔk-fib fibroblast cell number in response to PDGFBB 
compared to WT controls was observed (p>0.05; Figure 3.9A). 
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Figure 3.9 – TβRIIΔk-fib lung fibroblasts exhibit increased proliferative and 
migratory response to PDGFBB 
Platelet derived growth factor (PDGFBB) mediated proliferation in wildtype (WT) 
and TβRIIΔk-fib mice explant cultured fibroblasts was examined. Data represent the 
fold proliferation induced by PDGFBB compared to vehicle controls and are 
expressed as a mean of three donors. Proliferation was assessed after 72 hours (A). 
*p<0.05, Unpaired T-test (A).Confluent monolayers of WT and TβRIIΔk-fib lung  
fibroblasts were scratched and migratory responses assessed in response to 1% FCS 
(FCS) and 10 ng/ml of PDGFBB (PDGF) in the presence of 10 μg/ml Mitomycin C 
for 48 hours. Experiments were performed on three mice per group in triplicate. (B). 
Migration was assessed after 24 hours, images were taken using the Olympus CDK2 
microscope and data analysed using Axio Vision software.  *p<0.05, Mann-Whitney 
Test (C). 
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3.4 Discussion 
It has been previously reported that the TβRIIΔk-fib transgenic mouse model of SSc 
spontaneously develops an enhancement of RVSP and many key features PAH. 
These animals exhibit a paradoxical enhancement in TGFβ signalling, including 
activation of the canonical Smad signalling pathway, which is conveyed in elevated 
levels of phosphorylated Smad2/3 [52]. Consistent with the observed phenotype of 
the TβRIIΔk-fib transgenic mouse model, Loeys-Dietz syndrome patients who 
possess TβR-II mutations exhibit increased levels of phosphorylated Smad2 in the 
nuclei. In SSc similar phenotypes have been observed with increased levels of 
phosphorylated Smad2 reported in the skin of SSc patients [118]. There are also 
three other variants of disease with mutations also observed in TGFβ-R2, TGFβ2 and 
Smad 3. 
 
TβRIIΔk-fib transgenic mice display increased expression of latent TGFβ in the 
ECM and develop dermal fibrosis, as well as fibrosis in a number of internal organs 
[54, 57]. The administration of bleomycin to these mice induced the appearance of 
myofibroblasts, and increased apoptosis of type II alveolar epithelial cells suggesting 
that these mice have an increased susceptibility to injury [55]. The TβRIIΔk-fib mice 
develop a more much severe fibrotic phenotype than wildtype mice.  Interestingly 
these mice exhibit vascular defects in the lung independently of pulmonary fibrosis 
[56].  
In this study key recent findings related to clinical aspects of SSc associated PAH 
have been elucidated and observations using a mouse model of SSc that is induced 
by targeted genetic perturbation of TGFβ signalling in fibroblasts. These mice have 
been reported to develop enhanced RVSP and vascular remodelling compared to 
wildtype controls [119]. 
This mouse model has recently been found to be highly sensitive to a 
pharmacological inhibitor of VEGF signalling (SU5416), the administration of 
SU5416 leads to the pharmacological induction of a phenotype reminiscent of SSc-
PAH. The background of these mice is similar to SSc patients and these mice also 
spontaneously develop mild PAH and in this context, observation that SU5416 
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induced PAH in the TβRIIΔk-fib model of SSc provided an opportunity to explore 
potential mechanisms of susceptibility that may be relevant to human SSc. As 
highlighted in Figure 3.1 the TβRIIΔk-fib mice display mild PAH but the addition of 
SU5146 leads to the formation of concentric lesions, further elevation of RVSP, 
medial wall thickening and inflammatory infiltrate [56, 119]. 
In figure 3.2 and 3.3 it is demonstrated that that the TβRIIΔk-fib mice display 
elevated levels of phosphorylated Smad2/3, phosphorylated ERK 1/2 and 
phosphorylated p38 expression in lung fibroblasts These mice also display an 
increase in phosphorylated Smad 2/3 in whole lung tissue compared to wild type 
controls [52]. Furthermore this data suggests a key role for heightened activity of the 
TGFβ pathway in driving this process in SSc-PAH. Several reports have 
demonstrated enhanced TGFβ responsiveness in PASMCs from HPAH patient’s 
with BMPRII mutations, including elevated secretion of inflammatory chemokines 
[13] and an enhanced pro-proliferative response, a phenomena replicated in mice 
harbouring nonsense BMPRII mutations [13, 14]. Enhanced TGFβ signalling has 
previously been reported in IPAH vessels [15-17]. A number of groups have also 
demonstrated that preclinical models of PAH exhibit enhanced TGFβ activity 
including the monocrotaline rat, hypoxia and hypoxia SU5416. [10-12]. A plethora 
of studies have demonstrated pharmacological antagonists of the TGFβ signalling 
pathway can inhibit and reverse the development of PAH in preclinical models 
which exhibit genetically independent reduction in BMPRII levels in tissues [17].  
Consistent with this the TβRIIΔk fib model of SSc which exhibits enhancement in 
TGFβ signalling including phosphorylated levels of Smads 2 and 3, develops PAH 
under normoxic conditions [1, 7]. Collectively these studies and this thesis support 
the notion that enhanced TGFβ signalling contributes to the development of PAH 
and SSc-PAH. 
Previously studies have shown the reduction of functional cell surface expression of 
BMPRII in patients is strongly associated with the development of HPAH and IPAH 
[183, 184]. The next investigation was to examine if TβRIIΔk-fib mice that 
spontaneously develop PAH also have reduced BMPRII protein levels. In figure 3.2 
and 3.3 it has been highlighted that the TβRIIΔk-fib mice display a reduction of 
functional BMPRII in both whole lung tissue and lung fibroblasts and this may 
represent a common susceptibility mechanism in HPAH, SSc-PAH and IPAH 
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patients. There was no change in phosphorylated Smad 1 levels in either whole lung 
tissue or lung fibroblasts in the TβRIIΔk-fib model. A number of groups have also 
demonstrated that preclinical models of PAH, including the monocrotaline rat, 
hypoxia and hypoxia SU5416 also exhibit reduction in BMPRII levels [141,146, 
176]. This suggests along with the observations in the TβRIIΔk-fib model that a 
reduction in BMPRII may lead to an increased susceptibility of developing PAH. 
Following on from these observations the next experiment was to investigate the 
impact of the reduction in BMPRII levels in the TβRIIΔk model on the BMP 
activated canonical and non-canonical signalling pathways. Explant lung fibroblasts 
from WT controls exhibited a robust phosphorylation of Smad1 in response to 
BMP4. In contrast, fibroblasts isolated from TβRIIΔk mice were less responsive, 
consistent with reduced BMPRII receptor expression, and previously reported 
studies in patients with HPAH harbouring defined BMPRII gene mutations [24, 
177]. This disrupted BMP signalling is another parallel mechanism between the 
TβRIIΔk model and PAH patients.  
 
To assess the functional effects of reduction of BMPRII protein in TβRIIΔk mice, 
relevant functional assays in explants cultured lung fibroblasts were examined 
Migration and proliferation are key pathological features in PAH by which 
fibroblasts contribute to the remodelling and occlusion of pulmonary vessels [143, 
147, 150, 181, 182]. PDGFBB is a potent mitogen for fibroblasts and PASMCs, and 
expression of the PDGFA, PDGFB, PDGFR-α, and PDGFR-β have been reported to 
be increased in patients with severe PAH [185, 186]. Furthermore, PASMCs isolated 
from HPAH patients with functional mutations in the BMPRII gene exhibit impaired 
migration (Holmes et al, unpublished observations). Building on this work the 
migratory responses of fibroblasts isolated from the TβRIIΔk model of SSc was 
investigated. Fibroblasts isolated from the TβRIIΔk-fib model, which express less 
BMPRII than WT fibroblasts exhibited enhanced response to PDGF-BB leading to 
increased fibroblast migration. Fibroblasts from the TβRIIΔk model also display 
enhanced proliferation compared to WT controls suggesting that fibroblasts from this 
model exhibit a phenotype that can contribute to more vascular remodelling. It has 
been previously demonstrated that fibroblasts that are exposed to hypoxia display 
elevated levels of phosphorylated-p38 and that this increase in expression is linked to 
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enhanced proliferation [187, 188]. This suggests that the elevated phosphorylated-
p38 levels in fibroblasts from the TβRIIΔk model might be contributing to the 
enhanced proliferation in this model. These changes have also been reported in 
IPAH and IPF where fibroblasts display increased proliferation and migration, two 
cellular processes that can contribute to vascular remodelling [22, 189]. 
These results have made a link between an enhanced TGFβ environment that may 
contribute to a reduction in BMPRII. The hypoxia, SU5146/hypoxia and MCT 
models of PAH have also demonstrated a reduction of BMPRII and an increase in 
phosphorylated Smad 2/3 levels in the lungs of these animals [141, 144, 164, 190]. 
This is the first time these results have been demonstrated in an SSc model and the 
link between a reduction in BMPRII in a model of SSc and the development of PAH. 
The TβRIIΔk model can provide a platform that might provide a better 
understanding to the mechanism by how SSc patients develop PAH. This model 
represents a model to represent SSc patients that exhibit enhanced TGFβ activity and 
a reduction in BMPRII can allow us to investigate novel therapeutics that targets this 
signalling axis. The bleomycin model of SSc-PH also exhibits a reduction in BMPRI 
and this raises the question do other SSc models, for example the FRA-2 model 
display a reduction in BMPRII that may be increases the susceptibility of these mice 
developing PAH. 
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3.5 Conclusion 
The TβRIIΔk mouse model of SSc develops a mild PAH phenotype and following 
exposure to the VEGFR antagonist SU5416 these mice develop a more severe 
pulmonary vasculopathy, enhance RVSP and increased infiltration of immune cells 
into vascular lesions [119]. These transgenic mice exhibit enhanced TGFβ activity, 
highlighted by elevated phosphorylated Smad 2 and 3 expression in the lungs in 
concordance with a reduction in BMPRII protein levels in both whole lung tissues 
and fibroblasts.  
Mutations in the BMPRII gene which lead to the reduction of functional BMPRII at 
the cell surface have been strongly implicated in the susceptibility of developing 
PAH in HPAH and IPAH patients [7, 14, 17, 24, 26, 28, 183, 184, 191, 192]. A 
number of studies have shown in pre-clinical insult models of PAH a reduction in 
protein levels of BMPRII is associated with enhanced TGF activity [141, 144, 146, 
193, 194]. Collectively supporting the notion that imbalance in TGFβ/BMP pathway 
is a key component in the development of PAH. TβRIIΔk mice exhibit reduced 
BMPRII expression in the lung, which is further reduced by the in-vivo 
administration of SU5416. Fibroblasts from these mice also display reduced BMPRII 
expression, dysregulated BMP signalling and blunted responses to BMP ligands. 
Functionally TβRIIΔk fibroblasts exhibited increased rates of proliferation and 
migration, two features that can contribute to occlusion of the lumen in the 
pulmonary arteries.  
Future studies will seek to assess the relevance of these observations in the context 
of SSc patients. 
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4. Reduction of BMPRII in patients with scleroderma may 
increase susceptibility to the development of PAH  
4.1 Introduction 
SSc is a heterogeneous autoimmune rheumatic disease characterised by vascular 
dysfunction and fibrosis that leads to pathological remodelling of tissues [18]. PAH 
is an important complication occurring in up to 10% of SSc cases [195]. The risk of 
developing PAH persists through the disease and is time dependent, suggesting that 
SSc operates as a susceptibility factor [38]. SSc-PAH patients have a significantly 
poorer prognosis compared to those with idiopathic and heritable forms of the 
disease [196, 197]. A number of gene mutations are associated with heritable PAH 
and are discussed extensively in chapter 1. Many of these reported mutations are 
associated with genes in the TGF superfamily and downstream signalling pathway. 
The most prevalent gene mutated being in the type II BMP receptor BMPRII. A 
number of mutations in this gene have been identified and lead to the reduction in 
expression or loss of function of BMPRII at the cell surface [102]. In contrast, 
genetic studies on SSc and SSc-PAH patients have not detected mutations in the 
BMPRII gene [198]. Wang et al demonstrated that heightened DNA methylation of 
the BMPRII promoter contributes to a reduction in BMPRII expression in dermal 
microvascular endothelial cells of patients with SSc [175]. In addition to this a 
number of studies have also highlighted non-genetic mechanisms that can lead to 
reduced BMPRII protein levels, including ubiquitination and proteasomal 
degradation mediated by Smurf1, K5 and E3 ligase and Itch [17, 190]. Collectively 
non-genetic mechanisms may also contribute to a reduction in BMPRII expression 
and therefore a predisposition to the development of PAH.   
A number of studies have highlighted the key role for TGFβ in the development of 
PAH [146, 192] and speculated that imbalance between the BMP and TGFβ axes 
contributes to the development of PAH [17, 102]. A significant body of evidence has 
implicated TGFβ in the development of SSc. Consistent with the importance of the 
TGFβ superfamily, in chapter three, a pre-clinical model of SSc (TβRIIΔk-fib mouse 
strain) which develops pathological remodelling of lung and raised right ventricular 
systolic pressures due to upregulation of TGFβ signalling in fibroblasts and an 
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aberrant BMP signalling axis [57, 101]. Further lungs and fibroblasts from these 
mice exhibited reduced expression of BMPRII 
In chapter three the role of altered BMPRII expression and signalling in determining 
susceptibility to PH in the TβRII∆k-fib murine model of SSc was explored and the 
aim was to translate these key findings to human SSc lung samples. Results have 
shown constitutive reduction in BMPRII expression in the lung of the TβRII∆k-fib 
strain and the aim was to investigate BMPRII expression in lung tissue and explants 
cultured fibroblasts from donor controls and SSc-PAH patients. It will be interesting 
to investigate if impaired BMP signalling is observed in SSc patients which would 
elude to a fundamental susceptibility mechanism for the development of PAH 
associated with SSc. The TβRII∆k-fib model displayed no change in mRNA 
expression of BMPRII suggesting that post-translational modifications that affect 
protein turnover may be contributing to a reduction in BMPRII expression. This 
mechanism of proteasomal degradation was also investigated in SSc patients. 
Proteasomal degradation and regulation has been linked to pulmonary fibrosis and 
the ubiquitin-proteasome system has been linked to cellular protein turnover [199]. 
The proteasome is located in both the cytoplasm and nucleus with a 20s barrel like 
structure that has 19s regulatory proteins at both ends [199]. The proteasome has two 
main functions, scaffold and proteinase that are ATP dependent [200]. Different sites 
on the proteasome has different functions, the threonine residues are the active site 
and the hydroxyl groups function as catalytic nucleophils that have three separate 
cleavage partialities that are known as chyotryptic, tryptic and caspase like [199]. 
Proteasomal inhibitors, for example MG132 and bortezomib target these functions 
and exert their effects by binding to one or more for these sites, for example MG132 
can inhibit chyotryptic and tryptic enzymatic activites and bortezomib only inhibits 
chyotryptic activity. In the proteasome there is the regulatory 19s complex that 
recognises, bind and unwinds proteins and together with the 20s core forms the 26s 
proteasome [201]. In relation to TGFβ signalling which is of interest to this work and 
SSc-PAH both protein degradation and ubiquitin are believed to modulate this 
pathway [202, 203]. As mentioned earlier a number of papers have also highlighted 
non-genetic mechanisms that lead to reduced BMPRII protein levels, including 
ubiquitination and proteasomal degradation mediated by Smurf1, K5 and E3 ligase 
and Itch [17, 190]. KSHV has been shown to downregulate BMPRII and it is 
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believed that this occurs through the expression of the ubiquitin ligase K5, this work 
shows that expression of K5 can dowregulate BMPRII through ubiquitation and 
lysosomal degradation leading to aberrant BMP signalling [204]. Following on from 
this work the same group showed that by inhibiting lysosomal degradation using 
chloroquine that the development and progression of PH in MCT rats was prevented. 
In addition using the MCT model of PH where BMPRII levels are significantly 
reduced, chloroquine, elevated BMPRII expression in the lung of MCT rats 
compared to vehicle controls. In-vitro chloroquine increased BMPRII expression 
suggesting that lysosomal degration of BMPRII might contribute to the development 
of PH and that inhibition of the lysosome may be a novel approach in the treatment 
of PAH [205]. 
Due to this alteration in BMPRII protein turnover in the TβRII∆k-fib model and 
patients, MG132 a proteasomal degradation inhibitor was investigated. Bortezomib 
is another example of a proteasomal degradation inhibitor which is currently FDA 
approved for the treatment of patients with multiple myeloma [206].In animal 
models, proteasomal inhibition has demonstrated an ability to alleviate liver fibrosis, 
cardiac fibrosis, renal fibrosis and myelofibrosis [207-210]. Interestingly bortezomib 
has already demonstrated efficacy in the bleomycin model of fibrosis, it promoted 
normal wound healing and prevented the development of skin and lung fibrosis. 
Bortezomib significantly reduced collagen content in the lung and skin thickness in 
the bleomycin model and also significantly reduced TGFβ induction of α-SMA and 
CTGF in lung fibroblasts [132]. This study highlights the potential for proteasomal 
inhibition in pulmonary complications of SSc however another study reported 
conflicting data. This study showed that neither bortezomib nor MG132 
demonstrated efficacy in the bleomycin model of lung fibrosis or the in the TSK-
1/+model of skin fibrosis [211].  
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4.2 Aims 
In the TβRIIΔk-fib model of SSc, BMPRII expression and downstream signalling 
pathways were altered, suggesting dysfunctional expression of BMPRII and altered 
phosphorylation of signalling proteins that comprise the TGFβ superfamily 
signalling pathways. Building on these observations the aim of this chapter was to 
explore the relevance in SSc patients. Expression of BMPRII and components of the 
TGFβ superfamily signalling pathways was assessed in whole lung tissues and 
explant cultured fibroblasts from SSc patient. Downstream signalling BMP pathways 
are altered in the TβRIIΔk-fib model, and using SSc explant lung fibroblasts the 
donor controls and SSc fibroblasts were exposed to BMP4 treatment to assess the 
activation of downstream signalling pathways. Following on from interrogating the 
TGFβ and BMP signalling pathways the aim was to demonstrate functional changes 
in explant cultured lung fibroblasts that might contribute to the development of PAH 
and vascular remodelling. 
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4.3 Results 
4.3.1 SSc lung exhibits enhanced TGFβ activity in both whole tissue and explant 
cultured fibroblasts. 
Initially I sought to determine whether the TGFβ/BMP axis imbalance observed in 
the lungs of the TβRIIΔk-fib mouse model of SSc had clinical relevance to SSc 
patients. Using Western blot, the expression of components of the TGFβ superfamily 
downstream signalling pathway was assessed in explant cultured lung fibroblasts 
established from SSc patients and compared these to control lung fibroblasts. The 
expression profile of the TGFβ superfamily from explant cultured lung fibroblasts 
from patients with SSc and healthy controls was assessed by Western blot (Figure 
4.1 A). Lung fibroblasts from SSc patients demonstrated significantly elevated levels 
of phosphorylated-Smad 2/3 and phosphorylated-ERK 1/2 (p<0.05; Figure 4.1 A). 
There was no significant change in expression of phosphorylated Smad 1 and 
phosphorylated-p38 in explant cultured lung fibroblasts from SSc patients (Figure 
4.1 A). There was no significant difference in Smad 1, Smad 2/3, ERK 1/2 and p38 
protein expression in normal fibroblasts compared to fibroblasts from SSc patients 
(Figure 4.1). 
Given the enhanced phosphorylation of Smad 2/3 expression in explant lung 
fibroblasts, a number of classically TGFβ regulated genes were assessed by qPCR in 
explant cultured lung fibroblasts. Expression of PAI-1, CTGF and the BMP 
antagonist Gremlin-1 (Figure 4 C) demonstrated elevated basal expression, however 
this failed to reach statistical significance (Figure 4 C). Collectively suggesting the 
TGF signalling pathway may be elevated in SSc lung fibroblasts. Interestingly 
enhanced TGFβ activity has been observed in skin fibroblasts from SSc patients 
suggesting that heightened TGFβ activity might be a shared mechanism in both the 
skin and lung of SSc patients [174]. 
Fibroblasts are a key cell type involved in the SSc and SSc-PAH but the expression 
of TGFβ and BMP patways in whole lung tissue was also of interest. From this the 
the expression of TGFβ superfamily and downstream signalling pathways in whole 
lung tissue were investigated. Interestingly results in whole lung tissue was similar to 
explant cultured fibroblasts, Lung tissue from SSc patients demonstrated 
significantly elevated levels of phosphorylated-Smad 2/3 and phsphorylated-ERK 
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1/2 (p<0.05;Figure 4.2 A). There was no significant change in expression of 
phosphorylated-Smad 1 and phosphorylated-p38 in whole lung tissue from SSc 
patients (Figure 4.2 A). There was no significant difference in Smad 1, Smad 2/3, 
ERK 1/2 and p38 protein expression in normal fibroblasts compared to fibroblasts 
from SSc patients (Figure 4.2A). 
Immunohistochemistry (IHC) was used to explore the expression and distribution of 
phosphorylated-Smad 1 and phosphorylated-Smad2/3 in paraffin embedded lungs 
from control lung tissue and lung tissue from SSc-PAH patients. Lungs from both 
controls and SSc-PAH patients exhibit similar staining patterns for phosphorylated-
Smad 1 (Figure 4.3A). IHC assessment of phosphorylated-Smad2/3 expression 
demonstrated enhanced levels in the SSc-PAH lungs compared to controls (Figure 
4.3B). 
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Figure 4.1 – Expression of components of the TGFβ superfamily and 
downstream signalling pathways in explant cultured fibroblasts 
Western blots were performed on proteins isolated from confluent monolayers of 
explant cultured lung fibroblasts from control (NLF) and SSc (SLF) patients (n=6). 
Blots were probed for expression of phosphorylated-Smad 2/3 (pSmad 2/3), Smad 
2/3, phosphorylated-Smad1 (pSmad1), Smad1, phosphorylated-ERK 1/2 (pERK 
1/2), ERK 1/2, phosphorylated-p38 (p-p38) and p38 (A). Protein loading was 
determined by β-tubulin levels and representative blots are shown above (A). 
Densitometry was performed and the mean ± SEM expression of p-Smad 2/3, 
Smad2/3, pSmad1, Smad1, pERK 1/2, ERK 1/2, p-p38 and p-38 was normalised to 
β-tubulin expression and plotted (B). Quantitative polymerase chain reaction (qPCR) 
of RNA from NLF and SLF explant cultured fibroblasts (n=6) for TGFβ regulated 
genes PAI-1, connective tissue growth factor (CTGF) and Gremlin-1 and expression 
was normalised to succinate dehydrogenase complex, subunit A (Sdha) gene and the 
mean ± SEM plotted (C). *p<0.05 using Mann-Whitney Tests (C).  
NLF                   SLF
pSmad 1
Smad1
pSmad 2/3
Smad 2/3
pERK 1/2
ERK 1/2
p-p38
p38
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C
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Figure 4.2 – Expression of components of the TGFβ superfamily and 
downstream signalling pathways in whole lung tissue 
Western blots were performed on proteins homogenates of whole lung tissue from 
control (N) and SSc patients (n=6). Blots were probed for expression of 
phosphorylated-Smad 2/3 (pSmad 2/3), Smad 2/3, phosphorylated-Smad1 (pSmad1), 
Smad1, phosphorylated-ERK 1/2 (pERK 1/2), ERK 1/2, phosphorylated-p38 (p-p38) 
and p38 (A). Protein loading was determined by β-tubulin levels and representative 
blots are displayed above (A). Densitometry was performed and expression 
normalised to β-tubulin levels and the ratio of the mean ± SEM expression of p-
Smad 2/3 to Smad2/3, p-Smad1 to Smad1, p-ERK 1/2 to ERK 1/2, p-p38 and p-38 
plotted (B). *p<0.05 using Mann-Whitney Test.  
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Figure 4.3 – Immunohistochemistry of phosphorylated-Smad 1 and 
phosphorylated-Smad 2/3 in SSc-PAH lung 
Immunohistochemical staining for phosphorylated-Smad 1 (pSmad1) (A) and 
phosphorylated-Smad2/3 (pSmad2/3) (B) on paraffin embedded formalin fixed lung 
sections from control lung (Normal) and SSc-PAH patients was performed. 
Representative images shown of n=3 per group. Black arrow indicates vascular 
staining. Magnification x20. Images were taken using the Carl Zeiss microscope.  
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4.3.2 A reduction in BMPRII in SSc lung may be a susceptibility factor to the 
development of PAH in SSc patients 
The expression of BMPRII in whole lung tissue and fibroblasts from SSc patients 
was investigated to examine if BMPRII reduction was observed in concordance with 
enhanced TGFβ activity. Using Western blot analysis the expression of BMPRII was 
assessed from confluent explant cultured lung fibroblasts and homogenised whole 
lung tissue from SSc patients and patients from other diseases with no lung 
involvement (Figure 4.4 A, C). SSc-PAH explant cultured lung fibroblasts exhibited 
a significant reduction in BMPRII expression compared to healthy controls (p<0.05; 
Figure 4.4 C.)  
 
BMPRII protein expression in whole lung tissue was investigated by Western blot 
analysis, there was a significant reduction in BMPRII expression in whole lung 
tissue in SSc-PAH patients compared to control lung (p<0.05; Figure 4 B, D). 
 
IHC confirmed a reduction in BMPRII in SSc-PAH patients, normal unaffected lung 
displayed BMPRII expression around vascular structures as indicated by black 
arrows compared to control tissue (Figure 4.4F). 
 
The levels of BMPRII gene transcripts were then investigated by qPCR. Whereas 
BMPRII protein levels were significantly reduced, BMPRII gene expression was 
elevated and was trending towards significance (Figure 4.4 E); suggesting that post 
transcriptional effects are responsible for the reduction in BMPRII protein 
expression. Proteasomal degradation and ubiquition that has previously been 
implicated in pulmonary fibrosis and PAH and this suggests there might be a similar 
mechanism in SSc and the development of PAH in these patients.  
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Figure 4.4 – Expression of BMPRII in explant cultured fibroblasts and whole 
lung. 
Western blots were performed on proteins isolated from confluent monolayers of 
explant cultured lung fibroblasts from control (NLF) and SSc (SLF) patients and 
whole lung tissue from control (normal) and SSc-PAH patients (n=3). Blots were 
probed for expression of BMPRII (A, B). Protein loading was determined by β-
tubulin levels (A, B). Densitometry was performed and the mean ± SEM expression 
of BMPRII was normalised to β-tubulin expression and plotted (C, D). *p<0.05 
using Mann-Whitney Test. BMPRII expression levels was determined by 
quantitative polymerase chain reaction (qPCR) of RNA isolated from explant 
cultured fibroblasts from NLF and SLF and expression normalised to succinate 
dehydrogenase  complex, subunit A (Sdha) gene (n=6) (E). Immunohistochemical 
staining for BMPRII on paraffin embedded formalin fixed lung sections from normal 
and SSc patients. Black arrow indicates vascular staining. Representative images 
shown (n=3). Magnification x100 using Carl Zeiss Microscope, (F). 
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4.3.3 SSc fibroblasts exhibit an aberrant response to BMP ligands 
BMP’s acting via the receptor BMPRII activates a number of downstream signalling 
pathways including the canonical signalling pathways Smad 1, 5 and 8 as well as 
non-canonical signalling pathways ERK 1/2 and p-38. 
 
To assess if the reduced expression of BMPRII in SSc fibroblasts resulted in a 
functional reduction in response to BMP ligands, the effect of BMP4 on 
phosphorylation of downstream signalling proteins was assessed. Explant cultured 
fibroblasts from SSc-PAH and control patients were serum starved for 24 hours 
followed by stimulation with BMP4 (5 ng/ml) for 30 minutes to assess the 
phosphorylation of Smad1 and ERK 1/2 and p38 proteins. Explant cultured 
fibroblasts from SSc-PAH fibroblasts exhibited similar basal levels of 
phosphorylated-Smad 1. Control donors exhibited significantly higher induction of 
phosphorylated Smad1 in response to BMP4 compared with SSc-PAH fibroblasts, 
which displayed a blunted induction of phosphorylated Smad1 levels in response to 
BMP4, (p>0.05; Figure 4.5A, B).  
 
Assessment of explant cultured fibroblasts from SSc-PAH fibroblasts demonstrated a 
significant elevation in basal levels of phosphorylated-ERK 1/2 compared to healthy 
controls. Stimulation of control donor fibroblasts with BMP4 induced a significant 
induction of phosphorylated-ERK 1/2, whereas SSc-PAH fibroblasts displayed a 
blunted response to BMP4 with no significant induction of phosphorylated-ERK 1/2 
levels observed, (p>0.05; Figure 4.5A, B).  
Explant cultured fibroblasts from normal and SSc-PAH fibroblasts exhibited similar 
basal levels of phosphorylated p38 and no significant induction of phosphorylated-
p38 by BMP4 was noted in healthy control or SSc fibroblasts.  
Taken collectively, these results suggest that a reduction in BMPRII expression leads 
to a blunted response to BMP 4 in SSc fibroblasts. 
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Figure 4.5 - SSc lung fibroblasts exhibit a blunted response to BMP4 which 
results in a perturbed BMP signalling profile 
Monolayers of explant lung fibroblasts established from control (NLF) and SSc 
patients (SLF) were stimulated with BMP4 [5 ng/ml] for 0.5 hours in three 
independent experiments and phosphorylated-Smad1 (pSmad1), Smad1, 
phosphorylated-ERK 1/2 (pERK 1/2), ERK 1/2, phosphorylated-p38 (p-p38) and 
p38 levels determined by Western blot (A). Densitometry was performed and the 
mean ± SEM expression of pSmad1, pERK 1/2 and p-p38 normalised to Smad 1, 
ERK 1/2 and p38 expression and plotted (B). *p<0.05 using Mann-Whitney Test.  
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4.3.4 Proteasomal degradation inhibitor MG132 can upregulate BMPRII 
expression and restore responses to BMP ligands. 
Previously ubiquitination and proteasomal degradation of BMPRII have been 
proposed to contribute to further reduction of BMPRII protein levels in HPAH 
patients [190, 204]. To investigate the effect of proteasomal degradation on the 
reduced BMPRII protein expression in lung fibroblasts established from SSc patients 
the effect of the inhibitor MG132 was assessed.  
Explant cultured lung fibroblasts were serum starved for 24 hours followed by 
exposure to MG132 (1 μM) or vehicle control for a further 16 hours and expression 
of BMPRII was assessed by Western blot. Consistent with 4.3.3, there was a 
significant reduction in BMPRII expression in SSc fibroblasts compared to healthy 
controls. The addition of MG132 led to a significant increase in BMPRII protein 
levels both in healthy control and SSc fibroblasts (p<0.05; Figure 4.6 A, B).  
As highlighted in figure 4.5 explant cultured fibroblasts display a blunted response to 
BMP4 stimulation. To establish if elevation in BMPRII levels in response to MG132 
led to a composite restoration of cellular responses to BMP4, phosphorylation of 
Smad1 was assessed. Serum starved explant cultured lung fibroblasts exposure to 1 
μM of MG132 or vehicle control for 16 hours were exposed to BMP4 (5 ng/ml) for 
30 minutes and phosphorylated Smad1 assessed by Western blot. Pre-treatment of 
lung fibroblasts from control and SSc donors with MG132 resulted in an increase in 
BMP4 ligand induction of phosphorylated Smad1 compared with BMP4 treatment 
alone. MG132 exhibited significantly greater effects on phosphorylation of Smad1 in 
fibroblasts derived from SSc patients compared to healthy donor controls (p<0.05; 
Figure 4.6 C). 
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Figure 4.6 – The proteasomal inhibitor MG132 enhances BMPRII levels in 
explant cultured fibroblasts in normal and SSc patients 
Western blots were performed on proteins isolated from confluent monolayers of 
explant cultured lung fibroblasts from normal and SSc patients (n=3).  Blots were 
probed for expression of BMPRII. Protein loading was determined by β-tubulin 
levels (A). Densitometry was performed and the mean ± SEM expression of BMPRII 
normalised to β-tubulin expression and representative blots plotted (B). Monolayers 
of explant lung fibroblasts established from normal and SSc patients were stimulated 
with FCS (0.1%), MG132 (1 μM) for 16 hours followed by BMP4 (5 ng/ml) for 0.5 
hours in three independent experiments and phosphorylated-Smad1 (pSmad1) 
determined by Western blot. p-Smad1, protein levels was determined by β-tubulin 
levels (C). Densitometry was performed and the mean ± SEM expression of pSmad1 
was normalised to β-tubulin expression and plotted (D). *p<0.05 using Mann-
Whitney Tests.  
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4.3.5 SSc fibroblasts display pro-migratory and proliferative properties 
Proliferation and migration are two key characteristics that can contribute to vascular 
remodelling in SSc-PAH. Fibroblasts that exhibit enhanced migration and 
proliferation may contribute to medial thickening and muscularisation in pulmonary 
vessels. 
The ability of explant cultured fibroblasts from normal and SSc patients to migrate in 
response to stimulation with FCS (1%) or PDGFBB (10 ng/ml) was assessed. 
Confluent monolayers of fibroblasts were scratched and treated with either 1% FCS 
alone or 10ng/ml of PDGFBB in the presence of the anti-proliferative Mitomycin-C 
(10 µg/ml) and migration assessed after 48 hours (Figure 4.7 A). Migration was 
observed in both normal and SSc explant cultured lung fibroblasts in the presence of 
PDGFBB. However fibroblasts from SSc patients demonstrated a significant 
increased ability to migrate across the scratched monolayer in response to PDGFBB 
treatment compared to normal lung fibroblasts (p<0.05; Figure 4.7 B). 
To assess the ability of explant cultured fibroblasts to proliferate, lung fibroblasts 
were treated with FCS (1%) or PDGFBB (10 ng/ml). Lung fibroblasts from SSc 
patients demonstrated a significant increase in cell numbers compared to normal 
fibroblasts in response to FCS (1%) or PDGFBB (10 ng/ml). PDGFBB exhibited 
greater rates of proliferation in both normal and SSc fibroblasts compared to 1% 
FCS (p<0.05; Figure 4.7 C). Collectively these results suggest that SSc fibroblasts 
exhibit an increased capacity to migrate and proliferate in response to PDGFBB and 
suggest that this is a potential mechanism that contributes to vascular remodelling in 
SSc-PAH. 
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Figure 4.7 – SSc lung fibroblasts exhibit increased migratory and proliferative 
capacity compared to healthy donors in response to PDGFBB 
Confluent monolayers of scleroderma (SLF) and control donor lung fibroblasts 
(NLF) were scratched and migratory responses assessed in response to 1% FCS  and 
10 ng/ml of Platelet derived growth factor (PDGFBB) in the presence of 10 μg/ml 
Mitomycin C for 48 hours (A). Experiments were performed on three patients per 
group in triplicate. Migration was assessed after 24 hours, images were taken using 
the Olympus CDK2 microscope and data analysed using Axio Vision software.  
*p<0.05, Mann-Whitney Test (B). Basal and 50 ng/ml PDGFBB mediated 
proliferation in NLF and SLF. Data represents the fold proliferation induced by 
PDGFBB compared to vehicle controls and are expressed as the mean of three 
donors. Proliferation was assessed after 72 hours (C). *p<0.05, Mann-Whitney Test 
(C). 
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4.4 Discussion 
Clinical observations suggest that SSc provides a permissive phenotype in which 
PAH can occur, but that this may be independent of other manifestations of the 
disease. For example, PAH occurs from around 36 months of disease duration and 
with equal frequency in the two major SSc subsets suggesting it is does not reflect 
skin involvement. Also, unlike other cardio-respiratory manifestations that tend to 
occur early in the disease, PAH develops in 1-2 percent of cases throughout follow 
up and represents a time dependent risk [38]. Thirdly, borderline elevation of mean 
pulmonary artery pressure confers a higher risk factor for the development of PAH 
suggesting that there is progressive pulmonary haemodynamic change in SSc 
patients that can in some cases progress to PAH [212]. Since it has been shown 
previously highlighted that a reduction of functional cell surface expression of 
BMPRII is strongly associated with the development of HPAH and IPAH, I wanted 
to investigate BMPRII expression in the lung of SSc patients [183, 184]. In this 
chapter it is highlighted that patients with SSc have a reduction of BMPRII in whole 
lung tissue and explant cultured lung fibroblasts and this may represent common 
susceptibility mechanism in HPAH, SSc and IPAH patients. Furthermore this data 
suggests a key role for heightened activity of the TGFβ pathway in driving this 
process in SSc. 
Previous reports have demonstrated PASMCs from HPAH patients with BMPRII 
mutations exhibit enhanced responsiveness to TGFβ1, including elevated secretion of 
inflammatory chemokines and enhanced pro-proliferative response, a phenomenon 
replicated in mice harbouring nonsense BMPRII mutations [17, 173]. Enhanced 
TGFβ signalling has previously been reported in IPAH vessels [152,174,194]. 
Indicative of enhanced TGFβ signalling, in both whole lung tissue and lung 
fibroblasts from SSc patients elevated phosphorylated levels of Smads 2/3 was 
observed. Consistent with this a number of groups have demonstrated that preclinical 
models of PAH exhibit enhanced TGFβ activity including the monocrotaline rat, 
chronic hypoxia and hypoxia SU5416 models, and in concordance with a reduction 
in BMPRII levels [141,146,176]. A number of studies have demonstrated 
pharmacological antagonists of the TGFβ signalling pathway can inhibit and reverse 
the development of PAH in preclinical models which exhibit a non-genetic reduction 
in BMPRII levels in tissues [194].  Consistent with this the TβRIIΔk fib model of 
117 
 
SSc which exhibits enhancement in TGFβ signalling including phosphorylated levels 
of Smads 2/3, spontaneously develops PAH under normoxic conditions. Collectively 
these studies support the notion that enhanced TGFβ activity and downstream 
signalling contributes to the development of PAH. These results support the role of 
TGFβ signalling in the development of PAH both in SSc and other forms of PAH. 
Previous studies have demonstrated PASMCs with reduced BMPRII expression 
exhibit altered responses to TGFβ [17, 177]. There is a marked reduction in 
pulmonary vascular BMPRII expression in both whole lung and lung fibroblasts 
from TβRIIΔk fib mice compared to wildtype controls as discussed in chapter three. 
In this chapter BMPRII expression was found to be reduced in both lung fibroblast 
and whole lung tissue from SSc patients. Interestingly BMPRII transcripts were not 
significantly different in control or SSc lung fibroblasts, suggesting the reduction in 
BMPRII may result from changes in protein turnover or dysfunctional protein 
stability.  
 
It has also been implicated that a reduction in BMPRII in PASMCs from PAH 
patients is associated with a blunted induction by BMP ligands of downstream 
signalling pathways [23]. Similarly, as shown in chapter three, fibroblasts isolated 
from the TβRIIΔk fib model exhibited reduced BMPRII expression and a blunted 
response to BMP ligands. Consistent with this BMP4 induced a significant increase 
in phosphorylated Smad1 and phosphorylated ERK 1/2 in healthy control fibroblasts, 
whereas little or no effect on the induction of phosphorylated-Smad1 or 
phosphorylated-ERK 1/2 was observed in SSc lung fibroblasts. This suggests that 
the reduction in BMPRII protein levels in SSc lung may be contributing to aberrant 
BMP signalling. 
 
A number of studies have demonstrated that non-genetic mechanisms can impact on 
expression of BMPRII [190, 213]. A recent study demonstrated reduction of protein 
and mRNA of BMPRII in microvascular endothelial cells and skin of SSc patients 
resulted from epigenetic repression [175]. Other studies have demonstrated a 
putative role for ubiquitination and subsequent degradation of BMPRII [213]. 
Kaposi sarcoma-associated herpesvirus (KSHV) has been implicated as an 
etiological agent promoting the development of PAH. Durrington et al. revealed that 
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the KSHV expressed protein K5, ubiquitinates the cytoplasmic domain of BMPRII, 
leading to lysosomal degradation [204]. Further, overexpression of Smurf1 reduces 
steady-state levels of BMPRII through ubiquitination and subsequent proteasomal 
and lysosomal degradation [17, 190]. Consistent with this Smurf1 mRNA levels are 
elevated in SSc lung fibroblasts (Personal communication, A Holmes). These 
findings suggest that enhanced protein degradation may be responsible for reduced 
BMPRII expression in SSc.  
Using the proteasomal inhibitor MG132 which has previously been reported to 
reverse bleomycin-induced fibrosis in mice suggesting that MG132 has therapeutic 
efficacy in the lung [132]. BMPRII protein expression in fibroblasts from SSc 
patients was up-regulated in the presence of MG132, although not to those levels 
observed in healthy controls. Consistent with the partial restoration of BMP 
signalling, treatment of SSc fibroblasts with MG132 and the subsequent addition of 
BMP4 led to a significant induction of phosphorylated-Smad1. This suggests that 
proteasomal inhibitors may reduce the risk of SSc patients developing PAH and may 
be a potential protective mechanism in patients that are borderline PAH. 
Interestingly explant cultured fibroblasts from SSc patients exhibited increased 
migratory and proliferative capacity compared to healthy controls. The proliferation 
and expansion of α-SMA positive cells in vascular remodelling suggest that the 
activated fibroblast in SSc patients could contribute to vascular remodelling and 
occlusion of the lumen. Interestingly Hummers and colleagues has shown PDGFBB 
to be elevated in the serum of SSc patients, and thus contribute to remodelling in SSc 
patients [214]. 
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4.5 Conclusion 
In conclusion, experiments in this chapter have shown a reduction in BMPRII 
protein in lung tissue and fibroblasts from patients with SSc. This was associated 
with enhanced activation of downstream components of the TGFβ signaling 
pathway. In contrast to HPAH and IPAH patients, where a significant proportion 
harbour mutations in the BMPRII gene, data suggests that the blunted response of  
SSc lung fibroblasts to BMP ligands results from post-transcriptional events that lead 
to reduction in the levels of BMPRII protein, and that this could be partially restored 
in-vitro using the proteasomal inhibitor MG132. Collectively these results suggest 
SSc may act to phenocopy HPAH by promoting an environment where BMPRII 
protein levels and downstream signalling is reduced and promotes increased 
susceptibility to the development of PAH in the background of SSc. 
  
120 
 
5. Differentiated PASMCS may resemble PASMCs isolated 
from patients with non-heritable forms of PAH 
5.1 Introduction 
PH is defined as elevated blood pressure in the arteries of the lung; greater than 
25mmHg at rest and is sub-divided into a number of groups (Table 1.1). PAH 
(Group 1) results from specific vascular changes in the structure of the pulmonary 
vessels that in turn leads to the increased pulmonary vascular resistance and elevated 
mean PAP [16]. It is believed that PASMCs are a cell type that can contribute to the 
development of PAH in both HPAH and SSc-PAH. In the development of PAH 
associated with other underlying pathologies, such as the connective tissue diseases 
like SSc the disease is more diverse since it may fall into Group I or other Groups of 
pulmonary hypertension. SSc patients may develop elevated pulmonary pressures as 
a result of pulmonary fibrosis, termed SSc-PH (Group 3; Table 1) or independently 
of major pulmonary fibrotic complications termed SSc-PAH (Group 1; Table 1). The 
work in chapter three and chapter four have focused on the role of fibroblasts in the 
development of SSc-PAH and in this chapter the work focuses on the potential role 
of PASMCs another key cell type involved in PAH pathology.  
It is currently considered that the majority of SSc patients with increased develop 
SSc-PAH which was highlighted in the recent DETECT study [15]. The overall 
prevalence of all types of PAH is estimated to be between 30-50 cases per million 
[58]. Of these, the heritable forms of PAH represent a relatively small component of 
cases, 2-3 per million per year [58, 59]. The incidence of all PAH in SSc patients has 
been estimated to be between 6-60% of all patients [60]. Survival studies have 
shown patients with SSc-PAH have a particularly poor prognosis compared to those 
with PAH alone, with 1-year survival estimated at 55% compared to 84% in HPAH 
patients [62].  
The more severe prognosis of SSc-PAH compared PAH alone suggests that 
comparing the PAH pathobiology in non-heritable forms of PAH in patients with 
IPAH and SSc-PAH may provide further information into disease prognosis and 
elucidate factors that are different or the same in these diseases. There has been 
extensive research based around PASMCs in PAH but in SSc, the main body of in-
vitro research is based around the transition of the fibroblast to a myofibroblast; and 
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more recently the role circulating progenitor cells for example fibrocytes in SSc 
[109]. 
SSc-PAH exhibits similar pathological changes to other forms of PAH including 
excessive pulmonary vasoconstriction, vascular remodelling and occlusion and the 
occurrence of plexiform lesions [16]. These processes that affect the intima, media 
and adventitia, lead to the narrowing of the lumen. These changes are associated 
with cellular changes in smooth muscle cell morphology, apoptosis of endothelial 
cells and proliferation of vascular cells including SMCs endothelial cells and 
fibroblasts [16]. Collectively these processes lead to the narrowing and occlusion of 
the pulmonary arterioles.  
The major focus of this study was PASMC differentiation and alterations in the 
microenvironment, for example increased secretion of pro-inflammatory cytokines, 
IL-6, IL-8, PDGFBB and CTGF may also contribute to the differentiation of 
PASMCs from a contractile to synthetic cell [16, 17] Furthermore, contractile 
PASMCs are less proliferative and migratory than synthetic PASMCs [21], whereas 
synthetic PASMC deposit more matrix proteins such as collagen-type I [114]. The 
switching of a contractile PASMC to a synthetic cell type plays a key role in PH by 
promoting vascular remodelling and occlusion of the vessel [21]. The maintenance 
of a healthy contractile cell that controls these factors discussed above is determined 
by a host of factors including hypoxia, cell-to-cell contact, growth factors and 
cellular injury [21]. When these changes occur a contractile cell differentiates into a 
synthetic PASMC and cellular responses are altered. 
It has been previously highlighted that BMPs promote the maintenance contractile 
SMC phenotype which is characterised by the up-regulation of the contractile marker 
α-SMA, while the addition of PDGFBB in culture to PASMCs reduces the 
expression of α-SMA promoting a synthetic SMC phenotype [20]. In HPAH, 70% of 
patients have mutations in the BMPRII gene [2], which leads to a reduction in the 
expression of functional BMPRII receptors on the cell surface and reduced 
responsiveness to BMP ligands. This dysregulation of BMP signalling in patients 
with HPAH is likely to play a role in the normal homeostasis of PASMCs and their 
phenotypic modulation, promoting differentiation from a contractile to synthetic 
phenotype [20]. Moreover, mechanistic studies involving BMP4 and miR-21 have 
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highlighted a key mechanism by which PASMC differentiation occurs and 
potentially contributes to the development of PAH. The addition of BMP4 to 
PASMCs leads to Smad signalling, association with primary transcripts of miR-21 
and the knockout of a negative regulator of contractile gene expression, programmed 
cell death 4 (PDCD4). Furthermore, PDGFBB induces miR-221, which leads to 
uncontrolled cell proliferation and down regulation of contractile genes [215]. In-
vivo it has been reported that miR-21 is unregulated in the distal small arteries in the 
lungs of the hypoxia murine model of PAH [216]. It has been reported a number of 
times that in patients with atherosclerosis that their aortic SMCs located in the intima 
compared to both the media and adventitia have increased expression of PAI-1 and 
phosphorylated-Smad2. The expression of these markers suggests in atherosclerosis 
the aortic SMC phenotype displays enhanced TGFβ activity [217]. Interestingly it 
has been reported that in PAH there is an increase in phosphorylated-Smad 2/3 
expression in concentric lesions suggesting that the synthetic PASMC might also be 
contributing to this enhanced activity [152].  
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5.2 Aims 
The aim of this chapter was to develop a robust assay of PASMC differentiation to 
better assess the contribution of this cell to the development of SSc-PAH. During the 
development of PAH changes in the cellular microenvironment leads to alterations in 
proliferation, migration, and apoptosis rates in vascular cells including fibroblasts, 
PAECs and PASMCs [16, 217-220]. These changes contribute to the differentiation 
of contractile PASMCs to the more disease relevant ‘synthetic’ PASMCs. The aim 
of this chapter was to develop a robust assay of PASMC differentiation to better 
assess the contribution of this cell to the development of SSc-PAH. I initially sought 
to compare the functional differences of contractile and synthetic PASMCs 
extending these studies to investigate BMPRII expression and TGFβ signalling. 
Finally the impact of PASMCs differentiation on the capacity of PAECs to form a 
functional barrier was assessed. 
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5.3 Specific methods 
5.3.1 PASMC differentiation in-vitro 
PASMCs (Promocell) were maintained in contractile PASMC medium (Promocell) 
supplemented with 5 % (v/v) FBS (Gibco) and 1 % (v/v) Penicillin-Streptomycin 
(Gibco). PASMCs were removed from the monolayer by trypsinisation (Trypsin-
EDTA, Sigma) and counted using the trypan-blue method. The trypan blue method 
is used for determining cell number and the assay is based on the fact that non-viable 
cells turn blue due to loss of their membrane integrity while the viable cells do not 
absorb the trypan blue because there membrane remains intact. 10 µl of cell 
suspension was transferred into an eppendorf along with 10µl of trypan blue. A 
cover slip was placed on top of the haemocytometer and 10 µl of the mix was added 
to the cover slip to fill the counting chambers. The cells were then counted using a 
Carl Zeiss Axio Cam microscope. Contractile PASMCs were seeded at 2 x 10
4
 cells 
per well of a 6 well plate for 24 hours. After 24 hours medium of each well was 
replaced with fresh medium, supplemented with 5 % (v/v) FBS and 1 % (v/v) 
Penicillin-Streptomycin (Gibco) for contractile and 15 % (v/v) FBS and 1 % (v/v) 
Penicillin-Streptomycin (Gibco) for synthetic PASMCs. Contractile PASMCs were 
observed to be spindle like cells and synthetic cells were a more rhomboid shape. 
The increased concentration of FCS with increased growth factors may be 
contributing to the differentiation observed and an example of one growth factor that 
may be inducing this differentiation is PDGF. At each time point day 3, day 7, day 
10 and day 14 the PASMCs were serum starved in 0.1% FCS for 24 hours and 
medium collected. Cell monolayers were washed in 1xPBS and lysed in 120 μl lysis 
buffer comprising Radio Immuno Precipitation Assay (RIPA) buffer (Sigma) 
containing 150 mM NaCl, 50mM Tris pH 7.4; 1mM PMSF; 1% PMSF; 1% NP-40; 
1% Sodium deoxycholic acid; 0.1% SDS; 10% complete, Mini, EDTA-free protease 
inhibitor cocktail (Roche) and phosphatase inhibitor cocktail 3 serine/threonine 
protein phosphatases and L-isozymes of alkaline phosphatase inhibitor (Sigma,UK). 
Protein concentrations were determined using the BCA Protein Assay kit (Pierce # 
23225), and 15 g of protein mixed with 4x SDS Loading Buffer (8% SDS, 250mM 
Tris HCl pH 6.8, 20% glycerol) 5% -mercaptoethanol and denatured at 96C for 5 
minutes. 
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5.4 Results 
5.4.1 PASMC differentiation leads to changes in morphology and protein 
markers of contractile PASMCs. 
Pathological changes in PASMCs are believed to be a key feature in the 
development of PAH [16]. The switching of the contractile PASMC phenotype to a 
synthetic SMC phenotype is believed to be a feature of vascular remodelling in a 
number of diseases including PH [16]. Initial experiments sought to define 
conditions to promote differentiation of PASMCs cells from contractile to synthetic 
phenotype and assess this using a series of techniques, including Western blotting 
and immunofluorescence (IF). Based upon previous studies on SMC differentiation 
the effects of increased serum and, cell to cell contact on contractile PASMCs and 
synthetic PASMCs morphology and markers was assessed. Contractile PASMCs 
exhibit a more spindle like morphology, whilst synthetic PASMCs differentiate into 
a more rhomboid like cell (Figure 5.1 A). α-SMA was identified as a contractile 
marker and was mostly highly expressed at day 3 in contractile PASMCs with a 
significant reduction observed in synthetic PASMCs from day 3 to 7, 10 and 14 
(p<0.05). Smoothelin expression was elevated in contractile PASMCs at day 3, 
whilst a reduction was observed in synthetic PASMCs with significance achieved at 
day 14 (Figure 5.1 B, C; p<0.05). Expression of calponin and SM-22-alpha did not 
change significantly in contractile nor synthetic PASMCs. CTGF expression was 
elevated in synthetic PASMCs compared to contractile PASMCs at day 3, 7 and 10 
with significant elevation of CTGF expression at day 14 in synthetic PASMCs 
(Figure 5.1; p<0.05). Type-1 collagen expression was elevated in synthetic PASMCs 
compared to contractile PASMCs at day 3, 7 and 10 with significant elevation of 
type-1 collagen expression observed at day 14 in synthetic PASMCs (Figure 5.1 B, 
C; p<0.05). IF studies echoed these observations, α-SMA and smoothelin expression 
(Figure 5.2 A) was elevated in contractile PASMCs compared to synthetic PASMCs, 
whilst type-I collagen and CTGF expression was elevated in synthetic PASMCs 
compared to contractile PASMCs (Figure 5.2 B). 
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Figure 5.1 - Protein markers of contractile and synthetic PASMCs 
Representative images of contractile and synthetic PASMCs after 10 days in culture 
(A). Western blot analysis was performed on protein extracts from contractile and 
synthetic PASMCs at different timepoints day (D) 3,7,10 and 14. Blots were probed 
for the expression of α-SMA, smoothelin, calponin, SM-22, CTGF and type-I 
collagen (n=3) (B) Protein loading was determined by GAPDH expression. 
Densitometry was performed and the mean ± SEM expression of α-SMA, 
smoothelin, calponin, SM-22, CTGF and type I collagen  plotted (C). *p<0.05 using 
Mann Whitney Test.  
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Figure 5.2 - Immunofluorescence staining of contractile and synthetic PASMCs 
Immunofluorescence staining was performed on contractile and synthetic PASMCs 
for α-SMA, smoothelin, CTGF and type-I collagen. Images were taken using the 
Carl Zeiss Axiovison microscope and representative images of 3 independent 
experiments shown. White line indicates 100 µM using the x 40 magnification.  
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5.4.2 PASMC differentiation leads to changes in secreted inflammatory 
proteins.  
Elevated levels of circulating pro-inflammatory proteins have been reported in the 
sera of PAH patients, and in the conditioned media from PASMCs isolated from 
patients [218]. The secretion of a number of these factors was assessed in 
conditioned serum free medium from contractile and synthetic PASMCs. PASMCs 
were either maintained as contractile PASMCs or differentiated into synthetic 
PASMCs, growth medium for both cell types was replaced with serum free medium. 
Conditioned media was collected after 24 hours and the concentration of a series of 
pro-inflammatory proteins assessed using a multiplex system. Contractile and 
synthetic PASMCs secreted detectable levels of IL-1β, IL-6, IL-8, and TNF-α and 
TNF-β. Synthetic PASMCs demonstrated increased secretion of IL-6, IL-8 and TNF-
 compared to contractile conditioned medium. Only synthetic PASMCs 
demonstrated detectable levels of IL-10 and INF. There was no significant 
difference in secreted levels of IL1-β or TNF-α in contractile or synthetic PASMCs 
(Figure 5.3A).  
 
To further assess the secretion of pro-inflammatory cytokine secretion, a temporal 
secretion of IL-6 and IL-8 in synthetic conditioned medium by ELISA was 
performed. IL-6 secretion was significantly elevated on day 3, 7, 10 and 14 in 
synthetic PASMCs compared to contractile PASMCs but maximal secretion 
occurred at day 14 (p>0.05; Figure 5.3B). IL-8 secretion was also significantly 
elevated on day 3, 7, 10 and 14 in synthetic PASMCs compared to contractile 
PASMCs. However maximal secretion occurred at day 7 with a temporal reduction 
observed at day 10 and 14 (p>0.05; Figure 5.3B). 
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Figure 5.3 – Secreted markers of PASMC contractile and synthetic switching 
Conditioned medium from contractile and synthetic PASMCs was collected at day 
(D) 3, 7, 10 and 14. Multiplex analysis was performed on the conditioned medium 
for inflammatory mediators and fold change determined of detectable proteins (A). 
Levels of interleukin-6 (IL-6) (B) and interleukin-8 IL-8 (C) were determined by 
ELISA Secretion was normalised to protein levels in the cell monolayer. The mean ± 
SEM of 3 independent experiments were plotted (B and C). *p<0.05 compared to 
contractile PASMCs, Mann-Whitney Test.  
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5.4.3 Functional differences between contractile and synthetic PASMCs. 
As demonstrated in figure 5.1, 5.2 and 5.3 contractile and synthetic PASMCs exhibit 
differences in protein and secretion profiles that may contribute to the development 
of PAH and vascular remodelling. The literature has also reported functional changes 
in PASMCs from patients of PAH so using this assay it was important to compare 
functional responses in these cells. Migration is a key cellular activity in the 
pulmonary artery that contributes to the formation of concentric lesions in the artery. 
The capacity of contractile and synthetic PASMCs to migrate in response to 
stimulation with PDGFBB was assessed. Confluent monolayers of PASMCs were 
scratched and treated with either 1% FCS as a negative control or 50ng/ml of 
PDGFBB and migration assessed after 48 hours (Figure 5.4A). These experiments 
were performed in the presence of an anti-proliferative Mitomycin-C (10 µml). 
Migration was observed in both contractile and synthetic PASMCs but a significant 
increase in migration in response to PDGFB was observed in contractile PASMCs 
compared to synthetic PASMCs (p<0.05).  
Pooled data from a series of independent experiments and donors of contraction 
assays using type-1 collagen lattices show that contractile PASMCs were 
significantly more contractile than synthetic PASMCs (p<0.05; Figure 5.4 B). 
Contractile and synthetic PASMCs were exposed to 10% FCS for 24 hours and 
results showed that this condition induced further contraction in contractile PASMCs 
compared to synthetic PASMCs (p<0.05). Contraction was assessed by measuring 
the diameter of each individual gel or the gel weight. 
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Figure 5.4 – Contractile PASMCs displays increased migration and collagen gel 
contraction compared to synthetic PASMCs 
Confluent monolayers of contractile and synthetic PASMCs were scratched and 
migratory responses assessed in response to 1% FCS alone or supplemented with 
PDGFBB (50 ng/ml). All experiments were performed in the presence of 10 μg/ml 
Mitomycin C in three independent experiments in triplicate. (A). Migration was 
assessed after 48 hours, images were taken using the Olympus CDK2 microscope 
and data analysed using Axio Vision software to determine area covered by each 
treatment group and the mean ± SEM plotted (B). Contractile and synthetic 
PASMCs were seeded in to type I collagen gels and treated with 10% FCS and gel 
contraction after 48 hours was assessed by measuring gel weight and the mean ± 
SEM plotted (C) (n=3). *p<0.05 Mann Whitney Tests. 
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5.4.3 Synthetic PASMCs display a reduction in BMPRII similar to that 
observed in PASMCs from IPAH patients. 
Previous work has suggested the importance of BMPRII and downstream signalling 
pathways in PASMCs in patients with PAH.  Expression of BMPRII and the impact 
of the BMPRIIl signalling pathway were investigated in contractile and synthetic 
PASMCs. A significant reduction in BMPRII protein expression was observed in 
synthetic compared to contractile PASMCs (p<0.05, Figure 5.5A), however there 
was no significant change in phosphorylated-Smad1 protein expression in contractile 
and synthetic PASMCs. qPCR studies were also performed to investigate BMPRII 
and Gremlin gene expression. There was a reduction in BMPRII gene expression and 
an increase in Gremlin expression in synthetic PASMCs which echoes observations 
in PASMCs from HPAH and IPAH patients (Figure 5.5B). The observation of 
reduced BMPRII, led us to investigate how both contractile and synthetic PASMCs 
respond to BMP ligands. It has been previously reported that BMP ligands induced 
apoptosis in PASMCs, to assess the implication of reduced BMPRII in PASMCs the 
effect of 0, 5, 50 and 500 ng/ml of BMP4 and BMP7 on cellular apoptosis was 
investigated [24, 151, 219, 220]. Results highlighted that at baseline there was 
reduced apoptosis in synthetic PASMCs compared to contractile PASMCs, the 
addition of BMP4 and 7 at varying concentrations displayed a blunted response in 
synthetic PASMCs but these ligands induced apoptosis in contractile PASMCs 
(p<0.05, Figure 5.6 A).  
Pooled data from a series of independent experiments and donors of contraction 
assays using type-1 collagen lattices show that contractile PASMCs promoted 
significantly more contraction than synthetic PASMCs. Exogenous addition of 50 
ng/ml of BMP4 significantly induced further contraction in contractile PASMCs but 
had little or no effect in synthetic PASMCs. Contraction was assessed by measuring 
the diameter of each individual gel or the gel weight (Figure 5.6 B). 
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Figure 5.5 – Protein and gene expression of BMPRII in PASMCs and 
downstream signalling factors 
Western blots were performed on protein isolated from both contractile and synthetic 
pulmonary arterial smooth muscle cells (PASMCs) (n=3). Blots were probed for 
expression of BMPRII and phosphorylated-Smad1, protein loading was determined 
by β-tubulin levels (A). Densitometry was performed and the mean ± SEM 
expression of BMPRII and phosphorylated-Smad1 was normalised to β-tubulin 
expression and plotted (B). *p<0.05 using Mann Whitney Tests. (B). Quantitative 
polymerase chain reaction (qPCR) of RNA for BMPRII and Gremlin 1 (C).    
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Figure 5.6 – Synthetic PASMCs displayed a blunted response in to BMP ligands 
leading to altered functional responses 
Contractile and synthetic PASMCs were seeded and exposed to 0, 5, 50, and 500 
ng/ml of BMP4 and BMP7 for 8 hours. Caspase-Glo® 3/7 reagent was then added in 
a 1:1 ratio to BMP4 and 7 and incubated for 2 hours. Plates were then read by 
luminescence to assess apoptosis (A). 
Contractile and synthetic PASMCs were treated with either 0.1% FCS or 50 ng/ml 
BMP4 for 48 hours and gel contraction was assessed by measuring gel weight (n=3). 
*p<0.05 using Mann Whitney Tests (C).   
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5.4.4 Contractile and synthetic PASMCs display differential responses to TGFβ. 
Previous studies have highlighted differences in control and HPAH PASMCs ability 
to respond to TGFβ; using the in-vitro assay of differentiation, the ability of 
contractile and synthetic PASMCs to respond to TGFβ was assessed [17]. There was 
no significant difference in phosphorylated-Smad2 protein levels in either contractile 
or synthetic PASMCs (Figure 5.7A).  qPCR was used to investigate gene expression 
of TGFβ regulated genes, both TGFβ regulated genes CTGF and PAI-1 were 
elevated in synthetic PASMCs that was trending towards significance [221].  
Pooled data from a series of independent experiments and donors of contraction 
assays using type-1 collagen lattices show that contractile PASMCs promoted 
significantly more contraction than synthetic PASMCs, furthermore TGFβ (5 ng/ml) 
significantly induces further contraction in both contractile and synthetic PASMCs 
compared to untreated PASMCs(p<0.05; Figure 5.7 B). Contraction was assessed by 
measuring the diameter of each individual gel or the gel weight.  
As previously highlighted, levels of the pro-inflammatory cytokine IL-6 were 
elevated in synthetic PASMCs (p<0.05; Figure 5.3B). However the exogenous 
addition of TGFβ (5 ng/ml) did not affect the IL-6 levels in contractile PASMCs, but 
led to a further significant increase in synthetic PASMCs which has been reported in 
PASMCs from HPAH patients [17].  
  
136 
 
 
Figure 5.7– Enhanced TGFβ activity in synthetic PASMCs 
Western blots were performed on protein isolated from monolayers of contractile 
and synthetic PASMCs (n=3). Blots were probed for expression of phosphorylated -
Smad2 (pSmad2), protein loading was determined by β-tubulin levels (A). 
Densitometry was performed and the mean ± SEM expression of pSmad2 was 
normalised to β-tubulin expression and plotted (A). 60 % confluent contractile and 
synthetic PASMCs were serum-starved (n=3) and total RNA was isolated from each 
sample and reverse-transcribed, cDNA was subjected to real-time PCR analysis PAI-
1 and CTGF and expression was normalized to succinate dehydrogenase complex, 
subunit A (Sdha) gene (C,D). Data are expressed as fold induction.. *p<0.05, using 
Mann Whitney Tests (C, D). 
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Figure 5.8 – TGFβ induces increased contraction and IL-6 secretion in synthetic 
PASMCs. 
Contractile and synthetic PASMCs were treated with either 0.1% FCS or 2 ng/ml 
TGFβ for 48 hours and gel contraction was assessed by measuring gel weight (n=3) 
(A). Conditioned medium from contractile and synthetic PASMCs was collected and 
secretion was normalised to protein levels in the cell monolayer. Levels of IL-6 was 
measured by ELISA in three independent experiments (n=3) (B). (A-B). *p<0.05, 
using Mann Whitney Tests. 
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5.4.5 The influence of contractile and synthetic PASMCs on endothelial cells. 
The paracrine interaction between PASMCs and PAECs is essential for maintaining 
haemostatic levels of migration and proliferation of medial SMCs, and the integrity 
of the endothelial barrier [222]. In healthy individuals this complex interaction is 
tightly regulated which results in an efficient endothelial barrier and controlled 
PASMC proliferation. However in patients with PAH and/or SSc, ‘healthy’ 
PASMCs differentiation into synthetic ‘disease’ like phenotypes, can become 
uncontrolled and lead to a reduction in endothelial barrier integrity and medial 
hyperplasia [223-225]. 
60% confluent contractile and synthetic PASMCs were serum starved for 24 hours in 
basal EMG-2 medium with 2% FCS, medium collected. 1x10
5
 PAECs were seeded 
into 24 well, 3µm pore transwell inserts and allowed to form a confluent monolayer 
for 24 hours. Conditioned medium from contractile and synthetic PASMCs was 
added to the inserts for 24 hours. Endothelial permeability was assessed by adding 
5mg/ml FITC-albumin into the insert and measuring fluorescence of the medium in 
the bottom of the well at 535nm to quantify permeability after one hour. Contractile 
PASMCs had no effect on endothelial cell permeability compared to control 
medium, in contrast synthetic PASMCs significantly increased endothelial cell 
permeability (p<0.05; Figure 5.8A).  
The effect of PASMCs on immune cell endothelial transmigration was measured by 
adding 1x10
6
 freshly isolated PBMCs to the inserts after incubation with the 
conditioned medium for 24 hours. Cells were counted in the bottom of the well after 
2 hours of transmigration (Figure 5.8B). Contractile PASMC medium had no 
significant effects on endothelial immune cell transmigration, however synthetic 
PASMC medium significantly elevated the immune cell movement across the 
endothelial barrier (p<0.05; Figure 5.8). In contrast to these findings, neither 
contractile nor synthetic SMC conditioned medium had an effect on PAEC migration 
or proliferation rates (p<0.05; Figure 5.9).  
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Figure 5.9 – Synthetic PASMCs increase endothelial permeability and 
neutrophil transmigration 
Control endothelial cell medium and conditioned medium from contractile and 
synthetic PASMCs was added to a confluent layer of PAECs to investigate the effect 
of PASMCs on endothelial cells. Contractile PASMCs exhibit no effect on FITC 
albumin leak whereas synthetic PASMCs exert a significant effect on FITC albumin 
leak equating to increased endothelial cell barrier leak (n=3) (A).Contractile 
PASMCs exhibit no effect on neutrophil transmigration whereas synthetic PASMCs 
exert a significant effect on neutrophil transmigration (n=3). *p<0.05 using Mann 
Whitney Tests. (A-B). 
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Figure 5.10 – Contractile and synthetic PASMCs have no effect on endothelial 
cell migration or proliferation 
Confluent monolayers of PAECs were exposed to 1% FCS, 50 ng/ml PDGFF-BB 
and conditioned medium from contractile and synthetic PASMCs to assess the effect 
of PASMCs on PAEC proliferation using the crystal violet cell proliferation method. 
Experiments were performed on three independent donors in triplicate. *p<0.05, 
using a Mann Whitney Test (n=3) (A). 
Confluent monolayers of PAECs were scratched and migratory responses assessed in 
response to 1% FCS, 50 ng/ml of PDGFBB and conditioned medium from 
contractile and synthetic PASMCs. All experiments were performed in the presence 
of 10 μg/ml Mitomycin C for 48 hours. Experiments were performed on three 
independent donors in triplicate. (B). Migration was assessed after 48 hours, images 
were taken using the Olympus CDK2 microscope and data analysed using Axio 
Vision software.  *p<0.05, Mann Whitney Test (C).  
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5.5 Discussion 
Pathological changes in PASMCs are believed to be a key feature in the 
development of PAH [16, 21]. The loss of a ‘normal’ contractile phenotype to that of 
a ‘disease’ synthetic phenotype is a feature of vascular remodelling in a number of 
diseases including PAH [21]. The differentiation of a SMC from a contractile to a 
synthetic cell induces a change in morphology and functionality of the cell, with the 
synthetic cell possessing increased proliferative and anti-apoptotic qualities [21]. As 
discussed earlier, in HPAH, 70% of patients have BMPRII mutations [2] and this 
perturbation of BMP signalling in patients of IPAH may play a key role in the 
homeostasis of a PASMC and their phenotypic modulation. Initial experiments were 
performed to investigate and establish robust markers of a contractile and a synthetic 
cell with a particular focus on PASMCs. The maintenance of a healthy contractile 
cell is determined by a host of factors, hypoxia, cell to cell contact, growth factors 
and cell injury all contribute to PASMC differentiation, therefore conditions were 
established that would promote differentiation of a contractile cell to a synthetic 
phenotype [21]. The hypothesis that increased serum and cell to cell contact would 
promote differentiation to a synthetic cell was confirmed and this allowed us to 
establish markers of each cell type. These markers were interrogated by both 
Western blot analysis and immunoflouresecent staining. α-SMA and smoothelin had 
previously been identified as contractile markers of SMCs [226, 227]. This work 
identifies α-SMA and smoothelin as markers specifically for contractile PASMC and 
Type-I collagen and CTGF were identified as protein markers of a synthetic 
PASMCs. These results are supported in the literature as it has been previously 
reported that a synthetic cell produces increased ECM and contributes to vascular 
remodelling [21]. 
 
In addition to identifying protein markers of both contractile and synthetic PASMCs, 
secreted factors from the conditioned medium of both cell types were also 
investigated. Multiplex analysis identified differences in secreted factors between 
contractile and synthetic PASMCs; IL-6, IL-8, IL-10, IFN-g and TNF-β levels were 
elevated in the synthetic phenotype. IL-6 and IL-8 were identified as key markers, 
because previous work has shown that both IL-6 and IL-8 serum levels are elevated 
in patients with both IPAH and HPAH [218]. In this study Kaplan-Meier curves 
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showed levels of IL-6 and IL-8 predicted survival in patients, 5-year survival rates 
for patients with IL-6 levels > 9 pg/ml was 30%, however patients with levels < 9 
pg/ml fared better with survival at 63% [218].  
 
Using functional assays it was possible to determine how contractile and synthetic 
PASMCs behave and how these changes in behaviour may contribute to the 
development of PAH via muscularisation in the pulmonary artery. Previous reports 
have suggested that synthetic PASMCs are more migratory but our data suggested 
the opposite to these reports [21, 226]. This result could be explained by increased 
expression of α-SMA in contractile PASMCs which might be contributing to the 
increased migratory capacity of the contractile PASMC. It may also be that in 
disease pathology the PASMC contributes more to endothelial dysfunction, whilst 
the fibroblast is the more migratory and proliferative cell that occludes the lumen. 
Contractile PASMCs exhibited increased contractility compared to synthetic 
PASMCs, and it has been previously reported that BMP signalling plays a key role 
in maintaining the contractile apparatus of the PASMC [215].  
 
Having identified cellular proteins, secreted markers and functional changes that 
characterise both contractile and synthetic PASMCs, I investigated the TGF-β/BMP 
axis in PASMCs. BMPRII levels have been reported to be reduced in PASMCs from 
patients in IPAH with a blunted response to BMPs [24, 177]. The reduction of 
BMPRII levels in the synthetic ‘disease’ phenotype at both the protein and gene 
level suggests these cells appear similar to PASMCs from isolated IPAH patients. 
There was also a rise in the gene expression of the BMP antagonist gremlin 1. It has 
been previously reported that gremlin 1 has higher expression in the lung than any 
other organ. Furthermore, Gremlin 1 is also elevated in the lung of PAH patients and 
novel gremlin 1 antibodies can reverse PAH in the pre-clinical sugen/hypoxia model 
of PAH [155, 228]. Functional assays were then used to determine the impact of 
reduced BMPRII levels on the PASMC. The rate of apoptosis is essential in 
maintaining normal vasculature so the rate of apoptosis in contractile and synthetic 
PASMCs was investigated. Synthetic PASMCs exhibit an apoptotic resistance in 
response to BMP 4 and 7 due to the reduction of BMPRII which prevents BMP 
ligands exerting their anti-apoptotic effects. This can lead to a rise in the synthetic 
PASMC population contributing to the occlusion of the lumen and vascular 
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remodelling [24,151,219]. As discussed previously contractile PASMCs exhibit 
increased contractility compared to synthetic PASMCs, BMPs are involved in the 
regulation of contractility and results in this chapter confirm this [215]. BMP4 
treatment induces contraction in the contractile PASMCs suggesting it plays a role in 
this cellular process; however synthetic PASMCs exhibit a blunted response to 
BMP4, and less contraction in synthetic PASMCs might be due to the reduction of 
BMPRII in synthetic PASMCs. These results suggest that the reduction of BMPRII 
in synthetic PASMCs leads to a dysregulation of cellular processes that contribute to 
vascular remodelling and the development of PAH.  Suggesting the ability to 
upregulate BMPRII or restore BMP signalling in the PASMC could provide an 
attractive therapeutic approach to preventing PASMC differentiation and the 
development of PAH. 
 
Previous reports have highlighted that enhanced TGFβ signalling in PAH may 
contribute to a reduction of BMPRII where patients with PAH have increased 
phosphorylated-Smad2/3 staining in concentric lesions in the lung [152]. In concert 
with the reduction of BMPRII in the TβRIIΔk fib model of SSc there is a possibility 
that this reduction of BMPRII may be a unifying mechanism and contributes to SSc-
PAH. Synthetic PASMCs also exhibited a perturbed response to BMP ligands and 
the dysregulation of both TGFβ and BMP canonical signalling pathways observed in 
synthetic PASMCs is similar to previous reports in PASMCs in HPAH patients, 
where a reduction in phosphorylated-Smad1 after BMP4 treatment has also been 
observed [24, 177].  
 
Enhancement of the TGFβ axis is observed alongside a reduction in BMPRII in 
PAH, and data in this chapter supports this trend. A significant increase in CTGF 
and PAI-1 gene expression, further corroborate the TGFβ/BMP axis imbalance, as 
they are markers of enhanced TGFβ activity. TGFβ does not affect IL-6 secretion in 
contractile PASMCs, however it significantly enhanced IL-6 secretion in synthetic 
PASMCs. It has been previously shown in PASMCs from HPAH patients that TGFβ 
treatment exhibits differential effects on control and HPAH PASMCs [17]. This 
study reported that HPAH PASMCs have enhanced transcription of IL-8 and IL-6 in 
response to TGF-β1 compared with control PASMCs. The regulation of these 
cytokines is dependent on the cell context and may differ between normal and 
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disease states [17]. There is substantial evidence in the literature supporting the role 
of inﬂammation in the development of PAH, it has been reported that pro-
inflammatory cytokines, for example, IL-8, TNF-α and IL-6 are significantly 
elevated in HPAH patients [218,229,230]. IL-6 is also elevated in pre-clinical 
models of PAH suggesting it plays a key role in the development of the disease [231, 
232].  This suggests that by neutralising IL-6 and IL-8 it is possible to restore the 
anti-proliferative effects of TGF-β1 on HPAH PASMCs [17]. Interestingly, anti-IL-6 
therapies have been shown to be safe and efficacious in the treatment of rheumatoid 
arthritis and other disorders [233]. Administration of tocilizumab, a humanized anti-
IL-6 monoclonal antibody, has improved PAH symptoms in patients with mixed 
connective tissue disease and severe PAH [234]. The data from our contractile and 
synthetic PASMCs and PASMCs from patients highlights the involvement of IL-6 in 
The interaction between PASMCs and endothelial cells is important in the 
development of PAH. Functional assays were performed to determine the effect of 
contractile and synthetic PASMCs on endothelial cells and their function on the 
vasculature. It has been previously shown that co-culture of SSc, but not control 
fibroblasts could induce transendothelial migration of U937 cells. It was also shown 
that conditioned medium from SSc fibroblasts had similar effects on Jurkat-6 (T 
lymphocyte) cells, and with peripheral blood mononuclear cells from a patient with 
dcSSc [235].This could be due to the increased levels of inflammatory cytokines and 
growth factors for example PDGF-BB in conditioned medium from SSc fibroblasts. 
This is similar to what is observed in synthetic PASMCs, these PASMCs have 
elevated levels of IL-6, IL-8 and CTGF. The anatomical location of endothelial and 
PASMCs in the artery suggests that their interaction could play a key role in the 
occlusion of the lumen and increased vascular leak. Conditioned medium from 
contractile PASMCs had no effect on endothelial cell leak suggesting in normal 
pulmonary artery there is not an imbalance in cytokines or growth factors that might 
contribute to this phenomenon. However during PASMC differentiation, the 
synthetic PASMC becomes a pro-inflammatory cell that significantly increases 
vascular leak. It has been previously reported that in the hypoxia rat model there is 
increased vascular permeability and leukocyte migration,  implicating vascular 
permeability in the development of PAH [236]. Synthetic PASMCs secrete 
significantly more IL-6, IL-8 and TNF-α, and these pro-inflammatory cytokines are 
possibly contributing to increased endothelial cell leak and immune cell influx. IL-6 
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and IL-8 have previously been reported to be elevated in the serum of SSc patients 
[40, 237], and IL-6 has been found to have detrimental effects on endothelial barrier 
integrity [238]. In addition, IL-6 and IL-8 increase expression of ICAM-1, VCAM-1 
and E-selectin, adhesion proteins known to increase the adherence and infiltration of 
immune cells [239, 240]. Similarly elevated IL-8 is known to activate endothelial 
cells and increase immune cell interactions as well as increase endothelial 
permeability [241-243]. Other groups have shown IL-8 reduces expression of tight 
junction proteins which again could contribute to increased leak [239]. Consistent 
with these studies the pro-inflammatory profile of synthetic PASMCs induces 
increased endothelial cell leak and immune cell influx compared to contractile 
PASMCs. 
Finally, it was investigated if conditioned medium from contractile or synthetic 
PASMCs can influence endothelial cell proliferation or migration. PDGFBB induced 
endothelial proliferation and migration but neither contractile nor synthetic PASMC 
conditioned media had any effect [244, 245]. It has been previously shown that 
PASMCs can inhibit endothelial cell migration but it was observed that PASMCs 
were unable to influence endothelial cell migration [246]. Sato et al conducted their 
studies in bovine cells whilst this study used human cells so this could a factor that is 
contributing to variable observations. In order to investigate this further it would be 
essential to profile both contractile and synthetic PASMCs for known endothelial 
cell mitogens, or inhibitors of migration and proliferation to determine if they might 
have an effect. Synthetic PASMCs have a pro-inflammatory phenotype that may be 
contributing this, the increase in growth factors and cytokines may be inducing 
downregulation of tight junction proteins. This downregulation may be the 
mechanism by which synthetic PASMCs are inducing endothelial cell leak. 
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5.6 Conclusion 
In conclusion this work has established and validated a novel assay to induce 
synthetic PASMC by promoting differentiation of contractile PASMCs through 
exposure to increased serum concentrations and cell-cell contact. Differentiated 
synthetic PASMCs display similar characteristics to PASMCs isolated from PAH 
patients, including enhanced secretion of pro-inflammatory chemokines. This study 
has highlighted a plethora of protein and pro-inflammatory markers to identify 
contractile and synthetic PASMCs. Smoothelin and α-SMA have been identified as 
robust markets of contractile PASMCs and type-I collagen and CTGF have been 
implicated as markers of synthetic PASMCs. IL-6 and IL-8 are pro-inflammatory 
cytokines that elevated in synthetic PASMCs. Furthermore synthetic PASMCs 
display reduced BMPRII expression and exhibit blunted responses to BMP ligands, 
whilst exhibiting enhanced responses to TGFβ, similar to PASMC from HPAH 
patients. Extending these observations further the effects on synthetic PASMCs on 
endothelial cell functions was investigated. Pro-inflammatory synthetic PASMC are 
also able to contribute to and influence vascular permeability, and immune cell 
influx, which are likely to contribute to the development of PAH. Given the 
challenges of obtaining PASMCs from SSc-PAH patients the generation of synthetic 
PASMCs cells in-vitro that shares many characteristics of PASMCs from PAH 
patients, will allow future studies to better understand the pathological mechanisms 
that contribute to the development of SSc-PAH.  
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6. The bromodomain inhibitor JQ1 can prevent the 
development of PAH in the TβRIIΔk-fib model of SSc-PAH 
6.1 Introduction 
The definition of epigenetics is contentious, currently there are a two definitions in 
the literature, one group defines it as: how genotypes create individual phenotypes 
during development that may be induced by differential environments and lifestyles 
endured by individuals [247]. However another group described epigenetics as all 
the (meiotically and mitotically) heritable changes that occur in gene expression that 
are not directly coded in the DNA sequence [248]. Epigenetic changes can occur 
through different processes know as histone modifications, acetylation, deacetylation 
and methylation. Histone acetyltransferases (HATs) act as writers and catalyse the 
addition of acetyl groups to lysine residues in histone tails, whereas histone 
deacetylases (HDACs) serve as erasers with opposing effects [249]. In general 
histone acetylation represents transcriptionally active regions whereas deacetylated 
residues can be found in transcriptionally inactive euchromatic or heterochromatic 
regions [250]. Histone methylation can be a marker for both active and inactive 
regions of chromatin. For example if methylation on lysine 9 on the N terminus of 
histone 3 (H3) it is associated with silent DNA, however if it occurs at lysine 4 of H4 
it represents activity at a promoter region [249]. Human tumours were the first to 
show global hypomethylation which was followed by the discovery of 
hypermethylated tumour-suppressor genes (TSGs) and most recently the inactivation 
of microRNA (miRNA) by DNA methylation [251-256]. The low levels of DNA 
methylation in tumours is mainly due to hypomethylation of repetitive DNA 
sequences and, demethylation of coding regions and introns that allow transcription 
of mRNA [257]. The progression of normal skin through the different stages of 
carcinoma has displayed a progressive loss of DNA methylation in the lesions [258].  
In TSGs hypermethylation of the regions of DNA where a cytosine nucleotide is 
located next to a guanine nucleotide in the linear sequence of bases (CpG islands) in 
promoter regions have been linked to the origin of many tumours. The initial reports 
of this were in the retinoblastoma (Rb) TSG and other reports have followed in the 
breast cancer susceptibility gene 1 (BRCA1) [253, 259]. This hypermethylation can 
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affect many cellular processes involved in the cell-cycle, for example DNA repair, 
apoptosis, cell-to-cell interaction and angiogenesis [257]. It is still unclear why 
hypermethylation is observed in some cancers but not in others; comprehension of 
this may lead to a better understanding of epigenetics in cancer. Methylation of 
BMPRII and the role of epigenetic changes have also been implicated in the skin of 
SSc patients. As mentioned earlier histone modifications through acetylation and 
deacetylation also contribute to the development of cancer through direct effects on 
nuclear processes, including gene transcription, DNA repair and replication [249]. In 
leukaemia and sarcomas, chromosomal translocations involve readers such as HATs, 
one example of this is histone methyltransferase in mixed-lineage leukaemia 1 
(MLL1) [260].  
Through a better understanding of the different epigenetic mechanisms that are 
contributing to cancers, novel-epigenetic inhibitors are currently being developed 
both pre-clinically and clinically for the treatment of cancers. Recently, two novel 
selective small molecule inhibitors that target the amino-terminal bromodomains 
(BRD) of BRD4 JQ1, and inhibitor of bromodomain extra terminal 762 (I-BET762), 
have been shown to exhibit anti-proliferative effects in a range of malignancies 
[261].  
 
The major focus of the work in this chapter will be JQ1 and its role in SSc-PAH. 
JQ1 is a BRD inhibitor, BRD is a conserved member of the BET family of 
chromatin readers, BRD consists of four members BRD2, BRD3, BRD4 and BRD 
testis (BRDT). When JQ1 binds to the BRD pocket it leads to the displacement of 
BRD4 from active chromatin and the subsequent removal of RNA polymerase II 
from target genes [262, 263]. In SSc and SSc-PAH the pathological mechanisms that 
contribute to the development of pulmonary complications are not completely 
understood but it is believed that a plethora of processes and cell types are involved 
in the disease [18, 45]. The SSc-PAH myofibroblast and synthetic PASMC share 
many features to cancer cells including resistance to apoptosis, uncontrolled 
proliferation and migration [18,21,75,264-269]. Epigenetic inhibitors have 
demonstrated efficacy in pre-clinical models and safety in clinical trials for the 
treatment cancer [263, 270], and recently it was published that JQ1 was able to 
attenuate bleomycin induced lung fibrosis and significantly reduce inflammatory cell 
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infiltrate [189]. Furthermore, JQ1 inhibited TGFβ induced fibroblast to 
myofibroblast transition (FMT) by preventing the upregulation of α-SMA and type-I 
collagen [189]. Tang et al showed JQ1 inhibited PDGFBB migration, proliferation 
and contraction in fibroblasts from (IPF) patients [180]. These publications have 
highlighted the potential for JQ1 in the treatment of fibrosis, and suggest potential in 
their use for SSc, with the hope that epigenetic treatments could prevent the 
development of PAH in SSc. Previous studies have demonstrated that JQ1 inhibits 
myofibroblast differentiation and the fibrotic fibroblast phenotype.  The hypothesis 
of this chapter was that inhibition of the BRD proteins using the pharmacological 
inhibitor JQ1 will attenuate the development of PAH in the TβRIIΔk-fib model of 
SSc-PAH and the SSc fibroblast phenotype. I have highlighted previously (Figure 
4.4) that BMPRII is reduced in whole lung and explant cultured fibroblasts in SSc-
PAH patients and it was hypothesised that a decrease in BMPRII might be a 
contributory risk factor for the development of PAH. Previous reports have shown 
that BMPRII is reduced in the skin and microvascular endothelial cells in SSc 
patients [175]. This study also showed that the use of epigenetic inhibitors, DNA 
methyltransferase inhibitor 5-Aza-2’-de-oxycytidine (5-AZA) and the histone 
deacetylase inhibitor trichostatin (TSA) had modest effects alone but in combination 
there was a significant rise in BMPRII expression in microvascular endothelial cells 
[175]. This suggests that the epigenetics may also modulate BMPRII expression in 
the lung of SSc patients. The epigenetic inhibitor JQ1 was used in-vitro and in-vivo 
to assess its role in modulating BMPRII expression in the lung of the TβRIIΔk-fib 
model and in explants cultured fibroblasts from SSc patients. 
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6.2 Aims 
The aim of this chapter was to investigate the role of the epigenetic inhibitor JQ1 in 
the modulation of both fibroblasts and PASMCs disease phenotype. SSc fibroblasts 
have altered phenotypes compared to normal fibroblasts; the effect of the epigenetic 
inhibitor JQ1 was investigated to assess its effect on the expression of different 
disease like markers, functional assays and the secretion of pro-inflammatory 
cytokines. I went on to investigate if JQ1 treatment in-vivo would prevent the 
development of PAH in the TβRIIΔk-fib model of SSc-PAH. To determine the effect 
of JQ1, investigated examined RVSP, histological changes, protein expression in the 
lung and the secretion of pro-inflammatory cytokines in serum. SSc-PAH 
Another aim based around other discoveries is that BMPRII expression might be 
modulated by the epigenetic inhibitor JQ1 and by upregulating BMPRII JQ1 might 
prevent the development of PAH in the TβRIIΔk-fib model. 
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6.3 Results 
6.3.1 The effect of the epigenetic inhibitor JQ1 in the SSc fibroblast 
SSc is a disease of unmet clinical need where pulmonary complications have a 
devastating effect [38]. The primary effector cell driving SSc in the lung is the 
myofibroblast which can be derived from fibroblasts, endothelial to mesenchymal 
transition, epithelial to mesenchymal transition or from circulating progenitor cells 
[18, 271].  
Previous reports have highlighted that elevated type-I collagen and CTGF are 
associated with pulmonary complications and a disease like phenotype in SSc lung 
[42, 266, 268, 272]. These proteins are implicated in the deposition of ECM and and 
vascular remodelling. 
Experiments were conducted to assess whether JQ1 had an effect on the expression 
of type-1 collagen and CTGF. To test this hypothesis, lung fibroblasts were treated 
with 1 μM JQ1 for 48 hours and assessed by Western blot to determine the effect of 
JQ1 on type-1 collagen and CTGF protein expression (p<0.05; Figure 6.1 A). Type-1 
collagen expression was significantly elevated in lung fibroblasts from SSc patients  
compared to healthy controls and treatment with JQ1 significantly attenuated 
expression in both lung fibroblasts from SSc patients  and healthy controls (p<0.05; 
Figure 6.1 B). CTGF was elevated in lung fibroblasts from SSc patients compared to 
controls and JQ1 reduced CTGF expression in lung fibroblasts from SSc patients 
suggesting that BRDs are playing a role in myofibroblast formation (p<0.05; Figure 
6.1 C).   
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Figure 6.1- JQ1 inhibits elevated type-I collagen and CTGF expression in both 
normal and SSc lung fibroblasts 
Western blots were performed on proteins isolated from confluent monolayers of 
explant cultured lung fibroblasts from control (NLF) and SSc (SLF) lung fibroblasts 
(n=3). Fibroblasts were maintained in the presence of either JQ1 (1uM) or vehicle 
control. Blots were probed for expression of type-I collagen and CTGF. Protein 
loading was determined by β-tubulin (A). Densitometry was performed and the mean 
± SEM expression of type-I collagen (B) and CTGF (C) normalised to β-tubulin 
expression was plotted. *p<0.05 using Mann Whitney Test. 
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6.3.2 The epigenetic inhibitor JQ1 can arrest the myofibroblast phenotype of 
the SSc fibroblast. 
Previously I have shown lung fibroblasts from SSc patients display increased 
migration, proliferation and contraction rates (Chapter 4), these are key processes 
that may contribute to the development of pulmonary pathologies in SSc patients 
such as PAH. To assess the functional involvement of bromodomain and extra 
terminal domain (BET) BRDs proteins phenotypic response assays were used to 
investigate the ability of JQ1 to inhibit migration, proliferation and contraction by 
lung fibroblasts from SSc patients. The initial aim was to investigate if inhibition of 
JQ1 can alter these processes that are thought/believed to contribute to the 
development of PAH in SSc (Figure 4.7). Both control lung fibroblasts and lung 
fibroblasts from SSc patients were treated with PDGFBB in the presence or absence 
of 1 M JQ1 for 24 hours to assess the effect of JQ1 on fibroblast migration (Figure 
6.2A). Confluent monolayers of fibroblasts were scratched and treated with either 
1% FCS or 50 ng/ml PDGFBB in the presence and absence of 1 M of JQ1. These 
experiments were also performed in the presence of the anti-proliferative mitomycin-
C. Consistent with previously studies in chapter 4, PDGFBB induced migration was 
significantly increased in lung fibroblasts from SSc patients compared to controls. 
JQ1 significantly inhibited migration in control and SSc lung fibroblasts (p<0.05; 
Figure 6.2B).  
The effect of JQ1 on PDGFBB induced proliferation of lung fibroblasts was 
assessed. Lung fibroblasts were incubated with 50 ng/ml PDGFBB and the effects of 
a range of JQ1 concentrations compared to vehicle controls were determined. 
PDGFBB treatment induced increased proliferation in lung fibroblasts from SSc 
patients, compared to control lung fibroblasts (p<0.05; Figure 6.3). Incubation with 
JQ1 led to a significant inhibition of PDGFBB-induced fibroblast proliferation in 
both normal and SSc lung fibroblasts in a concentration dependent manner (p<0.05; 
Figure 6.3). 
Gel contraction was assessed using pooled data from a series of independent 
experiments and donors using type-1 collagen lattices, these contraction assays show 
that both 5 ng/ml TGF and 10% FCS significantly induced increased contraction 
rates in lung fibroblasts from SSc patients compared to controls (p<0.05; Figure 6.4 
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A and B). Experiments were also performed in the presence of 1 M JQ1; JQ1 had 
no significant effects on gel contraction. Contraction was assessed by measuring the 
diameter of each individual gel or the each gel’s weight (Figure 6.4 A and B). 
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Figure 6.2 –PDGFBB induced migration is inhibited by JQ1 in SSc lung 
fibroblasts is by JQ1 
Confluent monolayers of control (NLF) and SSc lung fibroblasts (SLF) were scratch 
wounded and cellular migration in response to 1% foetal calf serum (FCS), or 50 
ng/ml PDGFBB in the presence of JQ1 (1uM) vehicle control assessed after 24hrs 
(A). Experiments were performed in the presence of 10 μg/ml mitomycin C on three 
independent donors in triplicate and the mean ± SEM plotted (B).  *p<0.05, using 
Mann Whitney Test (B). 
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Figure 6.3 - JQ1 antagonises PDGFBB induced proliferation in SSc lung 
fibroblasts. 
Control (NLF) and SSc (SLF) lung fibroblasts seeded at equal cell densities were 
stimulated with PDGFBB (50 ng/ml) and the dose dependent effects of JQ1 on cell 
numbers determined after 72 hours. Data represents the fold change in cell numbers 
after 72 hours to seeded cells and are expressed as the mean of three individual 
donors ± SEM. Proliferation was assessed after 72 hours. *p<0.05, Two-way 
analysis of variance (ANOVA). 
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Figure 6.4 – JQ1 does not modulate SSc gel contraction. 
Control (NLF) and SSc (SLF) lung fibroblasts were seeded at 2 x 10
4
 in 24 well 
plates into collagen matrix and exposed to either 5 ng/ml TGFβ (A) or 10% FCS (B) 
in the presence or absence of 1 μM JQ1 or vehicle control. After 72 hours, gel 
contraction was assessed by measuring gel weights and the mean ± SEM of three cell 
lines plotted. *p<0.05 using  Mann Whitney Test test (C).   
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6.3.4 The pro-inflammatory phenotype of SSc fibroblasts is reduced by 
treatment in JQ1. 
Elevated levels of circulating pro-inflammatory cytokines have been reported in the 
sera of SSc and IPAH patients by many groups [218, 273]. A number of studies have 
demonstrated the SSc fibroblast secrete elevated levels of pro-inflammatory 
cytokines, for example IL-6. BRD inhibitors have previously been shown to 
modulate a number of inflammatory chemokines including IL-6. I sought to assess 
the effects of JQ1 on SSc fibroblast secretion of inflammatory chemonkines using 
the MSD multiplex array.  
SSc lung fibroblasts secreted detectable levels of IL-2, IL-4, IL-10, and TNF-, 
whilst levels secreted by healthy control lung fibroblasts were below the detectable 
limits of the array. IL-6 and IL-13 was detectable in control lung fibroblast 
conditioned media, however was significantly elevated in SSc lung fibroblast 
conditioned media (p<0.05; Figure 6.5) JQ1 had no significant effect effects on IL-2, 
IL-4, IL-10 and IL-13 secretion by SSc lung fibroblasts. In contrast IL-6 secretion 
was significantly inhibited by JQ1 in control and SSc lung fibroblasts levels were 
significantly increased in SSc lung fibroblasts compared to healthy controls (p<0.05; 
Figure 6.5A) and JQ1 significantly reduced IL-6 secretion in SSc lung fibroblasts 
(p<0.05; Figure 6.5 A). IL-8 secretion levels were significantly increased in SSc lung 
fibroblasts compared to healthy controls (p<0.05; Figure 6.5B) but JQ1 had no effect 
on IL-8 secretion in either normal or SSc lung fibroblasts. 
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Figure 6.5 – SSc lung fibroblasts exhibit a pro-inflammatory profile compared 
to normal lung fibroblasts 
Conditioned medium from normal lung fibroblasts (NLF) and SSc lung fibroblasts 
(SLF) was collected after 48 hours and secretion was normalised to protein levels in 
the cell monolayer. Multiplex analysis was performed on the conditioned medium 
for inflammatory mediators and concentrations (ng/ml) tabulated, IL-2, IL-6, IL-8 
and IL-13 were significantly elevated in SLF compared to NLF (A). Levels of IL-6 
(A) and IL-8 (B) were confirmed and values plotted ± SEM. *p<0.05, Unpaired T-
test (A-C). * denotes significance between JQ1 treated and untreated groups. ¶ 
denotes significance between NLF and SLF.  
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6.3.5 Synthetic phenotype is modulated by the bromodomain inhibitor JQ1 
The role of the PASMC is important in maintaining a healthy vasculature. 
Pathological differentiation from a contractile to synthetic PASMC is believed to be 
a key feature in vascular remodelling [21]. It has already demonstrated that the BRD 
inhibitor JQ1 can modulate disease characteristics of the fibroblast (Figure 6.1, 
Figure 6.2), the complexity of SSc and PAH suggest more than one cell type 
contribute to the development of SSc and PAH and another key cell type involved in 
these diseases is the PASMC.  
Using contractile and synthetic PASMCs (as discussed in section 5.4.1) and 
PASMCS isolated from healthy controls and IPAH patients, I investigated the effect 
of JQ1 on protein and secreted markers of a synthetic PASMCs. Type-I collagen was 
established as a marker of synthetic PASMCs (Figure 5.1) and using Western blot 
analysis (Figure 6.6 A) and immunofluorescence (Figure 6.6 B), the effect of JQ1 on 
type-I collagen in synthetic PASMCs was assessed. The BRD inhibitor JQ1 was able 
to significantly reduce type-I collagen expression in synthetic PASMCs (p<0.05; 
Figure 6.6 C).  
Synthetic PASMCs were also treated with PDGFBB and JQ1 to determine the effect 
of JQ1 on cell proliferation. PASMCs were incubated with 50 ng/ml PDGFBB alone 
and in varying concentrations of JQ1. PDGFBB treatment induced proliferation and 
in a concentration dependent manner JQ1 significantly inhibited proliferation of 
synthetic PASMCS (p<0.05; Figure 6.6 D).  
PASMCs were then treated with JQ1 to examine the effect of JQ1 on pro-
inflammatory cytokines that are elevated in the sera of PAH patients and correlate to 
patient survival [218]. PASMCs were maintained in either contractile or synthetic 
medium (section 5.4.1) and growth medium replaced with 0.1% FCS medium for 
serum starvation with or without 1 M JQ1. After 24 hours medium was collected to 
determine the effect of JQ1 on pro-inflammatory cytokines After 24 hours IL-1, IL-
6, IL-10 and IL-13 were significantly elevated in synthetic compared to contractile 
PASMCs. JQ1 significantly inhibited secretion of IL-1, IL-6, IL-10 and IL-13 in 
synthetic PASMCs (p<0.05; Figure 6.7 A-D).  
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Figure 6.6 – Synthetic PASMC’s phenotype is modulated by JQ1 
Western blots were performed on proteins isolated from confluent monolayers of 
synthetic pulmonary arterial smooth muscle cells (PASMCs; n=3). Blots were 
probed for expression of type-I collagen. Protein loading was determined by β-
tubulin (A). Immunofluorescence staining was performed on type-I collagen (B). 
Images were taken using the Carl Zeiss Axiovison microscope and images shown are 
representative of three independent experiments. Platelet derived growth factor 
(PDGFBB) mediated proliferation in synthetic PASMCs and JQ1 inhibits 
proliferation at 0.1 μM to 30 μM. Data represent the fold proliferation induced by 
PDGFBB compared to vehicle controls and are expressed as a mean of three donors. 
Proliferation was assessed after 72 hours (C). (*p<0.05, Two-way analysis of 
variance (ANOVA) (C). White line indicates 100 µM using the x 40 magnification. 
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Figure 6.7 – Synthetic PASMCs display a pro-inflammatory phenotype that can 
be attenuated by JQ1 
Conditioned medium from contractile and synthetic pulmonary arterial smooth 
muscle cells PASMCs was collected after 48 hours serum starvation. Secretion was 
normalised to protein levels in the cell monolayer. Multiplex analysis was performed 
using three individual donors in duplicate for IL-1β (A), IL-6 (B), IL-10 (C) and IL-
13 (D). *p<0.05, Mann-Whitney Test (A-D).  
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6.3.6 IPAH PASMCS can be modulated by JQ1 to resemble control PASMCs  
Using type-1 collagen which has been previously validated as a marker of synthetic 
PASMCs (Figure 5.1), I investigated the expression of type-I collagen in PASMCS 
isolated from IPAH patients.  
Interestingly type-I collagen expression is also elevated in PASMCs from IPAH 
patients compared to healthy controls and JQ1 significantly reduced expression of 
type-I collagen in both control and IPAH patients (*p<0.05; Figure 6.7B). 
Both control and IPAH PASMCs were serum starved in 0.1% FCS for 24 hours in 
the presence or absence of 1 M JQ and IL-6 and IL-8 levels were measured by 
ELISA.  Both IL-6 and IL-8 levels were significantly elevated in IPAH PASMCs 
compared to healthy controls, but JQ1 significantly reduced IL-6 secretion but had 
no effect on IL-8 (*p<0.05; Figure 6.8 C).  
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Figure 6.8 – IPAH PASMCS resemble synthetic PASMCs and JQ1 can inhibit 
their disease like phenotype 
Western blots were performed on proteins isolated from confluent monolayers of 
control (n=3) and IPAH PASMCs (n=3) in the presence of JQ1 (1uM) or vehicle 
control. Blots were probed for expression of type-I collagen and protein loading 
determined by β-tubulin (A). Densitometry was performed and the mean ± SEM of 
type-I collagen expression normalised to β-tubulin expression plotted (B). 
Conditioned medium from control and IPAH PASMCs (n=3) treated with JQ1 
(1uM) or vehicle control was collected after 48 hours in serum starvation medium 
and IL-6 and IL-8 levels determined by ELISA. Secreted IL-6 and IL-8 levels were 
normalised to β-tubulin protein levels and the mean ± SEM of IL-6 (C) and IL-8 (D) 
plotted. *p<0.05, Unpaired T Test.  
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6.3.7 TβRIIΔk-fib mice develop elevated RVSP that can be prevented by the 
administration of JQ1 
It has been previously reported that TβRIIΔk-fib mice display constitutive 
pulmonary vasculopathy with medial thickening, a perivascular proliferating chronic 
inflammatory cell infiltrate, and significantly elevated pulmonary artery pressure 
compared to wild type controls [119].  
Addition of the VEGFR antagonist SU5416 by intraperitoneal injection induced a 
pulmonary vascular phenotype that was more severe, with pulmonary arteriolar 
luminal obliteration by apoptosis-resistant proliferating endothelial cells. These 
changes resulted in right ventricular hypertrophy, confirming haemodynamically 
significant PAH [119]. This chapter investigateds how the TβRIIΔk-fib model 
spontaneously develops PAH and how the exposure to an epigenetic inhibitor JQ1 
might prevent the development of PAH in these mice. 
For this experiment the effect of the BRD inhibitor JQ1 in the development of mild 
PAH in the TβRIIΔk-fib model of SSc-PAH was investigated. JQ1 was infused in 
feed doses calculated based on the assumption that the mice would consume 2.5 g 
per day and food consumption was monitored. Animals remained on this diet every 
day 21 at the end of the study. Consistent with previous studies the TβRIIΔk-fib 
mice displayed a significant increase in RVSP compared to WT controls (*p<0.05; 
Figure 6.9A). JQ1 did not affect RVSP in WT mice but JQ1 significantly reduced 
RVSP in TβRIIΔk-fib mice (*p<0.05; Figure 6.9A). There was no difference in the 
RV mass index (Fulton index) between TβRIIΔk-fib and WT mice and JQ1 had no 
effect on RV mass index in either TβRIIΔk-fib or WT mice (Figure 6.9B). 
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Figure 6.9 – The effect of JQ1 on RVSP and fulton index in the TβRIIΔk-fib 
model of SSc-PAH 
Right ventricular systolic pressure (RVSP) (A) and right ventricle:left ventricle plus 
septum ratio (RV/LV+S) (Fulton Index) (B) in wildtype and TβRIIΔk-fib exposed to 
vehicle control or 20mg/kg JQ1 infused in feed (n=6). Data was analysed by one-
way analysis of variance (ANOVA) with Bonferroni post-hoc analysis. Results 
presented are expressed as the mean ± S.E.M, *p<0.05; ** p<0.01. 
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6.3.8 TβRIIΔk-fib mice display a pulmonary structural vasculopathy that is 
attenuated by JQ1 
In this experiment the TβRIIΔk-fib model is not exposed to the VEGR antagonist 
SU5416 which previously induced a more severe phenotype in the TβRIIΔk-fib 
model [119]. This work is investigating how the TβRIIΔk-fib model spontaneously 
develops PAH and how the exposure to an epigenetic inhibitor JQ1 might prevent 
the development of PAH in these mice. The TβRIIΔk-fib model of SSc-PAH 
displays muscularisation and the formation of concentric lesions in small pulmonary 
arteries of approximately 20 μm [119]. 
Immunohistological staining for the smooth muscle cell marker α-SMA (brown) and 
the endothelial cell marker vWF (brown) displayed increased vessel wall thickening. 
There were no cardinal features of advanced or severe PAH such as plexiform 
lesions observed in TβRIIΔk-fib vessels (Figure 6.10). The epigenetic inhibitor JQ1 
was able to reduce muscularisation and vessel thickness in TβRIIΔk-fib mice 
compared to vehicle control treated mice (Figure 6.10). 
Hematoxylin and eosin (H&E) staining highlights a slight increase perivascular 
inflammatory cell infiltrate and medial thickening in the TβRIIΔk-fib mice group 
compared to wild-type controls. JQ1 was able to reduce medial thickening and 
inflammatory cell infiltrate in TβRIIΔk-fib mice (Figure 6.11). 
The examination of medial wall thickening in the lungs of TβRIIΔk-fib mice was 
performed by IF double staining. IF staining of α-SMA (red), vWF (green) and 
nuclear dapi (blue) was performed on paraffin embedded formalin fixed lung 
sections from WT and TβRIIΔk-fib mice exposed in-vivo to JQ1 or vehicle alone 
(Figure 6.12). Both WT and JQ1 treated mice displayed similar staining with a single 
layer of smooth muscle cells highlighted by red fluorescence and a single layer of 
endothelial cells highlighted by green fluorescence (Figure 6.12). However in the 
pulmonary artery of TβRIIΔk-fib the formation of concentric rings due to the 
expansion of smooth muscle cells is observed which may result from the increase in 
α-SMA positive cells. This vessel thickening is only seen in the media due to no 
endothelial cell dysfunction being reported in the pulmonary artery of TβRIIΔk-fib 
mice. In the TβRIIΔk-fib JQ1 treated group there is slight medial thickening but a 
decrease compared to TβRIIΔk-fib mice treated with vehicle (Figure 6.12). 
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Figure 6.10 – JQ1 prevents the development of muscularisation in the TβRIIΔk-
fib model of SSc-PAH 
Immunohistochemical double staining for alpha-smooth muscle actin (α-SMA) and 
von Willebrand factor (vWF) on paraffin embedded formalin fixed lung sections 
from wild type (WT) and TβRIIΔk-fib mice exposed in-vivo to JQ1 or vehicle alone 
(n=6 mice per group). Representative images shown of n=6 mice per group. 
Magnification x20.  
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Figure 6.11 – JQ1 reduces medial thickening and inflammatory infiltrate in the 
TβRIIΔk-fib model of SSc-PAH 
Hematoxylin and eosin (H&E) staining of paraffin embedded formalin fixed lung 
sections from wild type (WT) and TβRIIΔk-fib mice exposed in-vivo to JQ1 or 
vehicle alone (n=6 mice per group). Representative images shown; Magnification 
x20.  
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Figure 6.12 – JQ1 reduces muscularisation in the TβRIIΔk-fib model of SSc-
PAH 
Expression of alpha-smooth muscle actin (α-SMA; red), von Willebrand factor 
(vWF; green) and nuclear DAPI (blue) was determined by immunofluorescence on 
paraffin embedded formalin fixed lung sections from wild type (WT) and TβRIIΔk-
fib mice exposed in-vivo to JQ1 or vehicle alone (n=6 per group). Representative 
images shown. White line indicates 20 μm. Magnification x20.  
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6.3.9 The effect of JQ1 on the TGFβ/BMP superfamily in the TβRIIΔk-fib 
model 
The work of this thesis has highlighted the involvement of enhanced TGFβ activity 
and a reduction of BMPRII in the development of PAH in SSc patients. The next 
question was to investigate the role of JQ1 on the expression of components of the 
TGFβ superfamily in the TβRIIΔk-fib model of SSc-PAH. 
Using whole lungs isolated from WT controls and TβRIIΔk-fib mice treated with 
JQ1 or vehicle, the protein expression of components of the TGF-β superfamily was 
explored and downstream signalling pathways in TβRIIΔk-fib mice (Figure 6.13).  
Expression of BMPRII, BMPRIA phosphorylated-Smad2/3, Smad 2/3, 
phosphorylated-Smad 1, Smad 1, phosphorylated-ERK1/2, ERK 1/2, 
phosphorylated-p38 and p38 was determined in whole lung protein homogenates 
isolated from the WT controls and TβRIIΔk-fib treated with JQ1 or vehicle control 
by Western blot (Figure 6.13). 
Lung homogenates from TβRIIΔk-fib and WT displayed no significant change in 
BMPRIA expression in TβRIIΔk-fib or WT either treated with JQ1 or vehicle 
control (Figure 6.13 A). 
As previously demonstrated in figure 5.2 lung homogenates from TβRIIΔk-fib 
exhibited significantly lower levels of BMPRII compared to that of WT mice 
(p<0.05; Figure 6.13 B).Levels of BMPRII in the lungs from WT and TβRIIΔk-fib 
mice treated with JQ1 compared to vehicle treated mice exhibited a significant 
reduction in BMPRII expression (p<0.05; Figure 6.13 B). 
Following examination of the BMPR proteins the assessment of the TGFβ/BMP 
canonical pathways were investigated. Lung homogenates from TβRIIΔk-fib and 
WT displayed no significant change in phosphorylated Smad1/Smad1 expression in 
TβRIIΔk-fib or WT either treated with JQ1 or vehicle control (Figure 6.13 A).  
As previously demonstrated, levels of phosphorylated-Smad2/3/Smad 2/3 were 
elevated in TβRIIΔk-fib mice compared to WT controls (p<0.05; Figure 6.13 B). 
TβRIIΔk-fib mice treated with JQ1 exhibited a reduction in phosphorylated 
Smad2/3/Smad 2/3 that was trending but did not quite reach signifcance (Figure 6.13 
D).  
Finally lung homogenates of the TβRIIΔk-fib were assessed for the phosphorylation 
of the non-cannonical signalling pathway. TβRIIΔk-fib mice lung homogenates 
displayed an increase in the level of phosphorylated-ERK1/2/ERK1/2 but JQ1 had 
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no effect on phosphorylated-ERK1/2/ERK1/2 expression in JQ1 treated mice (Figure 
6.13 E). TβRIIΔk-fib mice lung homogenates displayed an increase in the level of 
phosphorylated-p38/p38 and JQ1 significantly reduced p-p38/p38 expression in both 
WT and TβRIIΔk-fib mice (*p<0.05; Figure 6.13 F). 
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Figure 6.13 – The effect of the epigenetic inhibitor JQ1 on the BMP receptors 
and components of the TGFβ superfamily signalling pathways 
Western blots were performed on protein extracts prepared from whole lungs 
isolated from wild type (WT) and TβRIIΔk-fib mice exposed in-vivo to JQ1 or 
vehicle controls (n=3). Blots were probed for expression of BMPRII, BMPR1A, 
phosphorylated Smad2/3 (pSmad2/3), Smad 2/3, phosphorylated Smad 1 (pSmad 1), 
Smad 1, phosphorylated ERK1/2 (pERK), ERK, phosphorylated p38 (p-p38) and 
p38. Protein loading was determined by GAPDH levels and representative blots 
show above (A). 
 
174 
 
 
 
Figure 6.14 – Densitometry displaying the effect of the epigenetic inhibitor JQ1 
on the TGFβ/BMP family and downstream signalling pathways 
Densitometry was performed and the mean ± SEM expression of (A) BMPRII, (B) 
phospho-Smad2/3 (pSmad2/3), (C) Smad 2/3, phospho-Smad 1 (pSmad 1), (D) 
Smad 1, phospho-ERK1/2 (pERK), (E) ERK, phospho-p38 (p-p38) and (F) p38 
plotted (n=3). *p<0.05 using Mann-Whitney Tests. (A-F).  
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6.4 Discussion 
Several studies to date have been published around the role of JQ1 and BRD proteins 
in IPF, multiple myeloma and prostate cancer [180, 261, 263]. JQ1 has demonstrated 
the ability to inhibit fibrosis in the pre-clinical bleomycin model, attenuate fibroblast 
to mesenchymal transition and to exert anti-inflammatory effects in-vitro [180, 274]. 
These characteristics of JQ1 make it a suitable candidate to investigate the role of 
JQ1 in the development of PAH in the TβRIIΔk-fib model of PAH-SSc and to 
examine JQ1’s effect on the SSc-PAH fibroblast. The BRD inhibitor JQ1 prevented 
the development of PAH in the TβRIIΔk-fib model and demonstrated an ability to 
reverse disease like phenotypes in scleroderma lung fibroblasts and IPAH PASMCs 
suggesting that BRD proteins might play a key role in the development PAH and 
provides a novel therapeutic for the treatment of PAH.  
Previous studies from our group and others have highlighted the differences between 
normal lung fibroblasts and scleroderma lung fibroblasts. Fibroblasts isolated from 
patients display altered phenotypic responses that might be contributing to the 
development of PAH in SSc patients [18, 267-269, 275, 276]. During vascular 
remodelling fibroblasts undergo phenotypic changes that result in altered cellular 
responses. These changes have been reported in IPAH and IPF where fibroblasts 
display increased proliferation and migration, two cellular processes that can lead to 
remodelling by occlusion of the lumen in the pulmonary artery [22, 189]. These 
fibroblasts also exhibit an enhanced inflammatory phenotype which is highlighted by 
an increase in secretion of pro-inflammatory cytokines [153]. It has been previously 
reported that these cellular changes could be linked to epigenetic modifications such 
as histone acetylation, deacetylation or microRNA expression [22, 277].  
This study highlights an essential role for BRDs in reprogramming an activated and 
epigenetically modified fibroblast and PASMC. These cells are characterised by 
abnormal cellular processes, inflammation and overproduction of ECM contributes 
to the development of PAH. SSc lung fibroblasts have previously been reported to 
express elevated levels of CTGF and type-1 collagen that contribute to increased 
ECM production [278-283], and this work demonstrates that type-1 collagen is 
elevated in PASMCs from IPAH patients. JQ1 is able to reduce the expression of 
CTGF and type-I collagen in both SSc lung fibroblasts and PASMCs isolated from 
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IPAH, suggesting that JQ1 can reduce the secretion of ECM in the lung and 
pulmonary artery. Functionally explant cultured lung fibroblasts from SSc display 
cellular activities that may contribute to vascular remodelling and the development 
of PAH. It has been previously reported that JQ1 can arrest cell proliferation in 
cancerous cells and fibroblasts from IPF patients [189, 284, 285]. Fibroblast 
proliferation and migration is elevated in SSc lung fibroblasts and one study has 
reported the expansion of α-SMA positive cells by increased rates of migration and 
proliferation in both SSc and IPAH cells may be potentially contributing to the 
occlusion of the lumen that is observed in patients with SSc-PAH and PAH [22]. To 
the best of my knowledge this is the first report that SSc-PAH fibroblasts isolated 
from the lung of SSc patients displayed elevated rates of proliferation and migration. 
Interestingly JQ1 had no significant effect on migration of normal fibroblasts and 
this may be due the normal fibroblasts exhibiting an unaltered epigenetic profile 
which prevents JQ1 from interacting with these normal fibroblasts. The inhibition of 
both proliferation and migration in SSc fibroblasts by the BRD inhibitor JQ1 is also 
a novel observation in SSc lung fibroblasts. This suggests that the anti-proliferative 
and migratory attributes of JQ1 might be able to contribute to slowing down the 
progression of vascular remodelling in SSc-PAH and PAH patients by epigenetically 
modifying the phenotype of the activated fibroblast. PASMCs play a key role in the 
development of PAH, JQ1 exhibited anti-proliferative effects on “disease” like 
synthetic PASMCs. Here it has been demonstrated that JQ1 can inhibit disease 
characteristics in two key cell types that contribute to the development of PAH [21].  
Activated SSc lung fibroblasts, PASMCs from IPAH patients and “disease” like 
synthetic PASMCs exhibit an inflammatory phenotype that may contribute to the 
development of PAH. It has been previously reported that pro-inflammatory 
cytokines are elevated in SSc, for example IL-6 and IL-1β have been associated with 
disease involvement and progression [40, 286]. In PAH, previous work has shown 
that IL-1β, IL-6, IL-8, IL-10 and IL-13 serum levels are elevated in patients with 
both IPAH and HPAH [218, 230]. In this study Kaplan-Meier curves showed that 
levels of IL-6, IL-8 and IL-10 predicted survival in patients, 5-year survival rates for 
patients with IL-6 levels > 9 pg/ml was 30%, however patients with levels < 9 pg/ml 
fared better with survival at 63% [218]. IL-13 was also elevated in serum of IPAH 
and HPAH patients but this cytokine did not correlate with survival [218]. 
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Histologically it has been highlighted that inflammation plays a key role in PAH, in 
SSc-PAH it has been reported that an increase in mononuclear inflammatory cells 
locate around affected vessels with concentric lesions and vascular remodelling, 
however unaffected areas of the lung seem to exhibit features of a normal lung [287-
290]. In HPAH Tuder et al were the first to demonstrate the influx of inflammatory 
infiltrates in severe PAH [291]. The importance of inflammation in the disease has 
been highlighted by Savai et al and currently therapeutics that target cytokines are 
being investigated. One example of this is Tocilizumab the anti-IL6 monoclonal 
antibody that is currently undergoing pre-clinical and clinical studies in SSc and 
PAH [292-294]. 
By identifying inflammatory cytokines that are elevated in patient serum it provides 
inflammatory markers to examine that contribute to the development of PAH, in key 
cell types, for example the fibroblast and PASMC. Interestingly IL-6, IL-8 and IL-13 
are elevated in SLF, IL-1β, IL-6, IL-8 IL-10 and IL-13 are elevated in “disease” like 
synthetic PASMCs compared to “healthy” contractile PASMCs. Since these 
inflammatory markers play a key role in PAH and correlate with survival so the 
effect of JQ1 on anti-inflammatory markers was investigated [218]. JQ1 exhibits 
attenuation of IL-6 in SSc lung fibroblasts and IPAH PASMCs but has no effect on 
IL-8 secretion, inhibiting the secretion of IL-6 is important due to its levels in serum 
correlating to survival in IPAH patients [218]. Interestingly there are also active 
clinical trials for the treatment of SSc with specific IL-6 antibodies; one example of 
this is Tocilizumab the anti-IL6 monoclonal antibody [292, 293]. Similar results 
were observed in fibroblasts in IPF patients with JQ1 inhibited elevated IL-6 levels. 
JQ1 also reduced IL-1β, IL-10 and IL-13 which are all cytokines that implicated in 
PAH [218]. The ability of JQ1 to attenuate the pro-inflammatory effects of cytokines 
that are key to PAH progression and survival suggest JQ1 demonstrates potential to 
be a novel therapeutic for SSc patients at risk of developing PAH. Our in-vitro data 
suggests that JQ1 can epigenetically modify the activated phenotype of key cells 
involved in the development of PAH by altering their functional abnormalities and 
inflammatory attributes.  
Following on from positive in-vitro data, the role of JQ1 in-vivo was investigated 
and its effect on haemodynamics in the TβRIIΔk-fib model of SSc-PAH was 
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investigated. Initially I hypothesised that down regulation of BMPRII might be 
contributing to the development of PAH in this model and in patients in SSc-PAH.  
JQ1 prevented the development of PAH in the TβRIIΔk-fib by reducing elevated 
RVSP’s compared to TβRIIΔk-fib with vehicle control. There was no right ventricle 
hypertrophy observed in the TβRIIΔk-fib and JQ1 had no effect on this. 
Histologically it has been demonstrated that JQ1 can reduce the number of partial 
and fully muscularised arterioles in TβRIIΔk-fib mice and decrease mild 
perivascular inflammatory cell infiltrate and medial thickening. These histologically 
observations suggest a role for JQ1 and BRD inhibitors in preventing vascular 
remodelling in the TβRIIΔk-fib model. One possible mechanism for this might be 
the anti-proliferative and migratory properties JQ1 displayed in vitro as JQ1 has 
demonstrated these properties in other diseases, for example IPF and cancer [180, 
189, 299]. These characteristics might be curtailing the expansion of α-SMA positive 
fibroblasts and PASMCs. The reduction of α-SMA red staining in the IF studies 
suggests that this might be a mechanism by which JQ1 arrests the development of 
PAH in the TβRIIΔk model.  
In the TβRIIΔk-fib model (Figure 3.1 and 3.4.) BMPRII is reduced in whole lung and 
explant cultured fibroblasts and in clinical material from SSc-PAH BMPRII is also 
reduced (Figure 4.4). BMPRII mutations are associated with the development of 
HPAH and IPAH and this study shows by a non-genetic means BMPRII reduction is 
associated with PAH [14, 24, 26, 162, 183, 184, 295-298].Previous reports have 
shown that BMPRII is reduced in the skin and microvascular endothelial cells in SSc 
patients [175]. This study also showed that the use of epigenetic inhibitors, DNA 
methyltransferase inhibitor 5-Aza-2’-de-oxycytidine (5-AZA) and the histone 
deacetylase inhibitor trichostatin (TSA) had modest effects alone but in combination 
there was a significant rise in BMPRII expression in microvascular endothelial cells 
[175].  
The aim of this work was that JQ1 might modulate BMPRII expression by 
epigenetically modifications. BMPRII protein expression in the TβRIIΔk-fib model 
is reduced compared to WT controls, however unexpectedly BMPRII levels were 
significantly reduced in both WT and TβRIIΔk-fib JQ1 treated groups. Our 
hypothesis was that JQ1 might increase BMPRII by binding to the acetylated lysine 
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of the BRD residues. As mentioned above this hypothesis stemmed from a previous 
study where BMPRII is reduced in the skin of SSc patients and the use epigenetic 
inhibitors significantly increased BMPRII expression [175]. These results show the 
opposite in-vivo suggesting that JQ1 is exerting it’s affect by altering cellular 
phenotypes that contribute to vascular remodelling and by anti-inflammatory effects. 
This suggests that BMPRII increases the susceptibility of this model of PAH but is 
only one contributory factor in a complex disease. It also suggests that alone JQ1 
might not be effective due to its specificity to BRD proteins but in combination with 
other epigenetic inhibitors might demonstrate an ability to upregulate BMPRII. 
In concordance with a reduction in BMPRII an over activated TGFβ pathway is also 
associated with SSc-PAH and PAH. Enhanced TGFβ signalling has been previously 
observed in IPAH vessels [152, 174, 194]. Indicative of enhanced TGFβ signalling, 
whole lung tissue and explant cultured fibroblasts from SSc-PAH patients exhibited 
elevated levels of phosphorylated Smad 2 and 3. 
The TβRIIΔk-fib model of SSc-PAH also displays enhanced TGFβ activity with 
increased levels of phosphorylated levels of Smads 2 and 3 [40, 52, 54]. Another aim 
of this study was to investigate if JQ1 could reduce enhanced TGFβ and downstream 
signalling pathways. JQ1 displayed an ability to inhibit TGFβ pathway activity, 
elevated levels of phosphorylated-Smad 2/3 have been associated with SSc and PAH 
with increased phosphorylated-Smad 2/3 levels staining  in concentric lesions of 
PAH patients [152]. Here JQ1 demonstrates an ability to reduce phosphorylated-
Smad 2/3 expression in whole lung tissue. A number of studies have demonstrated 
pharmacological antagonists of the TGFβ signalling pathway can inhibit and reverse 
the development of PAH in preclinical models which exhibit genetically independent 
reduction in BMPRII levels in tissues [194]. This study supports the notion that 
enhanced TGFβ signalling contributes to the development of PAH and SSc-PAH. 
JQ1 also demonstrated an ability to reduce phosphorylated -p38 levels but had no 
effect on phosphorylated ERK 1/2. It has been previously reported that p38 inhibitor 
FR167653 significantly attenuates the expression of inflammatory cytokines in the 
MCT model of PH, ultimately preventing the progression of PH [300]. These results 
suggest that p38 might play a key role in the molecular events that are involved in 
the development and progression of PH; this supports the mechanism by which JQ1 
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is having a protective effect on the development of PAH in the TβRIIΔk model 
[300].  
 
6.5 Conclusion 
This chapter highlights the benefit of a novel epigenetic inhibitor in preventing the 
development of PAH in a transgenic model of SSc-PAH. The BRD inhibitor JQ1 
displays an ability in-vitro to decrease markers that contribute to increased ECM 
production, JQ1 also arrests the disease phenotype of fibroblasts and PASMCs by 
inhibiting migration, proliferation and excessive production of inflammatory 
cytokines. In-vivo JQ1 prevented the development of PAH in the TβRIIΔk model by 
reducing RVSP and also prevented muscularisation in some vessels, medial 
hypertrophy and inflammatory filtrates. Furthermore, JQ1 reduced phosphorylated 
Smad 2/3 and phosphorylated -p38 levels in the lungs of TβRIIΔk mice and both of 
these signalling proteins have been implicated in PAH. Previous reports have 
highlighted by targeting the TGFβ axis and inhibited phosphorylated-p38 prevents 
the development PAH in pre-clinical models suggesting benefits of JQ1’s inhibitory 
effects on TGFβ [194, 300]. 
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7. Final discussion and future studies 
7.1 Final Discussion 
In this thesis I have applied an integrated approach using in-vivo and in-vitro 
experimental studies to explore key biological pathways that underlie the 
development of PAH in SSc. A major focus has been the use of the TβRIIΔk-fib 
transgenic mouse model of SSc. This model provides a powerful tool for exploring 
the role of enhanced TGFβ activity, clinically implicated in the development of SSc 
and PAH, in the connective tissue microenvironment and on the relevance to the 
TGFβ superfamily receptor member, BMPRII and the downstream signalling 
pathways.  
The central findings of the work provide a plausible unifying model for SSc 
susceptibility to PAH that involves a TGFβ dependent perturbation of BMP 
signalling due to reduced protein expression of the receptor BMPRII as highlighted 
in figure 7.1. Extrapolation into human tissue samples provides additional validation 
of this mouse model. This work also profiled changes in the lung architecture in the 
TβRIIΔk-fib model and confirmed the utility of explant lung fibroblasts from these 
mice in exhibiting a disease like phenotype. These observations lead us to examine 
how these characteristics displayed in the TβRIIΔk-fib model might also be found in 
SSc patients.  
Extending the observation in the mouse model of reduced BMPRII expression and 
altered downstream signalling in components of the TGFβ/BMP pathways I assessed 
the relevance in clinically derived material. The TGFβ/BMP pathways in SSc and 
normal explant cultured fibroblasts were examined and functional differences in 
these fibroblasts were assessed. BMPRII protein expression was significantly 
reduced in SSc lung tissues and fibroblasts. In contrast BMPRII mRNA was elevated 
in SSc patient tissues compared to that of donor control tissues, suggesting that 
altered translation or enhanced protein degradation might be responsible for reduced 
BMPRII expression in SSc. To assess this the effects of the proteasomal inhibitor 
MG132, BMPRII protein expression and downstream signalling responses to the 
BMP ligands was assessed. MG132 led to a significant increase in BMPRII levels 
and concomitant increase in downstream signalling by SSc fibroblasts response to 
BMP4. Collectively these observations are supportive that enhanced proteasomal 
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degradation of BMPRII contributes to a reduction in BMPRII protein expression in 
SSc. 
Whilst many IPAH and HPAH patients harbour mutations in the BMPRII gene, no 
such mutations have been reported in SSc-PAH patients [198]. SSc is a complex 
disease in which a number of cell types including PASMCs and fibroblasts 
contribute to the development of SSc-PAH vascular remodelling and the deposition 
of ECM, including PASMCs and fibroblasts. Extending these studies I explored the 
cellular mechanisms that may contribute to vascular remodelling. Initial I sought to 
develop and characterise PASMCs either maintained in a contractile ‘healthy’ state 
or PASMCs driven to a synthetic and more ‘disease-like’ phenotype. Synthetic 
PASMCs exhibited many of the features of SSc fibroblasts including elevated levels 
of CTGF, type-I collagen and pro-inflammatory cytokines such as IL-6 and IL-8. 
Assessing the expression of components of the TGFβ superfamily of receptors and 
downstream signalling pathways, synthetic PASMCs exhibited reduced BMPRII 
expression. Consistent with the reduction in functional cell surface expression of 
BMPRII, synthetic PASMCs demonstrated a blunted response to BMP ligands 
compared to contractile PASMCs.  
Previous studies from our and other group have shown a key role for BRD proteins 
in modulating differentiation of fibroblasts into myofibroblasts and the SSc 
fibroblast phenotype [180, 189]. Using a novel epigenetic inhibitor of BRD proteins, 
JQ1 I sought to investigate the contribution of epigenetics in the SSc lung fibroblast 
and synthetic PASMCs phenotypes. JQ1 inhibited the SSc lung fibroblast and 
synthetic PASMC phenotype. Extending this further I investigated the effects of JQ1 
on the development of PAH in the TβRIIΔk-fib model. In addition JQ1 attenuated 
the development of PAH in the TβRIIΔk-fib and reduced the formation of concentric 
lesions in the vessels of TβRIIΔk-fib mice. 
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7.1.1 Reduction of BMPRII in scleroderma lung 
PAH is an important complication of SSc [195]. The risk of SSc patients developing 
PAH continues throughout the disease suggesting that SSc is the susceptibility factor 
[38]. SSc-PAH patients have a significantly poorer prognosis compared to those with 
IPAH or HPAH [196, 197]. Mutations that lead to a loss of expression or function of 
the BMPRII have been strongly implicated in the pathogenesis of HPAH and IPAH 
[102]. In contrast, genetic studies in SSc-PAH patients have not detected mutations 
in the BMPRII gene [198, 301]. Wang et al have recently demonstrated that BMPRII 
expression is reduced in the skin of SSc patients. The reduction of BMPRII has been 
linked to heightened DNA methylation of the BMPRII promoter [175]. 
In chapter three I demonstrated that the TβRIIΔk-fib model of SSc which 
spontaneously develops PAH exhibits a reduction in BMPRII protein expression in 
whole lung tissue and explant cultured fibroblasts. These observations in this pre-
clinical model coincide with reduced BMPRII expression in the rodent hypoxic, 
rodent SU5415/hypoxic and MCT models suggesting that a reduction in BMPRII 
expression might increase the susceptibility to developing PAH [141, 146, 193]. 
These results from the TβRIIΔk-fib model and other pre-clinical models that reduced 
BMPRII by non-genetic means may contribute to the development of PAH. [119].  
The observation that a reduction of BMPRII by a non-genetic means is observed in 
pre-clinical models of PAH and in the skin of SSc patients led us to examine 
BMPRII expression in the lung of SSc patients. BMPRII expression was reduced in 
whole lung tissue and explant cultured fibroblasts from SSc patients, whereas 
BMPRII mRNA expression was increased suggesting that enhanced protein 
degradation may be responsible for reduced BMPRII expression in SSc (Chapter 
four). One weakness of this study was that BMPRII is more highly expressed in 
PAECS and PASMCs compared to fibroblasts so it would be interesting to 
investigate BMPRII expression in both of these cell types. Interestingly our 
observations are in contrast to those of Wang et al who demonstrated reduction in 
both mRNA and protein levels of BMPRII in microvascular endothelial cells from 
SSc patients [175]. These results suggest that possibly different mechanisms by 
which BMPRII levels may be reduced in these cells or organ.  
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A number of studies have highlighted non-genetic mechanisms that lead to reduced 
BMPRII protein levels, including ubiquitination and proteasomal degradation 
mediated by Smurf1, K5 and E3 ligase and Itch [17, 190]. Collectively non-genetic 
mechanisms may also contribute to a reduction in BMPRII expression and therefore 
a predisposition to the development of PAH.  The use of a proteasomal degradation 
inhibitor MG132 led to an increase BMPRII protein levels in control and SSc lung 
fibroblasts. Consistent with MG132 treatment restoring functional BMPR2 to the 
cell surface, BMP ligands induced activation of downstream signalling pathways in 
SSc lung. The rise in BMPRII levels in both control and SSc lung fibroblasts in 
response to MG132 suggests proteasomal degradation is a normal mechanism of 
turn-over of BMPRII receptors. Interestingly Smurf1 has recently been demonstrated 
to be elevated in SSc lung tissues (Holmes et al; personal communication). 
Suggesting this mechanism may be enhanced in SSc patients. Collectively this 
suggests that proteasomal degradation inhibitors might provide a novel therapeutic 
approach to prevent the reduction in BMPRII levels in SSc patients and the 
development of non-genetic forms of PAH (chapter 4).  
PASMCs are another key cell type involved in vascular remodelling and the 
development of PAH and have been extensively investigated IPAH and HPAH, but 
not as frequently in SSc where access to PASMCs from patients has been limited. As 
highlighted in chapter five, I sought to use the differentiation of control PASMCs 
from contractile to synthetic forms to investigate this process and its relevance to 
SSc. The differentiation of PASMCs into a disease like synthetic phenotype led to a 
reduction in BMPRII and blunted responses to BMP ligands. BMPRII protein 
expression has previously been reported to be reduced in PASMCs from IPAH 
patients with defined BMPRII mutations and these cells exhibited dampened 
response to BMP ligands [24, 177]. The reduction of BMPRII levels in our synthetic 
‘disease’ phenotype at the protein and transcript level suggests these cells exhibit a 
similar phenotype to those isolated from IPAH patients. Synthetic PASMCs also 
demonstrated a rise in the gene expression of the BMP antagonist gremlin 1. It has 
been previously reported that gremlin 1 has higher expression in the lung than any 
other organ. Furthermore, Gremlin 1 is also elevated in the lung of PAH patients and 
novel gremlin 1 antibodies can reverse PAH in the pre-clinical sugen/hypoxia model 
of PAH [155, 228]. Elevated gremlin 1 may represent a novel mechanism by which 
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responses to BMP ligands may be blunted in diseases such as SSc-PAH. Future work 
to assess the levels in SSc patient lung tissues and serum would be interesting to 
define the contribution to the development of SSc-PAH. 
The development of vascular remodelling in the context of PAH involves a number 
of cell types. Consistent with this these results suggest that more than one cell type 
contributes to the development of PAH and the use of co-culture systems will be 
essential in gaining a better understanding of disease pathology, but also that a 
reduction of BMPRII is a shared mechanism between explant cultured lung 
fibroblasts and PASMCs. Interestingly both SSc lung fibroblasts and synthetic 
PASMCS display a blunted response to BMP similarly to PASMCs from IPAH 
patients [24, 177]. These results suggest that a reduction in BMPRII may predispose 
patients to the development of PAH and that more than one cell type can contribute 
to this. 
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7.1.2 Enhanced TGFβ activity in SSc lung 
It has been previously reported that heightened TGFβ activity is observed in the skin 
of SSc patients, highlighted by a rise in phosphorylated Smad 2/3 protein expression 
and PAI-1 gene expression [174]. The TβRIIΔk-fib model has also displayed 
increased activity in explant skin and lung fibroblasts and now whole lung tissue 
with a rise in phosphorylated Smad 2/3 expression [40, 52, 54, 302]. As mentioned 
earlier these mice also develop PAH so this enhanced TGFβ activity might 
contribute to the development of PAH and SSc. Enhanced TGFβ signalling has 
previously been reported in IPAH vessels highlighted by an increase in 
phosphorylated Smad 2/3 staining [152, 174, 194]. Indicative of enhanced TGFβ 
signalling, our work also demonstrated elevated phosphorylated Smad 2/3 levels in 
whole lung tissue and explant cultured lung fibroblasts from SSc patients. A number 
of groups have also highlighted that preclinical models of PAH exhibit enhanced 
TGFβ activity including the MCT rat, hypoxia and hypoxia SU5416, and this 
observation is in concordance with a reduction in BMPRII levels [141, 146, 176]. 
This suggests that both a reduction in BMPRII and enhanced TGFβ activity are 
linked to a mechanism that is contributing to the development of PAH. 
Further studies to elucidate the factors that drive the imbalance in TGFβ/BMP 
activity and how these pathways influence each other could be important in 
understanding the development of PAH. It seems that in the TβRIIΔk-fib model 
where TGFβ activity is elevated that may be a factor that causes a reduction in 
BMPRII. In the bleomycin lung model BMPRII is also reduced in both the 
inflammatory and active fibrosis phase suggesting that BMPRII reduction precedes 
the development of fibrosis in this model [133]. It raises another question that in 
early stages of SSc that a reduction in BMPRII might increase the risk of patients 
developing PAH. These observations suggest that a reduction in BMPRII and an 
enhanced TGFβ axis are observed in both SSc-PAH, HPAH and IPAH and may a 
unifying mechanism in the development of PAH as highlighted in figure 7.1 
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Figure 7.1 - TGFβ and BMP signalling in PAH and SSc-PAH patients 
compared to humans with no disease. 
TGF-β and BMP ligand-receptor complex activates the canonical Smad signalling 
pathway inducing phosphorylation and translocation from the cytoplasm to the 
nucleus (Smad 2/3 and Smad 1/5/8). Non-Smad (non-canonical) signalling 
mechanisms are also activated (ERK 1/2, p38). (A) In healthy humans, The TGF-
β/BMP receptor complex directly activates canonical and non-canonical pathways 
leading to phosphorylation and translocation from the cytoplasm to the nucleus. (B) 
In patients with PAH or SSc PAH due to a loss of BMPRII expression due to 
mutations or a reduction of protein on the cell surface there is a reduction of BMP 
activated canonical (pSmad 1) and non-canonical signalling pathways (p-ERK 1/2 
and p-p38) (grey italics), and an increase in canonical TGFβ signalling (pSmad 2/3) 
and non-cannonical TGFβ signalling (p-ERK 1/2 and p-p38)  (bold). It is believed 
that this imbalance increases the susceptibility to patients with SSc developing PAH. 
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7.1.3 The role of epigenetics in scleroderma  
As discussed in chapter six the definition or meaning of epigenetics is interpreted 
differently by researchers [247] [248]. The major focus of chapter six was the role of 
JQ1 in SSc-PAH. JQ1 is a BRD inhibitor, BRD is a conserved member of the BET 
family of chromatin readers, BRD consists of four members BRD2, BRD3 and BRD 
testis (BRDT). When JQ1 binds to the BRD pocket it leads to the displacement of 
BRD4 from active chromatin and the subsequent removal of RNA polymerase II 
from target genes [262, 263]. Other groups have highlighted that BMPRII is reduced 
in the skin and microvascular endothelial cells in SSc patients [175]. This study also 
showed that the use of epigenetic inhibitors similar to JQ1, DNA methyltransferase 
inhibitor 5-Aza-2’-de-oxycytidine (5-AZA) and the histone deacetylase inhibitor 
trichostatin (TSA) that these inhibitors had humble effects individually but in 
combination there was a significant rise in BMPRII expression in microvascular 
endothelial cells [175].  
The aim of this study was to investigate the role of JQ1 in PAH and delineate what 
pathways and cellular responses JQ1 affected. In-vitro JQ1 was able to reduce the 
secretion of ECM and pro-inflammatory cytokines from both SSc lung fibroblasts 
and PASMCs from IPAH patients.  
In-vivo using the TβRIIΔk-fib model JQ1 was able to prevent the development of 
PAH in the TβRIIΔk-fib by reducing elevated RVSP’s compared to TβRIIΔk-fib 
with vehicle control. In chapter three it was demonstrated that BMPRII protein 
expression is reduced in the TβRIIΔk-fib model, however unexpectedly BMPRII 
levels were significantly reduced in both WT and TβRIIΔk-fib JQ1 treated groups. 
The initial working hypothesis was that JQ1 might increase BMPRII expression by 
binding to the acetylated lysine residues of BRD 4. This was plausible because in a 
study where BMPRII is reduced in the skin of SSc patients epigenetic inhibitors 
increased BMPRII expression however in this study two epigenetic inhibits were 
required to significantly increase BMPRII expression [175]. The results in chapter six 
demonstrate the contrary in-vivo suggesting that JQ1 is exerting it’s affect by altering 
cellular phenotypes that contribute to vascular remodelling and by anti-inflammatory 
effects.  
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JQ1 did display positive effects on the TGFβ pathway, elevated levels of 
phosphorylated Smad 2/3 and phosphorylated-p38 have been associated with SSc and 
PAH with increased phosphorylated Smad 2/3 levels staining in concentric lesions of 
PAH patients [152]. Here JQ1 demonstrates an ability to reduce elevated levels of 
phosphorylated Smad 2/3 expression in whole lung tissue and reduce and 
phosphorylated-p38 expresssion. A number of studies have demonstrated 
pharmacological antagonists of the TGFβ signalling pathway can inhibit and reverse 
the development of PAH suggesting that JQ1 might be exerting it’s affecting 
indirectly through the TGFβ pathway [194]. 
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7.2 Future studies 
As well as providing fundamental insight into the mechanism by which the 
TβRIIΔk-fib model and SSc patients develop PAH, this thesis also provides a 
platform for future experimental studies. Although this work is consistent with other 
reports that enhanced TGFβ activity occurs in concordance with a reduction in 
BMPRII in the development of pulmonary diseases, but the mechanism by which 
these pathways interact require further elucidation. A number of experiments could 
be envisaged to assess this. For example, knockdown studies of BMPRII using 
shRNA or siRNA approaches on control lung fibroblasts or contractile PASMC, or 
complimentary overexpression BMPRII studies on SSc lung fibroblasts or synthetic 
PASMCs could be performed to assess effects on phenotypic changes in 
proliferation, migration and apoptosis. A previous study using pulmonary artery 
endothelial cells has reported that a loss of BMPRII lead to a rise in secretion in pro-
inflammatory cytokines, increased endothelial cell permeability and transmigration 
of mononuclear cells and neutrophils [303]. Other studies demonstrate a reduction in 
BMPRII levels expression in PASMCs is associated with increased IL-6 secretion 
suggesting BMPRII plays a key role in regulating the inflammatory environment. It 
has also been highlighted that BMPRII heterozygous null mice don’t display an 
overt PH phenotype unless an additional trigger is implemented [304-306]. This 
study again suggests that BMPRII reduction in the lung is a susceptibility factor but 
in order for PAH to develop, additional complications in combination with reduced 
BMPRII are required. These results and the work by Burton et al suggest that 
BMPRII may act to dampen inflammatory signals in the pulmonary vasculature and 
a reduction of BMPRII may predispose patients to an inflammation 
microenvironment and vascular damage. It would be interesting to repeat functional 
studies in PASMCs to gain a better understanding of the role of BMPRII in these 
cells.  
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7.2.1 Proteasomal inhibition as a novel potential therapy in SSc 
MG132 demonstrated an ability to upregulate BMPRII expression in both normal 
and SSc lung fibroblasts and restoring SSc lung fibroblasts responses to BMP4, 
leading to restoration of normal phosphorylated Smad1 induction. This suggests that 
MG132 has potential as a novel therapeutic for non-genetic forms for PAH; however 
these are only preliminary studies. 
As discussed in chapter four, bortezomib is a proteasomal degradation inhibitor 
which is currently approved for the treatment of patients with multiple myeloma. 
Future experiments to initially assess the effects of bortezomib on BMPRII and 
restoration BMP response and compare these MG132 effects would seek to confirm 
the suitability of this licenced therapy for SSc. Since BMPRII is expressed more 
highly in PASMCs and PAECs it would also be interesting to perform experiments 
in these cell types. 
The effect of MG132 and bortezomib on pro-inflammatory cytokines, for example 
IL-6 and IL-8 that are implicated in the development of SSc and PAH could also be 
assessed. Another important experiment would be to investigate if bortezomib and 
MG132 can prevent the deposition of ECM, for example type-1 collagen expression 
and CTGF. As discussed earlier the interaction and phenomenon observed in SSc of 
enhanced TGFβ and reduced BMPRII expression needs to be elucidated further. The 
question would be if MG132 can inhibit the heightened TGFβ activity in SSc and 
how does it exert its effect.  
In-vivo proteasomal inhibitors have demonstrated some positive but controversial 
results in models of lung, heart and kidney fibrosis so the exact role of these 
inhibitors is still unknown [132, 209-211].In-vivo it would be important to examine 
the role of MG132 and bortezomib in both the TβRIIΔk-fib model and the 
SU5416/hypoxia mouse model. Experimental readouts would initially be 
haemodynamic readouts, for example RVSP, MAP and Fulton index. Histologically 
it would be important to investigate if MG132 and bortezomib can reduce the 
number of muscularised vessels and the influx of inflammatory infiltrate in these 
models. It would also be interesting to collect serum and perform multiplex analysis 
to examine anti-inflammatory. In-vivo it would be important to investigate if MG132 
and bortezomib can upregualte BMPRII and inhibit TGFβ signalling in the TβRIIΔk-
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fib model of SSc-PAH and the SU5416/hypoxia mouse model of PAH as previously 
reported in-vitro. 
 
7.2.2 Interaction between TGFβ/BMP signalling pathways 
TGFβ and BMP signalling pathways demonstrate antagonistic activities during the 
development of many tissues. Although the crosstalk between BMP and TGFβ 
signalling pathways is well defined in bone development, it is poorly understood 
in the lung and in diseases like PAH and SSc [307]. The interaction between both 
TGFβ and BMP pathways can contribute to degradation of receptors and activity 
alterations in both pathways. The activity of type I and II TGFβ receptors can be 
altered by different methods, depshosphorylation of activated receptors, interfering 
with Smad signalling and proteasomal degradation. An example of this is how the 
inhibitory Smads (I-Smad) affect receptor Smads (R-Smad) activity but also by 
recruiting E3 ubiqutin ligases, for example Smurf 1 and 2 to the receptor complex. 
This leads to both ALK5 and TGFβR-II being ubiquitylated and degraded. Smad 7 
has also been shown to direct Smurf1 to ALK6 with forms a heterodimer with 
BMPRII leading to ubiquitylation and degradation [308]. All of these mechanisms 
suggest that this interaction is important in disease development and potentially in 
PAH and SSc, Smad 7 is more common to target ALK6 and BMP signalling 
leading to a reduction in BMP signalling and an enhancement in TGFβ activity 
[308]. 
LMP-1 is a LIM domain protein that has also been highlighted to interact with 
Smurf 1, which in turn can prevent Smurf 1, mediated ubiquitylation of Smad 1/5, 
this interaction leads to enhanced BMP signalling. Interestingly both Smurf 1 and 
I-Smad 7 expression is elevated in the MCT and hypoxia model of PAH whereas 
BMPRII expression is downregulated suggesting that induction of Smurf 1 can 
downregulate BMPRII and suppress BMP signalling and may play a key role in 
the development of PAH [190]. Smurf 1 is also elevated in the lung of SSc 
patients suggesting that this mechanism might be contributing to the development 
of PAH (Holmes et al, unpublished). 
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However LIM kinase 1 (LIMK1) is a kinase that regulates actin by 
phosphorylating cofilin, which is an actin depolymerising factor. An elegant study 
has isolated a LIMK-1 interacting protein that encompasses the tail region of 
BMPRII. The tail region is not involved in BMP signalling but mutations in 
HPAH are found in this region. Further studies suggested that BMPRII is able to 
prevent LIMK1 from phosphorylating cofilin, however in HPAH this mechanism 
is prevented due to BMPRII mutations in the tail region leading to deregulation of 
actin dynamics.  The complexity and balance of these pathways are essential for 
understanding the development of PAH and how BMPRII is down regulated in 
SSc [309]. 
 
7.2.3 The role of bromodomains and epigenetic modulation in SSc 
The work on epigenetics in this thesis (Chapter six), investigated the effect of a 
bromdomain inhibitor JQ1 on the development of PAH in the TβRIIΔk-fib model 
and its effect on SSc lung fibroblasts and synthetic and IPAH PASMCs phenotypes. 
Previous studies have demonstrated JQ1 can modulate the dermal SSc fibroblasts 
phenotype. Consistent with this we demonstrate JQ1 can modulate both the SSc lung 
fibroblasts and synthetic and IPAH PASMCs phenotypes, as determined by matrix 
deposition and inflammatory chemokine release. As discussed earlier JQ1 inhibits 
the BET family of chromatin readers, BRD which consists of four members BRD2, 
BRD3 and BRD testis (BRDT). When JQ1 binds to the BRD pocket it leads to the 
displacement of BRD4 from active chromatin and the subsequent removal of RNA 
polymerase II from target genes [262, 263]. Whilst we have demonstrated the 
efficacy of JQ1 in-vitro and in-vivo it remains unclear which of the family members 
contribute to the pathological phenotype of SSc lung fibroblasts and synthetic and 
IPAH PASMCs. To explore this further, future experiments to assess the effects on 
collagen type I expression and IL-6 of siRNA knockdown of members of the BRD 
family (BRD2, BRD3 and BRD4) could be performed. Although BRDT is restricted 
normally in its expression to the testis and ovaries, it remains unclear the spatial and 
temporal expression of other members of this family in SSc and SSc-PAH. 
Immunohistochemical studies to assess in SSc patient’s lung the differential 
expression of these family members and in other SSc disease sub types may offer 
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insight into the mechanisms which Brd proteins contribute to the pathological 
differentiation of fibroblasts and PASMCs in SSc and specifically the development 
in PAH. It would also be interesting to examine BRD expression in the TβRIIΔk-fib 
model and SU5146/hypoxia model to investigate if BRD expression is elevated in 
these models compared to controls and attenuated in JQ1 treated groups.  
It remains unclear the impact of chronic administration of epigenetic inhibitors for 
diseases such as SSc, and may have significant side effects for example effecting 
normal wound healing. Understanding the key members of the family that contribute 
to the development of SSc-PAH, will allow for the development of specific 
inhibitors of BRD family members. The development of specific inhibitors are likely 
to reduced side effects that would be expected with broad spectrum inhibitors.   
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7.3 Concluding remarks 
PAH is a devastating complication of SSc and the outcome is significantly worse in 
SSc-PAH compared to both IPAH and HPAH. However despite this difference, 
work described in this thesis suggests that key biological processes may be similar 
between these forms of PAH. Observations from the lungs of TβRIIΔk-fib and SSc-
PAH patients’ show that a reduction is BMPRII is linked to SSc and the complex 
phenotype observed in SSc patient’s phenocopies other types of PAH. 
These observations in a pre-clinical model and clinically derived material provide 
further insight to SSc with bi-directional translation. The observation of a reduction 
in BMPRII in SSc lung validates the TβRIIΔk-fib model of SSc, whilst the model 
also allows us to gain greater insight into the disease. The increased TGFβ 
microenvironment in the TβRIIΔk-fib model due to genetic alterations leads to a 
potential link between enhanced TGFβ and a reduction in BMPRII. This mechanism 
is validated in the both the lungs of SSc-PAH and IPAH patients. However the 
mechanism of cross talk where by enhanced activity of the TGF pathway impacts 
the BMPRII regulated signalling pathways needs further exploration. In the end SSc 
providers a susceptibility phenotype for PAH and this may explain why the 
understanding of mechanism has been so challenging. This thesis shows that to 
understand complex pathologies pre-clinical models provide a platform to 
understand disease pathology and to understand the human disease it is important to 
explore different cell types and whole lung tissue.  
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